Cochrane
Library

Cochrane Database of Systematic Reviews

Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients (Review)

Campbell D, Mudge DW, Craig JC, Johnson DW, Tong A, Strippoli GFM

Campbell D, Mudge DW, Craig JC, Johnson DW, Tong A, Strippoli GFM.
Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients.
Cochrane Database of Systematic Reviews 2017, Issue 4. Art. No.: CD004679.
DOI: [10.1002/14651858.CD004679.pub3](https://doi.org/10.1002/14651858.CD004679.pub3).

www.cochranelibrary.com

Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients (Review)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WILEY

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	3
BACKGROUND	9
OBJECTIVES	10
METHODS	10
RESULTS	12
Figure 1.	13
Figure 2.	15
Figure 3.	16
DISCUSSION	20
AUTHORS' CONCLUSIONS	23
ACKNOWLEDGEMENTS	23
REFERENCES	24
CHARACTERISTICS OF STUDIES	31
DATA AND ANALYSES	77
Analysis 1.1. Comparison 1 Oral or topical antibiotics versus placebo/no treatment, Outcome 1 Peritonitis (number of patients with one or more episodes).	78
Analysis 1.2. Comparison 1 Oral or topical antibiotics versus placebo/no treatment, Outcome 2 Peritonitis rate (episodes/total patient-months on PD).	79
Analysis 1.3. Comparison 1 Oral or topical antibiotics versus placebo/no treatment, Outcome 3 Exit-site/tunnel infection (number of patients with one or more episodes).	79
Analysis 1.4. Comparison 1 Oral or topical antibiotics versus placebo/no treatment, Outcome 4 Exit-site/tunnel infection rate (episodes/total patient-months on PD).	80
Analysis 1.5. Comparison 1 Oral or topical antibiotics versus placebo/no treatment, Outcome 5 Catheter removal or replacement (number of patients).	80
Analysis 1.6. Comparison 1 Oral or topical antibiotics versus placebo/no treatment, Outcome 6 Mortality (all-cause).	80
Analysis 1.7. Comparison 1 Oral or topical antibiotics versus placebo/no treatment, Outcome 7 Mortality due to peritonitis. ...	81
Analysis 1.8. Comparison 1 Oral or topical antibiotics versus placebo/no treatment, Outcome 8 Adverse effects.	81
Analysis 2.1. Comparison 2 Oral or topical antibiotics versus other antibiotic, Outcome 1 Peritonitis (number of patients with one or more episodes).	83
Analysis 2.2. Comparison 2 Oral or topical antibiotics versus other antibiotic, Outcome 2 Peritonitis rate (episodes/total patient-months on PD).	84
Analysis 2.3. Comparison 2 Oral or topical antibiotics versus other antibiotic, Outcome 3 Exit-site/tunnel infection (number of patients with one or more episodes).	84
Analysis 2.4. Comparison 2 Oral or topical antibiotics versus other antibiotic, Outcome 4 Exit-site/tunnel infection rate (episodes/total patient-months on PD).	85
Analysis 2.5. Comparison 2 Oral or topical antibiotics versus other antibiotic, Outcome 5 Catheter removal or replacement (number of patients).	85
Analysis 2.6. Comparison 2 Oral or topical antibiotics versus other antibiotic, Outcome 6 Mortality (all-cause).	86
Analysis 2.7. Comparison 2 Oral or topical antibiotics versus other antibiotic, Outcome 7 Technique failure.	86
Analysis 2.8. Comparison 2 Oral or topical antibiotics versus other antibiotic, Outcome 8 Adverse effects.	86
Analysis 3.1. Comparison 3 Nasal antibiotics versus placebo/no treatment, Outcome 1 Peritonitis (number of patients with one or more episodes).	88
Analysis 3.2. Comparison 3 Nasal antibiotics versus placebo/no treatment, Outcome 2 Peritonitis rate (episodes/total patient-months on PD).	88
Analysis 3.3. Comparison 3 Nasal antibiotics versus placebo/no treatment, Outcome 3 Exit site and tunnel infection (number of patients with one or more episodes).	88
Analysis 3.4. Comparison 3 Nasal antibiotics versus placebo/no treatment, Outcome 4 Exit site and tunnel infection rate (episodes/total patient-months on PD).	89
Analysis 3.5. Comparison 3 Nasal antibiotics versus placebo/no treatment, Outcome 5 Catheter removal or replacement (number of patients).	89

Analysis 3.6. Comparison 3 Nasal antibiotics versus placebo/no treatment, Outcome 6 Mortality (all-cause).	89
Analysis 3.7. Comparison 3 Nasal antibiotics versus placebo/no treatment, Outcome 7 Adverse effects.	89
Analysis 4.1. Comparison 4 Pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic, Outcome 1 Peritonitis (number of patients with one or more episodes).	92
Analysis 4.2. Comparison 4 Pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic, Outcome 2 Exit site/tunnel infection (number of patients with one or more episodes).	92
Analysis 4.3. Comparison 4 Pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic, Outcome 3 Catheter removal or replacement (number of patients).	93
Analysis 4.4. Comparison 4 Pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic, Outcome 4 Mortality (all-cause).	93
Analysis 5.1. Comparison 5 Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant), Outcome 1 Peritonitis (number of patients with one or more episodes).	94
Analysis 5.2. Comparison 5 Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant), Outcome 2 Exit site/tunnel infection (number of patients with one or more episodes).	95
Analysis 5.3. Comparison 5 Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant), Outcome 3 Exit site/tunnel infection rate (episodes/total patient-months on PD).	95
Analysis 5.4. Comparison 5 Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant), Outcome 4 Catheter removal or replacement (number of patients).	96
Analysis 5.5. Comparison 5 Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant), Outcome 5 Mortality (all-cause).	96
Analysis 5.6. Comparison 5 Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant), Outcome 6 Technique failure.	97
Analysis 5.7. Comparison 5 Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant), Outcome 7 Pruritus (local).	97
Analysis 6.1. Comparison 6 Germicidal chamber versus none, Outcome 1 Peritonitis rate (episodes/total patient-months on PD).	98
Analysis 6.2. Comparison 6 Germicidal chamber versus none, Outcome 2 Mortality (all-cause).	98
Analysis 7.1. Comparison 7 Dressing systems (any), Outcome 1 Exit site/tunnel infection (number of patients with one or more episodes).	99
Analysis 7.2. Comparison 7 Dressing systems (any), Outcome 2 Exit site/tunnel infection rate (episodes/total patient-months on PD).	99
Analysis 8.1. Comparison 8 Silver ring system on catheter versus none, Outcome 1 Peritonitis (number of patients with one or more episodes).	100
Analysis 8.2. Comparison 8 Silver ring system on catheter versus none, Outcome 2 Exit site/tunnel infection (number of patients with one or more episodes).	100
Analysis 8.3. Comparison 8 Silver ring system on catheter versus none, Outcome 3 Catheter removal or replacement (number of patients).	100
Analysis 8.4. Comparison 8 Silver ring system on catheter versus none, Outcome 4 Mortality (all-cause).	100
Analysis 9.1. Comparison 9 Antistaphylococcal vaccine (Staphypan) versus placebo, Outcome 1 Peritonitis rate (episodes/total patient-months on PD).	101
Analysis 9.2. Comparison 9 Antistaphylococcal vaccine (Staphypan) versus placebo, Outcome 2 Exit site/tunnel infection rate (episodes/total patient-months on PD).	101
Analysis 10.1. Comparison 10 Antifungal versus placebo/no treatment, Outcome 1 Fungal peritonitis (number of patients with one or more episodes).	101
Analysis 10.2. Comparison 10 Antifungal versus placebo/no treatment, Outcome 2 Fungal peritonitis rate (episodes/total patient-months on PD).	102
ADDITIONAL TABLES	102
APPENDICES	105
WHAT'S NEW	107
HISTORY	107
CONTRIBUTIONS OF AUTHORS	108
DECLARATIONS OF INTEREST	108
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	108
INDEX TERMS	109

[Intervention Review]

Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients

Denise Campbell¹, David W Mudge², Jonathan C Craig^{3,4}, David W Johnson⁵, Allison Tong^{1,3}, Giovanni FM Strippoli^{3,4,6,7,8}

¹Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Australia. ²Department of Nephrology, University of Queensland at Princess Alexandra Hospital, Woolloongabba, Australia. ³Sydney School of Public Health, The University of Sydney, Sydney, Australia. ⁴Cochrane Kidney and Transplant, Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Australia. ⁵Department of Nephrology, Princess Alexandra Hospital, Woolloongabba, Australia. ⁶Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. ⁷Medical Scientific Office, Diaverum, Lund, Sweden. ⁸Diaverum Academy, Bari, Italy

Contact address: Giovanni FM Strippoli, Cochrane Kidney and Transplant, Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, 2145, Australia. giovanni.strippoli@uniba.it, gfmstrippoli@gmail.com.

Editorial group: Cochrane Kidney and Transplant Group.

Publication status and date: Edited (no change to conclusions), published in Issue 6, 2017.

Citation: Campbell D, Mudge DW, Craig JC, Johnson DW, Tong A, Strippoli GFM. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. *Cochrane Database of Systematic Reviews* 2017, Issue 4. Art. No.: CD004679. DOI: [10.1002/14651858.CD004679.pub3](https://doi.org/10.1002/14651858.CD004679.pub3).

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Peritoneal dialysis (PD) is an important therapy for patients with end-stage kidney disease and is used in more than 200,000 such patients globally. However, its value is often limited by the development of infections such as peritonitis and exit-site and tunnel infections. Multiple strategies have been developed to reduce the risk of peritonitis including antibiotics, topical disinfectants to the exit site and antifungal agents. However, the effectiveness of these strategies has been variable and are based on a small number of randomised controlled trials (RCTs). The optimal preventive strategies to reduce the occurrence of peritonitis remain unclear.

This is an update of a Cochrane review first published in 2004.

Objectives

To evaluate the benefits and harms of antimicrobial strategies used to prevent peritonitis in PD patients.

Search methods

We searched the Cochrane Kidney and Transplant's Specialised Register to 4 October 2016 through contact with the Information Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE, and EMBASE; handsearching conference proceedings; and searching the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.

Selection criteria

RCTs or quasi-RCTs in patients receiving chronic PD, which evaluated any antimicrobial agents used systemically or locally to prevent peritonitis or exit-site/tunnel infection were included.

Data collection and analysis

Two authors independently assessed risk of bias and extracted data. Summary estimates of effect were obtained using a random-effects model, and results were expressed as risk ratio (RR) with 95% confidence intervals (CI).

Main results

Thirty-nine studies, randomising 4435 patients, were included. Twenty additional studies have been included in this update. The risk of bias domains were often unclear or high; risk of bias was judged to be low in 19 (49%) studies for random sequence generation, 12 (31%) studies for allocation concealment, 22 (56%) studies for incomplete outcome reporting, and in 12 (31%) studies for selective outcome reporting. Blinding of participants and personnel was considered to be at low risk of bias in 8 (21%) and 10 studies (26%) for blinding of outcome assessors. It should be noted that blinding of participants and personnel was not possible in many of the studies because of the nature of the intervention or control treatment.

The use of oral or topical antibiotic compared with placebo/no treatment, had uncertain effects on the risk of exit-site/tunnel infection (3 studies, 191 patients, low quality evidence: RR 0.45, 95% CI 0.19 to 1.04) and the risk of peritonitis (5 studies, 395 patients, low quality evidence: RR 0.82, 95% CI 0.57 to 1.19).

The use of nasal antibiotic compared with placebo/no treatment had uncertain effects on the risk of exit-site/tunnel infection (3 studies, 338 patients, low quality evidence: RR 1.34, 95% CI 0.62 to 2.87) and the risk of peritonitis (3 studies, 338 patients, low quality evidence: RR 0.94, 95% CI 0.67 to 1.31).

Pre/perioperative intravenous vancomycin compared with no treatment may reduce the risk of early peritonitis (1 study, 177 patients, low quality evidence: RR 0.08, 95% CI 0.01 to 0.61) but has an uncertain effect on the risk of exit-site/tunnel infection (1 study, 177 patients, low quality evidence: RR 0.36, 95% CI 0.10 to 1.32).

The use of topical disinfectant compared with standard care or other active treatment (antibiotic or other disinfectant) had uncertain effects on the risk of exit-site/tunnel infection (8 studies, 973 patients, low quality evidence, RR 1.00, 95% CI 0.75 to 1.33) and the risk of peritonitis (6 studies, 853 patients, low quality evidence: RR 0.83, 95% CI 0.65 to 1.06).

Antifungal prophylaxis with oral nystatin/fluconazole compared with placebo/no treatment may reduce the risk of fungal peritonitis occurring after a patient has had an antibiotic course (2 studies, 817 patients, low quality evidence: RR 0.28, 95% CI 0.12 to 0.63).

No intervention reduced the risk of catheter removal or replacement. Most of the available studies were small and of suboptimal quality. Only six studies enrolled 200 or more patients.

Authors' conclusions

In this update, we identified limited data from RCTs and quasi-RCTs which evaluated strategies to prevent peritonitis and exit-site/tunnel infections. This review demonstrates that pre/peri-operative intravenous vancomycin may reduce the risk of early peritonitis and that antifungal prophylaxis with oral nystatin or fluconazole reduces the risk of fungal peritonitis following an antibiotic course. However, no other antimicrobial interventions have proven efficacy. In particular, the use of nasal antibiotic to eradicate *Staphylococcus aureus*, had an uncertain effect on the risk of peritonitis and raises questions about the usefulness of this approach. Given the large number of patients on PD and the importance of peritonitis, the lack of adequately powered and high quality RCTs to inform decision making about strategies to prevent peritonitis is striking.

PLAIN LANGUAGE SUMMARY

Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients

What is the Issue?

People with kidney failure may be treated with peritoneal dialysis where a catheter is permanently inserted into the peritoneum (lining around abdominal contents) through the abdominal wall and sterile fluid is drained in and out a few times each day. The most common serious complication is infection of the peritoneum, which is called peritonitis. This may be caused by bacteria accidentally being transferred from the catheter.

What did we do?

We searched the literature up until 4 October 2016 and identified 39 studies randomising 4435 patients undergoing peritoneal dialysis that were evaluated in this review.

What did we find?

We found that antibiotics given when a peritoneal dialysis catheter is implanted may reduce the risk of early peritonitis but not of exit-site/tunnel infection. Antifungal prophylaxis with oral nystatin or fluconazole reduces the risk of fungal peritonitis following an antibiotic course. The available studies are of low quality evidence and consequently, it is uncertain if there is any benefit from using nasal mupirocin or topical disinfectants or other interventions to reduce exit-site/tunnel infection or peritonitis.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. Oral or topical or intraperitoneal antibiotics versus placebo/no treatment for preventing peritonitis in peritoneal dialysis patients

Oral or topical or intraperitoneal antibiotics versus placebo/no treatment for preventing peritonitis in peritoneal dialysis patients

Patient or population: patients with CKD on peritoneal dialysis

Settings: tertiary settings

Intervention: oral or topical or intraperitoneal antibiotics versus placebo/no treatment

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Oral or topical or intraperitoneal antibiotics versus placebo/no treatment				
Peritonitis (number of patients with one or more episodes)	Study population		RR 0.82 (0.57 to 1.19)	395 (5)	⊕⊕⊕⊕ low ^{1,2}	
	360 per 1000	295 per 1000 (205 to 428)				
	Moderate					
	385 per 1000	316 per 1000 (219 to 458)				
Exit-site/tunnel infection (number of patients with one or more episodes)	Study population		RR 0.45 (0.19 to 1.04)	191 (3)	⊕⊕⊕⊕ low ²	
	176 per 1000	79 per 1000 (34 to 184)				
	Moderate					
	231 per 1000	104 per 1000 (44 to 240)				
Catheter removal or replacement (number of patients)	Study population		RR 0.82 (0.46 to 1.46)	395 (5)	⊕⊕⊕⊕ low ^{1,2}	
	115 per 1000	94 per 1000 (53 to 168)				

Moderate	
156 per 1000	128 per 1000 (72 to 228)

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; **RR:** Risk ratio

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

¹ Unclear or high risk of bias in 3 of 5 studies

² Wide confidence intervals due to small patient numbers

Abbreviations: CKD - chronic kidney disease; GRADE - Grading of Recommendations Assessment, Development and Evaluation

Summary of findings 2. Nasal antibiotics versus placebo/no treatment for preventing peritonitis in peritoneal dialysis patients

Nasal antibiotics versus no treatment for preventing peritonitis in peritoneal dialysis patients

Patient or population: patients with CKD on peritoneal dialysis

Settings: tertiary settings

Intervention: nasal antibiotics versus placebo/no treatment

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Nasal antibiotics versus placebo/no treatment				
Peritonitis (number of patients with one or more episodes)	Study population		RR 0.94 (0.67 to 1.31)	338 (3)	⊕⊕⊖⊖ low ^{1,2}	
	294 per 1000	276 per 1000 (197 to 385)				
	Moderate					
	331 per 1000	311 per 1000				

	(222 to 434)			
Exit-site/ tunnel infection (number of patients with one or more episodes)	Study population	RR 1.34	338 (3)	⊕⊕○○ low ^{1,2}
	165 per 1000 221 per 1000 (102 to 473)	(0.62 to 2.87)		
	Moderate			
	188 per 1000 252 per 1000 (117 to 540)			
Catheter removal or re-placement (number of patients)	Study population	RR 0.92	289 (2)	⊕⊕○○ low ^{1,2}
	103 per 1000 95 per 1000 (49 to 183)	(0.48 to 1.78)		
	Moderate			
	265 per 1000 244 per 1000 (127 to 472)			

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; **RR:** Risk ratio

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

¹ Unclear risk of bias for allocation concealment in largest study ([Mupirocin Study 1996](#))

² Wide confidence intervals due to small patient numbers

Abbreviations: CKD - chronic kidney disease; GRADE - Grading of Recommendations Assessment, Development and Evaluation

Summary of findings 3. Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant) for preventing peritonitis in peritoneal dialysis patients

Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant) for preventing peritonitis in peritoneal dialysis patients

Patient or population: patients with CKD on peritoneal dialysis

Settings: tertiary settings

Intervention: topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant)				
Peritonitis (number of patients with one or more episodes)	Study population		RR 0.83 (0.65 to 1.06)	853 (6)	⊕⊕⊖⊖ low ^{1,2}	
	235 per 1000	195 per 1000 (153 to 250)				
	Moderate					
	152 per 1000	126 per 1000 (99 to 161)				
Exit-site/tunnel infection (number of patients with one or more episodes)	Study population		RR 0.97 (0.74 to 1.27)	913 (7)	⊕⊕⊖⊖ low ^{1,2}	
	238 per 1000	230 per 1000 (176 to 302)				
	Moderate					
	222 per 1000	215 per 1000 (164 to 282)				
Catheter removal or replacement (number of patients)	Study population		RR 0.89 (0.57 to 1.38)	792 (6)	⊕⊕⊖⊖ low ^{1,2}	
	97 per 1000	86 per 1000 (55 to 134)				
	Moderate					
	93 per 1000	83 per 1000 (53 to 128)				

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; **RR:** Risk ratio

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate

Very low quality: We are very uncertain about the estimate

¹ Unclear allocation in several studies

² Imprecision due to small number of patients and events in several studies

Abbreviations: CKD - chronic kidney disease; GRADE - Grading of Recommendations Assessment, Development and Evaluation

Summary of findings 4. Antifungal versus placebo/no treatment for preventing peritonitis in peritoneal dialysis patients

Antifungal versus placebo/no treatment for preventing fungal peritonitis in peritoneal dialysis patients

Patient or population: patients with CKD on peritoneal dialysis

Settings: tertiary settings

Intervention: antifungal versus placebo/no treatment during antibiotic course

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Antifungal versus placebo/no treatment				
Fungal peritonitis (number of patients with one or more episodes)	Study population		RR 0.28 (0.12 to 0.63)	817 (2)	⊕⊕⊖⊖ low ^{1,2}	
	64 per 1000	18 per 1000 (8 to 40)				
	Moderate					
	64 per 1000	18 per 1000 (8 to 40)				

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

¹ High risk of bias in one study ([Lo 1996](#))

² Imprecision due to small number of events and studies

Abbreviations: CKD - chronic kidney disease; GRADE - Grading of Recommendations Assessment, Development and Evaluation

BACKGROUND

Peritoneal dialysis (PD) is one of the renal replacement therapies available to people with end-stage kidney disease (ESKD). There is considerable variation in its use from country to country, with the proportion of total dialysis patients on PD in developed countries ranging from 3.3% (Japan), to 7.0% (USA), 8.3% (Greece), 17.0 % (UK), 36.3% (New Zealand), and up to 79.4% (Hong Kong) (Jain 2012). Because PD and haemodialysis have similar outcomes and patients feel that PD, compared with HD, allows them to live life more fully (Morton 2011), PD should be used more frequently than it is but the perceived risk of peritonitis may prevent this from occurring (Heaf 2004; Piraino 1998).

Description of the condition

Peritonitis due to various organisms (e.g. *Staphylococcus aureus*, *Pseudomonas aeruginosa*, coagulase-negative staphylococci) is a leading complication of PD resulting in technique failure (Woodrow 1997), hospitalisation (Choi 2004; Churchill 1997), peritoneal membrane failure, switching to haemodialysis (Jaar 2009; Piraino 1989) and increased mortality (Annigeri 2001; Digenis 1990; Fried 1996; Piraino 2000). There has been a dramatic reduction in the rates of peritonitis from the start of continuous ambulatory PD (CAPD), but rates above the minimum acceptable peritonitis rate recommended by the International Society for Peritoneal Dialysis (ISPD) of one episode every 33 months (0.36 episodes/year at risk) are still common (Piraino 2011).

Risk factors for peritonitis include older age (Nessim 2009; Oxtom 1994; Salusky 1997), depression (Troidle 2003), coexisting diseases such as diabetes (Chow 2005; Ghali 2011) and cardiovascular disease (McDonald 2004; Nolph 1987), obesity (McDonald 2004), connection methodology (Daly 2001), presence of a peritoneal catheter exit-site infection (Lloyd 2013; van Diepen 2012), and the presence of nasal carriage of *S. aureus* (Golper 1996; Mupirocin Study 1996; Perez-Fontan 1993; Schaefer 2003). Race is also an independent risk factor, with African-American, native Canadian and indigenous Australian Aborigines on PD being shown to be at increased risk (Farias 1994; Fine 1994; Golper 1996; Holley 1993; Lim 2005).

Description of the intervention

Different antimicrobial interventions are used at PD catheter insertion and on an ongoing basis to prevent peritonitis. These include intravenous antibiotics, oral antibiotics, topical antibiotics (Thodis 2000), topical disinfectants, prophylactic treatment of *S. aureus* nasal carriage primarily with intranasal antibiotic ointment (Piraino 2002), different exit-site dressing systems and antifungal prophylaxis. All of these strategies, particularly the use of antibiotic at catheter insertion and the cleansing and disinfection of the exit-site, are widely accepted, but practice patterns are variable and it is not clear which practices have most benefit (Piraino 2011; Van Biesen 2014). Studies on preventing PD-related infections are limited in number and quality (Piraino 2011). International guidelines differ in their recommendations on preventing PD-related infections, with some countries not having relevant guidelines (Table 1).

None of these interventions are free of risks or without cost. Antibiotic prophylaxis carries the risk of gastrointestinal toxicity and may be a cause of antibiotic resistance (Annigeri 2001;

Bernardini 1996); it may also be ineffective when patients already have resistance to some antibiotics. Care should be taken that any disinfectant used is at a concentration that is non-cytotoxic (Piraino 2011).

How the intervention might work

For a patient to be able to successfully use PD as a dialysis therapy, PD-related infections (exit-site infections, tunnel infections and peritonitis) need to be avoided. The most important infection is peritonitis and a number of prophylactic strategies have been employed to limit its occurrence. Bacteria are known to be able to gain entry to the peritoneum in a variety of ways and hence, various strategies have been used to prevent this occurring (Campbell 2015).

Oral antibiotics

Oral antibiotics such as rifampin have been given as prophylaxis to PD patients to reduce catheter infections and peritonitis due to *S. aureus* (Bernardini 1996; Zimmerman 1991). This organism is a major cause of PD catheter infections which can result in *S. aureus* peritonitis and catheter removal. *S. aureus* nasal carriage is known to be a significant risk factor for *S. aureus* PD-related infections (Bernardini 1996). Cyclic oral rifampin is superior to placebo in preventing *S. aureus* infections. Other oral antibiotics used include ofloxacin (Sesso 1994), cephalexin (Low 1980), and trimethoprim/sulphamethoxazole (Churchill 1988).

Topical antibiotics

Topical antibiotics such as mupirocin have been applied to the exit site once daily because this antibiotic has good activity against gram-positive organisms such as staphylococci and streptococci, which are a common cause of exit-site infection and peritonitis in PD patients (Keane 2000; Troidle 1998; Ward 1986). However, mupirocin is less active against most gram-negative bacilli and anaerobes (Sutherland 1985). Sodium fusidate ointment (2%) has also been applied to the exit site at one-month intervals and is known to have activity against staphylococci (Sesso 1994). Gentamicin cream is active against both gram-positive and gram-negative organisms and has been used long term on a once-daily basis at the exit site as prophylaxis for exit-site infection (Bernardini 2005; Chu 2008). Gentamicin is active against both *S. aureus* and *P. aeruginosa*, two important causes of exit-site infection (Bernardini 2005). Polysporin triple ointment (P3) consists of bacitracin/gramicidin/polymyxin and has bacteriostatic activity against a wide range of skin flora and other organisms including gram-negative bacteria (MP3 Study 2008).

Nasal antibiotic prophylaxis

Various antibiotic treatments have been trialled in attempts to eliminate *S. aureus* nasal carriage in PD patients. The nasal carriage of *S. aureus* is a well-recognised risk factor for the development of *S. aureus* infections in CAPD patients (Davies 1989; Luzar 1990; Piraino 1990). Neomycin sulphate ointment has been used prophylactically. Mupirocin has also been used to eliminate nasal *S. aureus*. While mupirocin is effective at reducing *S. aureus* nasal carriage rates, re-colonisation frequently occurs. Sodium fusidate ointment (2%) has also been used and is effective at reducing *S. aureus* nasal carriage rates (Sesso 1994).

Pre/peri-operative intravenous antibiotic prophylaxis

The administration of intravenous antibiotics at catheter insertion has been trialled in order to determine if this practice reduces the risk of post-operative peritonitis or exit-site infection after PD catheter insertion. Although the insertion of a PD catheter involves "clean surgery involving the placement of a prosthesis or implant", there is the potential for contamination of the peritoneum with micro-organisms from the patient's own body during surgery. Hence, the giving of a single dose of antibiotic prophylaxis intravenously on starting anaesthesia is recommended (Collier 2008).

Topical disinfectants of the exit site

Topical disinfectants have been applied to the exit site for many years, in an attempt to reduce the bacterial load around the exit site. It has been shown that PD patients with a history of an exit-site infection have twice the risk of experiencing a peritonitis episode (Canadian CAPD Clinical Trials Group 1989) so it is important to keep the exit-site infection-free. Povidone iodine ointment is a broad spectrum antiseptic ointment that has been used and has minimal adverse events associated with its use (Waite 1997). Povidone iodine solution (20g/L) has also been used and shown to successfully reduce the number of exit-site infections (Luzar 1990). Other antiseptic agents such as hydrogen peroxide, sodium hypochlorite and chlorhexidine have been used (Piraino 2011). The daily use of antibacterial honey at the exit site was trialled in the HONEYPOT Study 2009. This agent was used because it does not induce antimicrobial resistance and has been shown to be active against a broad range of bacteria and fungi (Cho 2014).

Dressing systems for exit sites

A number of exit-site dressing systems have been devised, all with the aim of reducing exit-site/tunnel infection and any subsequent peritonitis. The agents used include topical disinfectants and different dressing types and require more or less frequent removal. More frequent removal is seen to risk damaging the skin around the exit site and less frequent removal is felt to possibly encourage the growth of anaerobes. The concentration of topical disinfectants used need to be at non-cytotoxic levels.

Silver ring system on catheter

The addition of a silver ring device mounted onto the PD catheter was trialled by German researchers in the 1990s (SIPROCE Study 1997). The silver ring was used because of the antimicrobial properties of silver. The use of silver-coated catheters in animals had shown a reduction in infectious events (Dasgupta 1994; Fung 1996) and offered a non-pharmaceutical approach to reducing PD catheter-related infections.

Antistaphylococcal vaccine

An antistaphylococcal vaccine was trialled in the 1990s for the purpose of immunising patients with an anti-staphylococcal agent. The expectation was that the vaccine would promote a significant increase in the dialysate level of specific antibodies against *S. aureus* and that this would lead to reduced peritonitis and exit-site/tunnel infection rates (Poole-Warren 1991).

Antifungal agents

Antifungal prophylaxis to prevent fungal peritonitis when a PD patient receives an antibiotic course is based on the fact that most

episodes of fungal peritonitis are preceded by courses of antibiotics (Piraino 2011). Patients receiving prolonged or repeated antibiotic courses are at increased risk of fungal peritonitis, mostly due to *Candida* spp. The co-administration of an oral antifungal agent with an antibiotic course has been trialled to determine if this practice reduces the risk of fungal peritonitis (Lo 1996; Restrepo 2010).

Why it is important to do this review

The aim of this update was to include any new studies of antimicrobial interventions designed to prevent peritonitis in PD patients that have been published since the original review was published in 2004. We also aim to provide a critical appraisal of the current available evidence. As peritonitis is a significant problem for patients using PD, frequently leading to morbidity and technique failure and sometimes to mortality, we have updated the review.

OBJECTIVES

To evaluate the benefits and harms of antimicrobial strategies used to prevent peritonitis in PD patients.

METHODS

Criteria for considering studies for this review

Types of studies

We included randomised controlled trials (RCTs) and quasi-RCTs (studies in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) in which antimicrobial interventions designed to prevent peritonitis were compared in patients on PD.

Types of participants

We included adults and children with ESKD who were undergoing PD treatment.

Types of interventions

We included studies involving the use of any antimicrobial agent, whether the interventions were tested between themselves (head-to-head) or against placebo/no treatment. The inclusion criteria have been expanded in this update, with the intervention "oral antibiotics" becoming "oral or topical or intraperitoneal antibiotics" and with the interventions "dressing systems for exit sites" and "silver ring system on catheter" being added.

Specifically, the following antimicrobial interventions were analysed.

- Oral or topical or intraperitoneal antibiotics
- Nasal antibiotic prophylaxis (mupirocin, rifampicin, other)
- Pre/peri-operative intravenous antibiotic prophylaxis
- Topical disinfectants of the exit-site (povidone-iodine, chlorhexidine, triclosan, soap and water, other)
- Germicidal systems for connection devices
- Dressing systems for exit sites
- Silver ring system on catheter
- Antistaphylococcal vaccine
- Antifungal agents

Types of outcome measures

- Peritonitis-number of patients with peritonitis and peritonitis rate (peritonitis defined as dialysate count of > 100 cells/mm³ with $> 50\%$ being polymorphonuclear leukocytes; peritonitis rate defined as number of episodes of peritonitis over total patient months on PD)
- Peritonitis relapse (reoccurrence of peritonitis due to the same organism within two to four weeks)
- Death due to peritonitis
- All-cause mortality
- Exit-site and tunnel infection-number of patients with exit-site and tunnel infections and exit-site and tunnel infection rate
- Catheter removal/catheter replacement
- Technique failure (transfer from PD to haemodialysis/transplant due to peritonitis)
- Toxicity of antimicrobial treatments (nasal irritation, sneezing, generalised pruritus, headache, diarrhoea, nausea, vomiting, jaundice, local irritation, rash)
- Time to first peritonitis episode

Primary outcomes

- Peritonitis
- Exit-site infection/tunnel infection
- Catheter removal/catheter replacement

Secondary outcomes

- Peritonitis relapse
- Death due to peritonitis
- All-cause mortality
- Technique failure
- Toxicity of antimicrobial treatments
- Time to first peritonitis episode

Search methods for identification of studies

Electronic searches

We searched the [Cochrane Kidney and Transplant Specialised Register](#) to 4 October 2016 through contact with the Information Specialist using search terms relevant to this review. The Cochrane Kidney and Transplant Specialised Register contains studies identified from the following sources.

1. Monthly searches of the Cochrane Central Register of Controlled Trials CENTRAL
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals & the proceedings of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney journals
6. Searches of the International Clinical Trials Register (ICTRP) Search Portal & ClinicalTrials.gov.

Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of [Cochrane Kidney and Transplant](#). Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the

Specialised Register section of information about [Cochrane Kidney and Transplant](#).

See [Appendix 1](#) for search terms used in strategies for this review.

Searching other resources

1. Reference lists of review articles, relevant studies and clinical practice guidelines.
2. Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies.

Data collection and analysis

Selection of studies

The search strategy described was used to obtain titles and abstracts of studies that were potentially relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable. However, studies and reviews that might include relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts and where necessary, the full text of these studies, to determine which satisfied the inclusion criteria.

Data extraction and management

Data extraction and assessment of the risk of bias were performed independently by the same authors using standardised data extraction forms. Studies reported in non-English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions, these data were used. Any discrepancy between published versions was highlighted. Any further information required from the original author was requested by written correspondence and any relevant information obtained in this manner was included in the review.

Assessment of risk of bias in included studies

The following items were assessed using the risk of bias assessment tool ([Higgins 2011](#)) (see [Appendix 2](#)).

- Was there adequate sequence generation (selection bias)?
- Was allocation adequately concealed (selection bias)?
- Was knowledge of the allocated interventions adequately prevented during the study?
 - * Participants and personnel (performance bias)
 - * Outcome assessors (detection bias)
- Were incomplete outcome data adequately addressed (attrition bias)?
- Are reports of the study free of suggestion of selective outcome reporting (reporting bias)?
- Was the study apparently free of other problems that could put it at a risk of bias?

Measures of treatment effect

For dichotomous outcomes (peritonitis (number), peritonitis (rate), death due to peritonitis, all-cause mortality, exit-site/tunnel infection (number), exit-site/tunnel infection (rate), catheter removal/replacement, technique failure, toxicity of antimicrobial

treatments) results were expressed as risk ratios (RR) with 95% confidence intervals (CI). No continuous outcomes were identified.

Unit of analysis issues

Where data on the number of subjects with events (e.g. number of subjects with one or more episodes of peritonitis) were available, the RR was calculated as the ratio of the incidence of the event (one or more episodes) in the experimental treatment group over the incidence in the control group. Where data on the number of episodes were available the RR was calculated as the ratio of the rate of the outcome (e.g. the peritonitis rate) in the experimental treatment group (given by number of episodes of the outcome over total patient months on PD) over the rate in the control group.

Dealing with missing data

Where necessary, we contacted triallists to request missing patient data due to loss to follow-up and exclusion from study analyses in an effort to conduct intention-to-treat analyses. With the update, four authors responded to our requests. Where missing dichotomous data were few, and unlikely to affect the overall results, we analysed available data.

Assessment of heterogeneity

Heterogeneity was analysed using a Chi² test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (Higgins 2003). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity.

Assessment of reporting biases

The search strategy included searching major databases, conference proceedings and prospective trial registers without language restriction in an attempt to reduce publication bias related to failure of authors to publish negative results or inability to publish negative results in journals indexed in major databases. Insufficient studies were available to assess for publication bias using funnel plots. Where multiple publications of the same study were identified, data were included from the most recent publication, and preferably, the definitive publication. However, all publications were reviewed to identify outcomes not reported in the index publication in an attempt to reduce outcome reporting bias.

Data synthesis

Data were pooled using the random-effects model for dichotomous data.

Subgroup analysis and investigation of heterogeneity

Subgroup analysis was planned to explore potential sources of variability in observed treatment effect where possible (paediatric versus adult population, diabetic versus non-diabetic, time on PD before beginning of antimicrobial treatment). However, no subgroup analyses were performed due to lack of available data from the included studies.

Sensitivity analysis

Sensitivity analysis was planned to investigate the effect of year of study and study performance. However, there were insufficient studies to do this.

Summarising and interpreting results

We used the GRADE approach to assess the quality of evidence for each of the key outcomes (Guyatt 2008). We used the GRADE profiler to create 'Summary of Findings' tables (Schünemann 2011a).

For assessments of the overall quality of evidence for each outcome that included pooled data from RCTs, we downgraded the evidence from 'high quality' by one level for serious study limitations and by two levels for very serious study limitations. The evidence was appraised using the five GRADE considerations: risk of bias, imprecision of effect estimates, inconsistency, indirectness and potential publication bias. None were upgraded to moderate or high quality as most pooled estimates did not reveal a large magnitude of effect, there was potential for impact by confounders, and most did not show a strong dose-response gradient (Schünemann 2011b). The exception was the pooled estimate obtained for the comparison of the use of an antifungal agent versus placebo/no treatment for preventing fungal peritonitis, but the evidence was not upgraded from 'low' because only two studies contributed data for the outcome of fungal peritonitis and one of the studies had a high risk of bias. We used these assessments and the evidence for absolute benefit or harm of the interventions and the sum of available data on all important outcomes from each study included for each comparison, to arrive at conclusions about the effectiveness of antimicrobial agents at preventing catheter-related infection or the need for catheter removal/replacement in PD patients.

'Summary of Findings' tables consisted of the following clinically important outcomes identified in the selected studies:

- Peritonitis (number of patients with one or more episodes)
- Exit-site/tunnel infection (number of patients with one or more episodes)
- Catheter removal or replacement (number of patients)
- Fungal peritonitis (number of patients with one or more episodes).

RESULTS

Description of studies

See: [Characteristics of included studies](#); [Characteristics of excluded studies](#); [Characteristics of ongoing studies](#).

Results of the search

For this update we searched the Specialised Register to 4 October 2016 and identified 48 new reports. After full-text assessment 31 new studies were identified. Twenty new studies (33 reports) were included, 10 were excluded (14 reports), and one ongoing study was identified. We also identified four new reports of four existing included studies. Search results are shown in [Figure 1](#).

Figure 1. Study flow diagram.

Included studies

We included 39 studies in the review, 19 of which had been included in the original review. Of the 20 new studies, 10 had been published since the search was done for the previous review and 10 (Axelrod 1973; Cheng 1999a; Cocksedg 1993; Fuchs 1990; Moore 1989; Ryckelynck 1987; Sharma 1971; SIPROCE Study 1997; Wadhwa 1995; Wadhwa 1997) had not been identified in the previous search. There was one four-arm study (Swartz 1991), three three-arm studies (Fuchs 1990; Gadallah 2000c; Sesso 1994), and the remaining studies were two-arm studies. No cross-over studies were identified.

Of the 39 studies included (4435 randomised participants), all were parallel group studies. All participants were chronic PD patients treated in-centre or in satellite facilities. Two studies (Axelrod 1973;

Sharma 1971) reported the number of dialyses but not the number of participants in each group and hence, the data from these studies could not be added to the meta-analyses. Most studies included only adult patients; two studies (Blowey 1994; Mendoza-Guevara 2007) included only children and young adults on PD. Twenty-six studies (Bernardini 2005; Bernardini 1996; Chu 2008; Cocksedg 1993; Fuchs 1990; Gadallah 2000c; HONEYPOT Study 2009; Lo 1996; Luzar 1990; Lye 1992; MP3 Study 2008; Mupirocin Study 1996; Nolph 1985; Nunez-Moral 2014; Perez-Fontan 1992; Poole-Warren 1991; Restrepo 2010; Sesso 1994; SIPROCE Study 1997; Swartz 1991; Wadhwa 1995; Wadhwa 1997; Waite 1997; Wikdahl 1997; Wong 2003; Zimmerman 1991) identified the proportion of patients who had diabetes mellitus.

Most studies reported only some of the primary outcomes of interest to this review. The primary outcomes reported in the studies were as follows: peritonitis - number of patients (22 studies), peritonitis rate (14 studies), exit-site/tunnel infection - number of patients (22 studies), exit-site/tunnel infection - rate (12 studies) and catheter removal/replacement (15 studies). Other outcomes reported included death due to peritonitis (2 studies), all-cause mortality (13 studies), technique failure (3 studies) and toxicity of antimicrobial treatments (5 studies). No studies had data on peritonitis relapse and only two had time to first peritonitis episode (HONEYPOT Study 2009; MP3 Study 2008).

Three study authors responded to queries about study methods and/or requests for additional unpublished information (Chu 2008; Danguilan 2003; HONEYPOT Study 2009).

Oral or topical antibiotics versus placebo/no treatment

In seven studies (469 participants), patients were randomised to oral, or topical (exit site, nasal) or intraperitoneal prophylactic antibiotics versus placebo or no treatment (Blowey 1994; Churchill 1988; Low 1980; Sesso 1994; Swartz 1991; Wong 2003; Zimmerman 1991). The duration of follow-up ranged from one to 12 months.

Oral or topical antibiotics versus other antibiotic

Seven studies (640 participants) randomised patients to oral, or topical (exit site, nasal) or intraperitoneal antibiotics versus other antibiotics (Bernardini 1996; Bernardini 2005; Chu 2008; Danguilan 2003; MP3 Study 2008; Perez-Fontan 1992; Sesso 1994) with follow-up ranging from 7.8 to 18 months.

Nasal antibiotic prophylaxis versus placebo/no treatment

Three studies (338 participants) compared the use of nasal prophylactic antibiotics with placebo (Mupirocin Study 1996; Sesso 1994; Sit 2007). The duration of follow-up ranged from 7.8 to 18 months.

Pre/peri-operative antibiotic prophylaxis versus placebo/no treatment or other antibiotic

One study (178 participants) assessed the use of vancomycin with cefazolin as perioperative intravenous prophylaxis head-to-head (Gadallah 2000c), and four studies (379 patients) compared the use of perioperative intravenous antibiotic prophylaxis against no antibiotic treatment (Bennet-Jones 1988; Gadallah 2000c; Lye 1992; Wikdahl 1997). Follow-up periods ranged from 10 to 28 days.

Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant)

Nine studies (1039 participants) evaluated the effect of topical disinfectants versus standard care or other intervention at the exit site on a range of outcomes (Cheng 1999a; HONEYPOT Study 2009; Luzar 1990; Mendoza-Guevara 2007; Nunez-Moral 2014; Wadhwa 1995; Wadhwa 1997; Waite 1997; Wilson 1997). The duration of follow-up ranged from 6 to 24 months.

Other interventions

Other interventions included one study (167 participants) which compared the use of an ultraviolet germicidal chamber to disinfect the spike and the solution bag outlet port versus no treatment (Nolph 1985) while another study (50 participants) directed one group to soak their connectors in antiseptic before performing a bag exchange while the control group did not use antiseptic (Ryckelynck 1987). Three studies (140 participants) compared different dressing systems (Cocksedge 1993; Fuchs 1990; Moore 1989) and one study (195 participants) compared the addition of a silver ring device on the catheter versus no ring (SIPROCE Study 1997). One study (124 participants) compared the antistaphylococcal vaccine Staphypan Berna against placebo (Poole-Warren 1991).

Antifungal prophylaxis versus placebo/no treatment interventions

Two studies (817 participants) compared the administration of an antifungal agent with an antibiotic course against no treatment (Lo 1996; Restrepo 2010). Follow-up periods ranged from 1 to 18 months.

See Table 2 for comparisons included in Strippoli 2004a and this 2017 update.

Excluded studies

Twelve studies (17 reports) were excluded after full text review. The characteristics of the excluded studies are shown in "Characteristics of excluded studies". Reasons for excluding studies included focus of study was about treatment of PD-related infection not prevention, report was of a pharmacokinetics study, agent used in intervention was not an antimicrobial, and PD-related infection data was not readily available in the published report.

Risk of bias in included studies

The assessment of risk of bias is shown in Figure 2 and Figure 3. Figure 2 shows relative proportional rankings of studies for each risk of bias indicator. Figure 3 shows the risk of bias items for individual studies.

Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Axelrod 1973	+	+	+	+	-	-	-
Bennet-Jones 1988	+	+	+	+	+	-	?
Bernardini 1996	?	?	-	-	+	?	?
Bernardini 2005	+	+	+	+	+	+	+
Blowey 1994	?	?	-	-	+	?	?
Cheng 1999a	?	?	-	-	?	?	?
Chu 2008	-	-	-	-	-	?	?
Churchill 1988	+	+	+	+	+	-	-
Cocksedge 1993	?	?	-	-	?	-	?
Danguilan 2003	?	?	-	-	-	?	?
Fuchs 1990	?	?	-	-	+	-	?
Gadallah 2000c	-	-	-	-	+	?	?
HONEYPOT Study 2009	+	+	-	-	-	+	?
Lo 1996	-	-	-	-	+	-	?
Low 1980	+	+	+	+	+	?	+
Luzar 1990	+	+	-	-	+	?	-
Lye 1992	-	-	-	-	+	+	?
Mendoza-Guevara 2007	+	?	?	+	?	-	?
Moore 1989	-	-	-	-	?	-	?
MP3 Study 2008	+	+	+	+	+	+	+

Figure 3. (Continued)

MP3 Study 2008	+	+	+	+	+	+	+
Mupirocin Study 1996	?	?	?	?	+	+	-
Nolph 1985	+	+	-	-	-	-	-
Nunez-Moral 2014	+	?	?	?	+	?	?
Perez-Fontan 1992	+	?	?	?	+	?	?
Poole-Warren 1991	?	+	+	+	+	+	-
Restrepo 2010	+	?	?	?	?	?	?
Ryckelynck 1987	?	?	?	?	?	-	?
Sesso 1994	?	?	?	?	-	+	+
Sharma 1971	?	+	+	+	?	-	?
SIPROCE Study 1997	+	+	-	-	-	+	?
Sit 2007	+	?	?	?	+	?	?
Swartz 1991	+	?	?	?	+	-	?
Wadhwa 1995	?	?	?	?	?	+	?
Wadhwa 1997	?	?	?	?	?	+	?
Waite 1997	+	?	?	+	+	?	-
Wikdahl 1997	?	-	?	?	+	?	?
Wilson 1997	+	?	?	?	+	+	?
Wong 2003	?	?	?	?	+	+	?
Zimmerman 1991	+	?	-	-	-	?	-

Allocation

Randomisation of sequence generation was judged to be at low risk of bias in 19 studies (Axelrod 1973; Bennet-Jones 1988; Bernardini 2005; Churchill 1988; HONEYPOT Study 2009; Low 1980; Luzar 1990; Mendoza-Guevara 2007; MP3 Study 2008; Nolph 1985; Nunez-Moral 2014; Perez-Fontan 1992; Restrepo 2010; SIPROCE Study 1997; Sit 2007; Swartz 1991; Waite 1997; Wilson 1997; Zimmerman 1991). Randomisation method was unclear in 15 studies and was judged to be at high risk of bias in five studies (Chu 2008; Gadallah 2000c; Lo 1996; Lye 1992; Moore 1989).

Twelve studies reported allocation concealment adequately (Axelrod 1973; Bennet-Jones 1988; Bernardini 2005; Churchill 1988; HONEYPOT Study 2009; Low 1980; Luzar 1990; MP3 Study 2008; Nolph 1985; Poole-Warren 1991; Sharma 1971; SIPROCE Study 1997). Allocation concealment was unclear in 21 studies and six studies were judged to be at high risk of bias (Chu 2008; Gadallah 2000c; Lo 1996; Lye 1992; Moore 1989; Wikdahl 1997).

Blinding

Performance bias (blinding of participants and investigators) was judged to be at low risk of bias in eight studies (Axelrod 1973; Bennet-Jones 1988; Bernardini 2005; Churchill 1988; Low 1980; MP3 Study 2008; Poole-Warren 1991; Sharma 1971), was unclear in 15 studies, and was judged to be a high risk of bias in 16 studies (Bernardini 1996; Blowey 1994; Cheng 1999a; Chu 2008; Cocksedge 1993; Danguilan 2003; Fuchs 1990; Gadallah 2000c; HONEYPOT Study 2009; Lo 1996; Luzar 1990; Lye 1992; Moore 1989; Nolph 1985; SIPROCE Study 1997; Zimmerman 1991).

Detection bias (blinding of outcome assessors) was judged to be at low risk of bias in 10 studies (Axelrod 1973; Bennet-Jones 1988; Bernardini 2005; Churchill 1988; Low 1980; Mendoza-Guevara 2007; MP3 Study 2008; Poole-Warren 1991; Sharma 1971; Waite 1997), was unclear in 13 studies, and was judged to be at high risk of bias in 16 studies (Bernardini 1996; Blowey 1994; Cheng 1999a; Chu 2008; Cocksedge 1993; Danguilan 2003; Fuchs 1990; Gadallah 2000c; HONEYPOT Study 2009; Lo 1996; Luzar 1990; Lye 1992; Moore 1989; Nolph 1985; SIPROCE Study 1997; Zimmerman 1991).

Incomplete outcome data

Outcomes data reporting was considered to be complete with a low risk of bias in 22 studies (Bennet-Jones 1988; Bernardini 1996; Bernardini 2005; Blowey 1994; Churchill 1988; Fuchs 1990; Gadallah 2000c; Lo 1996; Low 1980; Luzar 1990; Lye 1992; MP3 Study 2008; Mupirocin Study 1996; Nunez-Moral 2014; Perez-Fontan 1992; Poole-Warren 1991; Sit 2007; Swartz 1991; Waite 1997; Wikdahl 1997; Wilson 1997; Wong 2003). Eight studies (Axelrod 1973; Chu 2008; Danguilan 2003; HONEYPOT Study 2009; Nolph 1985; Sesso 1994; SIPROCE Study 1997; Zimmerman 1991) reported that from 9.2% to 77.7% of patients were excluded from analyses, so were considered to be at high risk of bias. The risk of bias was unclear in nine studies because there was insufficient information provided to determine if data from all patients who entered the study were included in the analysis.

Selective reporting

We identified 12 studies (Bernardini 2005; HONEYPOT Study 2009; Lye 1992; MP3 Study 2008; Mupirocin Study 1996; Poole-Warren 1991; Sesso 1994; SIPROCE Study 1997; Wadhwa 1995; Wadhwa 1997; Wilson 1997; Wong 2003) and reported all outcomes based on the protocols described in the study methods and could be meta-analysed. Twelve studies were judged to be at high risk of bias of reporting bias (Axelrod 1973; Bennet-Jones 1988; Churchill 1988; Cocksedg 1993; Fuchs 1990; Lo 1996; Mendoza-Guevara 2007; Moore 1989; Nolph 1985; Ryckelynck 1987; Sharma 1971; Swartz 1991) because only one of our primary outcomes could be meta-analysed; two studies reported outcomes incompletely so they could not be included in any of our meta-analyses (Axelrod 1973; Sharma 1971). Reporting bias was unclear for 15 studies because only two (of our three) primary outcomes were reported or could be meta-analysed.

Other potential sources of bias

Eight studies (Axelrod 1973; Churchill 1988; Luzar 1990; Mupirocin Study 1996; Nolph 1985; Poole-Warren 1991; SIPROCE Study 1997; Waite 1997; Zimmerman 1991) reported receiving monetary support from pharmaceutical companies; one study received combined funding from industry and government (HONEYPOT Study 2009) and was judged to be at unclear risk of bias. Four studies were judged to be at low risk of bias (Bernardini 2005; Low 1980; MP3 Study 2008; Sesso 1994) and the remaining 26 studies were judged unclear.

Effects of interventions

See: [Summary of findings for the main comparison](#) Oral or topical or intraperitoneal antibiotics versus placebo/no treatment for preventing peritonitis in peritoneal dialysis patients; [Summary of findings 2](#) Nasal antibiotics versus placebo/no treatment for preventing peritonitis in peritoneal dialysis patients; [Summary of findings 3](#) Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant) for preventing peritonitis in peritoneal dialysis patients; [Summary of findings 4](#) Antifungal versus placebo/no treatment for preventing peritonitis in peritoneal dialysis patients

See: [Summary of findings for the main comparison](#): Oral or topical or intraperitoneal antibiotics versus placebo/no treatment for preventing peritonitis in PD patients; [Summary of findings 2](#): Nasal antibiotics versus no treatment for preventing peritonitis

in PD patients; [Summary of findings 3](#): Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant) for preventing peritonitis in PD patients; [Summary of findings 4](#): Antifungal versus placebo/no treatment for preventing fungal peritonitis in PD patients.

In most studies, the primary outcomes were peritonitis (number of patients), peritonitis rate, exit-site/tunnel infection (number of patients), exit-site/tunnel infection rate, and catheter removal or replacement (number). Many studies only included one or two of these outcomes. Other outcomes included all-cause mortality, time to first catheter-related infection, hospitalisation, death due to catheter-related infection, technique failure, local pruritus/rash, and toxicity.

Oral or topical antibiotics versus placebo or no treatment

The oral antibiotic used was ofloxacin, cephalexin, rifampin or cotrimoxazole, and the topical antibiotic used was mupirocin ointment (exit site, nasal).

The use of oral or topical antibiotic prophylaxis had uncertain effects on the risk of peritonitis ([Analysis 1.1](#) (5 studies, 395 participants): RR 0.82, 95% CI 0.57 to 1.19). There was low to moderate heterogeneity across these studies ($I^2 = 33\%$). The risk of peritonitis outcome was assessed as low quality because of unclear or high risk of bias in 3 of 5 studies and because of wide confidence intervals in all 5 studies due to small patient numbers.

The two interventions also had uncertain effects on the peritonitis rate ([Analysis 1.2.1](#) (3 studies, 1440 patient-months): RR 0.68, 95% CI 0.40 to 1.14), the risk of exit-site and tunnel infection ([Analysis 1.3.1](#) (3 studies, 191 participants): RR 0.45, 95% CI 0.19 to 1.04), exit-site/tunnel infection rate ([Analysis 1.4.1](#) (2 studies, 939 patient-months): RR 0.42, 95% CI 0.17 to 1.05), risk of catheter removal or replacement ([Analysis 1.5.1](#) (5 studies, 395 participants): RR 0.82, 95% CI 0.46 to 1.46), and all-cause mortality ([Analysis 1.6.1](#) (4 studies, 201 participants): RR 0.88, 95% CI 0.41 to 1.89), with no significant heterogeneity across studies for any of these analyses ($I^2 = 0\%$).

The risk of exit-site/tunnel infection outcome was assessed as low quality because of unclear or high risk of bias in all 3 studies and because of wide confidence intervals in all 3 studies due to small patient numbers. The risk of catheter removal/replacement outcome was also assessed as low quality because of unclear or high risk of bias in 3 of 5 studies and because of wide confidence intervals in all 5 studies due to small patient numbers.

Oral or topical antibiotics versus other antibiotic

The use of antibiotic ointment prophylaxis (either sodium fusidate (exit site plus nasal) or mupirocin (exit site)) was compared with another antibiotic (oral ofloxacin, oral rifampin or gentamicin cream (exit site)) in four studies.

The interventions had uncertain effects on the risk of peritonitis ([Analysis 2.1](#) (4 studies, 314 participants): RR 1.28, 95% CI 0.89 to 1.84). There was low heterogeneity across these studies ($I^2 = 9\%$). Similarly, topical antibiotic prophylaxis (either mupirocin ointment (exit site), sodium fusidate ointment (exit site plus nasal) or mupirocin cream (exit site)) compared with other antibiotic (either sodium fusidate ointment (exit site), oral ofloxacin or gentamicin cream (exit site)) had uncertain effects on the risk of exit-site and

tunnel infection ([Analysis 2.3](#) (4 studies, 336 participants): RR 1.28, 95% CI 0.71 to 2.31). There was medium heterogeneity across these studies ($I^2 = 56\%$).

Nasal antibiotic prophylaxis versus placebo or no treatment

The use of nasal antibiotic prophylaxis had uncertain effects on the risk of peritonitis ([Analysis 3.1](#) (3 studies, 338 participants): RR 0.94, 95% CI 0.67 to 1.31), the peritonitis rate ([Analysis 3.2](#) (2 studies, 2797 patient-months): RR 0.67, 95% CI 0.16 to 2.77), the risk of exit-site and tunnel infection ([Analysis 3.3](#) (3 studies, 338 participants): RR 1.34, 95% CI 0.62 to 2.87), the exit-site and tunnel infection rate ([Analysis 3.4](#) (2 studies, 2796 patient-months): RR 0.91, 95% CI 0.29 to 2.92), and the number of patients with catheter removal or replacement ([Analysis 3.5](#) (2 studies, 289 participants): RR 0.92, 95% CI 0.48 to 1.78). There was no significant heterogeneity across the studies for any of these analyses. Although in 1 study, there was a significant reduction in the exit-site/tunnel infection rate when CAPD patients identified as *S. aureus* carriers (nasal) were treated with mupirocin ointment (nasal application, twice/day for 5 days, every 1 month), there were no significant differences with any of the other primary outcomes of interest ([Mupirocin Study 1996](#)).

The risk of peritonitis and the risk of exit-site/tunnel infection outcomes were assessed as low quality because of unclear or high risk of bias in all 3 studies and because of wide confidence intervals in all 3 studies due to small patient numbers. The risk of catheter removal/replacement was assessed as low quality because of unclear to high risk of bias in the 2 studies and because of wide confidence intervals in the 2 studies due to small patient numbers.

Pre- or peri-operative antibiotic prophylaxis versus placebo or no treatment or other antibiotic

Pre- or peri-operative intravenous antibiotic prophylaxis compared with no treatment may reduce the risk of early peritonitis (less than one month from catheter insertion) in one study ([Gadallah 2000c](#)) but there was no difference between the interventions in three other studies using different antibiotics ([Analysis 4.1](#) (4 studies, 379 participants). The single 3-arm study ([Gadallah 2000c](#)) compared vancomycin with placebo, cefazolin with placebo and vancomycin with cefazolin and found the risk of peritonitis was reduced by vancomycin compared with placebo ([Analysis 4.1.1](#) (1 study, 177 participants): RR 0.08, 95% CI 0.01 to 0.61) and by vancomycin compared with cefazolin ([Analysis 4.1.6](#) (1 study, 178 participants): RR 0.11, 95% CI 0.01 to 0.84); there was no difference between cefazolin compared with placebo. None of the antibiotic interventions made a difference to the risk of exit-site and tunnel infection ([Analysis 4.2](#) (4 studies, 379 participants). When outcomes at more than one month after catheter insertion were considered, there was no difference between the interventions for the risk of peritonitis or exit-site/tunnel infection.

Because each study used a different antibiotic intervention, it is not possible to comment on heterogeneity across the studies.

Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant)

Eight studies reported on the use of disinfectant at the exit site versus standard care or other active treatment. As the test for subgroup differences was not significant for any of our outcomes the total summary estimates are reported here.

Overall topical disinfectants versus standard care or other active treatment had uncertain effects on the risk of peritonitis ([Analysis 5.1](#) (6 studies, 853 participants): RR 0.83, 95% CI 0.65 to 1.06), exit-site/tunnel infection ([Analysis 5.2](#) (8 studies, 973 participants): RR 1.00, 95% CI 0.75 to 1.33), catheter removal or replacement ([Analysis 5.4](#) (7 studies, 852 participants): RR 0.89, 95% CI 0.57 to 1.38), and all-cause mortality ([Analysis 5.5](#) (4 studies, 697 participants): RR 0.88, 95% CI 0.53 to 1.44), with no significant heterogeneity across studies for any of these analyses.

The risk of peritonitis outcome was assessed as low quality because of unclear allocation concealment and blinding in four of six studies and imprecision due to the small number of patients and events in five of six studies. The risk of exit-site/tunnel infection outcome was assessed as low quality because of unclear allocation concealment and blinding in six of eight studies and imprecision due to the small number of patients and events in seven of eight studies. The risk of catheter removal/replacement outcome was assessed as low quality because of unclear allocation concealment and blinding in five of seven studies and imprecision due to the small number of patients and events in six of seven studies.

Other interventions

Seven studies reported on other interventions designed to reduce PD-related infections. There was no difference in the peritonitis rate with other interventions.

- Germicidal chamber for connection devices or soaking of the connector in antiseptic prior to bag exchange versus none ([Analysis 6.1](#) (2 studies, 1855 patient-months): RR 1.05, 95% CI 0.74 to 1.51)
- Staphypan Berna antistaphylococcal vaccine ([Analysis 9.1](#) (1 study, 1099 patient-months): RR 1.11, 95% CI 0.77 to 1.59). Staphypan Berna compared with placebo was also shown to make no difference to the exit-site and tunnel infection rate ([Analysis 9.2](#) (1 study, 1107 patient-months): RR 0.98, 95% CI 0.65 to 1.48).

Three studies (140 participants) reported on the use of different dressing systems. There was no difference between the comparisons for the number of patients with one or more episodes of exit-site/tunnel infection ([Analysis 7.1](#)) or the exit-site/tunnel infection rate ([Analysis 7.2](#) (1 study, 679 patient-months).

There was no difference between use of a silver ring on the PD catheter versus none for the risk of peritonitis ([Analysis 8.1](#) (1 study, 195 participants): RR 0.90, 95% CI 0.49 to 1.66), risk of exit-site/tunnel infection ([Analysis 8.2](#) (1 study, 195 participants): RR 1.26, 95% CI 0.84 to 1.90) or risk of catheter removal/replacement ([Analysis 8.3](#) (1 study, 195 participants): RR 1.26, 95% CI 0.35 to 4.56).

Antifungal prophylaxis versus placebo or no treatment

The use of antifungal agents (oral fluconazole or oral nystatin) compared with no antifungal agent being given when a patient receives a course of antibiotics for bacterial peritonitis were reported in 2 studies. The antifungal intervention may reduce the risk of fungal peritonitis ([Analysis 10.1](#) (2 studies, 817 participants): RR 0.28, 95% CI 0.12 to 0.63). There was low heterogeneity across the two studies for this analysis. The risk of fungal peritonitis outcome was assessed as low quality because of unclear risk of bias in 1 study and high risk of bias in 1 study and imprecision due

to the small number of events and patient numbers. One study of oral nystatin in PD patients who were receiving treatment for bacterial peritonitis showed a significant reduction in the rate of fungal peritonitis due to *Candida* spp. with nystatin prophylaxis (Analysis 10.2 (1 study, 6864 patient-months): RR 0.31, 95% CI 0.10 to 0.95).

Adverse effects

For the comparisons which included oral or topical antibiotics versus placebo/no treatment, two studies (86 participants) provided some information on adverse effects of therapy. They were reported in relation to the use of oral rifampin and sodium fusidate ointment (nasal and exit site). More patients reported adverse effects with oral rifampin therapy but the results did not achieve significance. Heterogeneity could not be determined (Analysis 1.8).

For the studies which included oral or topical antibiotics versus other antibiotic, three studies (419 participants) reported on adverse effects of therapy. The antibiotics used were applied daily/routinely to the exit site and included Polysporin triple ointment, gentamicin cream and cyclic oral rifampin against mupirocin ointment or cream. There were fewer patients who reported adverse effects with mupirocin but the result was not significantly different; nausea (Analysis 2.8.1 (1 study, 82 participants): RR 0.09, 95% CI 0.01 to 1.59); pruritus (Analysis 2.8.2 (2 studies, 337 participants): RR 0.65, 95% CI 0.29 to 1.49).

Three studies (289 participants) compared nasal antibiotics against placebo/no treatment and two of them reported information on adverse effects of therapy. The antibiotics used included mupirocin ointment (nasal) and sodium fusidate ointment (nasal and exit site) versus placebo ointment (nasal) or placebo tablets. More patients reported adverse effects with the antibiotic treatments (headache, diarrhoea, nausea, vomiting, pruritus, nasal irritation/rhinitis) but the results did not achieve significance. Heterogeneity could not be determined (Analysis 3.7).

For the studies which included topical disinfectant versus standard care or other active treatment at the exit site, four studies reported on adverse effects of therapy. The interventions that these reports related to were sodium hypochlorite solution, antibacterial honey and povidone iodine dry powder spray against povidone iodine solution, mupirocin ointment (nasal) or alcohol wipes. More patients reported adverse effects with use of the former agents and a statistically significant increase in pruritus occurred with topical disinfectants versus standard care (Analysis 5.7 (4 studies, 609 participants): RR 2.80, 95% CI 1.21 to 6.48; $I^2 = 44\%$). There was low heterogeneity of results.

Antibiotic resistance was not adequately reported in the included studies (Table 3).

Outcomes sought but not reported

Very few studies reported on peritonitis relapse, development of antibiotic resistance (topical use), hospitalisation due to PD-related infections or peritonitis, time to first peritonitis episode, technique failure (transfer from PD to haemodialysis/transplant due to peritonitis), or death due to peritonitis.

DISCUSSION

Summary of main results

We identified 39 studies that compared antimicrobial agents with placebo/no treatment or other antimicrobial agent or standard care in CKD patients on PD. A range of antimicrobial agents were found and studies using antibiotic prophylaxis showed wide variability regarding the dose and duration of the interventions trialled. The duration of studies ranged from 1 month to 8 years. The quality of the evidence for all of the findings listed below was low.

Key findings are as follows.

- The use of oral or topical antibiotic had uncertain effects on the risk of exit-site/tunnel infection and the risk of peritonitis.
- The topical administration of antibiotic ointment to the anterior nares of PD patients (sodium fusidate or mupirocin ointment) had uncertain effects on the risk of exit-site/tunnel infection and the risk of peritonitis.
- Pre/peri-operative intravenous vancomycin may reduce the risk of early peritonitis in the first few weeks (< 1 month) following Tenckhoff catheter insertion but has an uncertain effect on the risk of exit-site/tunnel infection. The comparisons using other antibiotics (i.e. IV gentamicin; IV cefazolin plus gentamicin; IV cefuroxime plus cefuroxime intraperitoneal) did not reduce the risk of peritonitis or exit-site/tunnel infection.
- The use of topical disinfectant had uncertain effects on the risk of exit-site/tunnel infection and the risk of peritonitis.
- Oral antifungal prophylaxis (fluconazole or nystatin) with each antibiotic course given to a PD patient may reduce the risk of fungal peritonitis.
- No intervention reduced the risk of catheter removal or replacement.

Oral or topical antibiotics versus placebo/no treatment, oral or topical antibiotics versus other antibiotic, nasal antibiotics versus placebo/no treatment, pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic, topical disinfectants versus standard care or other active treatment, germicidal chamber versus none, or silver ring system on catheter versus none had an effect on all-cause mortality. Neither oral or topical antibiotics versus other antibiotic nor topical disinfectants versus standard care or other active treatment had an effect on the risk of technique failure.

Heterogeneity among the studies was low except for the interventions oral or topical antibiotics versus placebo/no treatment and oral or topical antibiotics versus other antibiotic. Heterogeneity in the former comparison for the risk of peritonitis was 33% and was likely related to the variety of antibiotics used, the frequency of administration (daily, monthly, every three months), the route of administration (oral, topical) and the population studied (adults in Brazil, Canada, USA, Hong Kong). Heterogeneity in the latter comparison for the risk of exit-site/tunnel infection was 56% and was probably related to the range of antibiotics used, the frequency of administration (twice daily, daily, every 2 days, weekly), the route of administration (oral, topical) and the population studied (adults in the Philippines, Brazil, Hong Kong, USA).

Overall completeness and applicability of evidence

Twelve studies reported all three primary outcomes of interest and could be meta-analysed (peritonitis, exit-site/tunnel infection, catheter removal/replacement), 15 studies reported two primary outcomes of interest, and 12 studies reported on one primary outcome of interest; two studies reported all primary outcomes in a way that could not be meta-analysed (Axelrod 1973; Sharma 1971). Our meta-analyses identified that use of oral or topical antibiotics had uncertain effects on the risk of exit-site/tunnel infection and the risk of peritonitis and did not appear to affect the exit-site/tunnel infection rate, peritonitis rate, or the risk of catheter removal/replacement. It is unclear if the use of nasal mupirocin in identified nasal carriers of *S. aureus* reduces the risk of exit-site/tunnel infection or peritonitis. The use of pre/peri-operative IV antibiotics at PD catheter insertion may reduce the occurrence of early peritonitis (within 1 month of insertion) with vancomycin being the most effective antibiotic to use. The RR of 0.08 for the outcome of early peritonitis could be classified as clinically important, should it be confirmed with future studies. The use of topical disinfectant had uncertain effects on the risk of exit-site/tunnel infection and the risk of peritonitis. The co-administration of antifungal agents with an antibiotic course appears to reduce the risk of fungal peritonitis developing in a PD patient. The risk ratio of 0.28 for the outcome of fungal peritonitis could prove to be clinically important, should it be confirmed with future studies.

No RCT was found which had the comparison of routine courses of intranasal mupirocin versus daily exit-site mupirocin. Likewise, no RCT was found which compared *S. aureus* nasal carriage eradication at the time of PD catheter insertion versus no eradication of *S. aureus* nasal carriage. In addition, some outcomes were either not addressed (development of antibiotic resistance with topical use) or not often addressed (peritonitis relapse, hospitalisation rates due to PD-related infections or peritonitis, technique failure due to peritonitis). It should also be mentioned that for most comparisons there are only a few studies and small numbers of patients.

Quality of the evidence

Our review included 39 studies that involved 4374 patients; all were either on PD (CAPD, CCPD or APD) or were having surgery to insert the Tenckhoff catheter prior to commencing PD. Two studies had paediatric populations, two studies had a mix of adults and children, with the remainder having only adult patients. We found the quality of evidence for all outcomes to be of low quality mainly due to unclear or high risk of bias in a majority of studies and imprecise results because of small patient numbers and events. This means that further research is likely to have an important impact on our confidence in the estimates of effect and is likely to change those estimates.

Of the 39 included studies, four were available only as abstracts; 19 reported adequate sequence generation, and 12 had adequate allocation concealment. Hence, allocation concealment was either unclear or inadequate in two-thirds of the studies. Studies that do not have adequate allocation concealment are felt to be at increased risk of bias (Moher 1998; Schulz 1995). Eight studies reported adequate blinding of patients and personnel, and 10 studies reported adequate blinding of outcome assessment. Therefore, blinding methodology was either unclear or inadequate in three-quarters of the studies. We found that 22 studies provided

complete data reporting, and 12 reported all primary outcomes. Seven studies reported receiving some form of sponsorship from pharmaceutical companies, four studies reported complete or partial funding from an institute or government organisation, one study received funding from both pharmaceutical and a government organisation, and 27 studies did not report any funding source. In this review, we did not observe a difference between studies that were sponsored by pharmaceutical companies and those that were not. Of the eight pharma-sponsored/pharma plus government funded studies, five had adequate allocation concealment; of the four studies with partial or full funding from an institute/government organisation, three reported adequate allocation concealment; and of the 27 studies that did not report a funding source, only four demonstrated adequate allocation concealment. Likewise, in terms of selective outcome reporting, two of the eight pharma-sponsored/pharma plus government funded studies reported all of our primary outcomes; three of the four institute/ government-sponsored studies reported all our primary outcomes; and seven of the 27 studies without a declared funding source included all our primary outcomes.

For the comparison of oral or topical antibiotics versus placebo/no treatment, the variable quality of relevant studies and the small patient numbers, meant the quality of evidence was rated as low for the outcomes of peritonitis, exit-site/tunnel infection and catheter removal/replacement (Summary of findings for the main comparison). For the comparison of nasal antibiotics versus placebo/no treatment, the variable quality of relevant studies and the small patient numbers, reduced the quality of evidence to low for the outcomes of peritonitis, exit-site/tunnel infection and catheter removal/replacement (Summary of findings 2). With the comparison of topical disinfectants versus standard care or other active treatment, the unclear allocation in several studies and imprecision due to small patient numbers and events in several studies, meant the quality of evidence was rated as low for the outcomes of peritonitis, exit-site/tunnel infection and catheter removal/replacement (Summary of findings 3).

With the comparison of antifungal prophylaxis versus placebo/no treatment, the quality of evidence for the outcome of fungal peritonitis was considered to be low because of high risk of bias in one study and modest patient numbers and the limited number of studies reporting this outcome (Summary of findings 4).

Potential biases in the review process

Four of the 39 included studies were available only as abstracts but this was not considered a major source of bias. Since the original version of this review was published, the literature search has been run several times (up to 4 October 2016), to increase the chance that all eligible studies published before that time have been included. Although the Cochrane Kidney and Transplant Specialised Register includes references of reports of studies identified by handsearching resources including conference proceedings, it is a possibility that relevant studies may have been added since our last search of the register. Some outcomes were reported in only a few studies, which increased the risk of the non-randomised selection of patients for the intervention or control group in a study. For example, the outcome of fungal peritonitis was reported in two studies (817 patients), with one study finding a significant difference between the fungal prophylaxis and control groups, while the second study did not have this finding. In addition, adverse effects were reported in only five studies.

Agreements and disagreements with other studies or reviews

A systematic review was performed as part of the [HONEYPOT Study 2009](#) and was published in 2014 ([Johnson 2014](#)). The authors systematically reviewed studies of topical antimicrobial prophylaxis for prevention of infections in PD. Nine studies were identified using a search strategy that included electronic searches of MEDLINE (through Ovid) and the Cochrane Central Register of Controlled Trials. Our review included all of the studies included by [Johnson 2014](#), as well as two studies not reported in that review ([Chu 2008](#); [Danguilan 2003](#)). This review concluded that the evidence from the nine studies was inconclusive for nasal mupirocin, exit-site mupirocin and exit-site gentamicin prophylaxis. In the present review, we reached a similar conclusion, with some individual studies making a significant difference to the risk of exit-site/tunnel infection or the exit-site/tunnel infection rate but not having an effect on the other outcomes of peritonitis, catheter removal/replacement and technique failure.

The Renal Association (UK) guidelines currently recommend that "topical antibiotic administration be used to reduce the frequency of *S. aureus* and Gram-negative exit-site infection and peritonitis" ([Woodrow 2010](#)). The suggested antibiotics are mupirocin ointment or gentamicin cream (the latter for patients with a known history of *Pseudomonas* infections). The ISPD position statement on exit-site care to prevent peritonitis ([Piraino 2011](#)) states that "antibiotic protocols against *S. aureus* are effective in reducing the risk of *S. aureus* catheter infections" and that "all PD patients should use topical antibiotic either at the catheter exit-site or intranasally or both". The Kidney Health Australia-Caring for Australasians with Renal Impairment (KHA-CARI) guidelines ([Walker 2014](#)) recommend that "prophylactic therapy using mupirocin ointment be used, especially for *S. aureus* carriage (intranasally or at the exit site) to decrease the risk of *S. aureus* catheter exit-site/tunnel infections and peritonitis" and suggest that the "PD catheter exit site be cleaned daily and a topical antimicrobial agent (either mupirocin or gentamicin) be applied". This review found that the use of oral antibiotic or mupirocin ointment (at the exit site) may reduce the risk of exit-site/tunnel infection and the risk of peritonitis but was not seen to reduce the exit-site/tunnel infection rate, the peritonitis rate or the number of patients with catheter removal/replacement. The head-to-head comparison of application of mupirocin ointment or cream against gentamicin cream is based on two studies and shows that there is no difference between the effectiveness of mupirocin and gentamicin in terms of preventing exit-site/tunnel infection and peritonitis. It is unclear if the nasal application of mupirocin reduces the risk of exit-site/tunnel infection or the risk of peritonitis.

The Renal Association (UK) guidelines state it is "recommended that initial catheter insertion be accompanied by antibiotic prophylaxis" and refer to the RCT evidence supporting the use of vancomycin ([Figueiredo 2010](#); [Woodrow 2010](#)). The ISPD position statement says that "prophylactic antibiotics administered at the time of insertion decrease the infection risk. A first-generation cephalosporin or vancomycin can be used, but suggested each program should weigh the potential benefit against the risk of vancomycin use (development of resistant organisms)" ([Piraino 2011](#)). The KHA-CARI guidelines say it is "recommended that intravenous antibiotic prophylaxis be used prior to PD catheter insertion to reduce the risk of early peritonitis" and "vancomycin,

cephalosporins and gentamicin have demonstrated effectiveness in reducing the risk of peritonitis" ([Walker 2014](#)). The inclusion of first generation cephalosporins is based on extrapolations from the results of pre-operative antibiotic studies in patients without chronic kidney disease. However, our study indicates that the evidence supporting the use of first generation cephalosporins in PD patients undergoing Tenckhoff catheter insertion is scant. In the present review, we identified four RCTs of different pre-operative antibiotic prophylaxis regimens, including parenteral gentamicin, vancomycin, cephazolin and cefuroxime, with only two evaluating a first generation cephalosporin. One small study involving 50 PD patients found that cephazolin and gentamicin were no better than no treatment ([Lye 1992](#)). The largest of the studies (265 patients) showed that cephazolin was inferior to vancomycin in preventing post-operative catheter-associated infections (7% versus 1%, respectively; $P < 0.05$) ([Gadallah 2000c](#)). However, the recommendation to use a first generation cephalosporin or vancomycin is understandable because of the risk of selecting for resistant organisms such as vancomycin-resistant enterococci and *S. aureus* ([HICPAC 1995](#)) and the development of *Clostridium difficile* colitis ([Figueiredo 2010](#)). The postoperative incidence of peritonitis in the control arms of three of the evaluated studies were high, ranging from 14% to 46% ([Bennet-Jones 1988](#); [Gadallah 2000c](#); [Wikdahl 1997](#)) and the applicability of these data to PD units with lower infection rates following PD catheter insertion is unclear.

The ISPD position statement suggests "most episodes of fungal peritonitis are preceded by courses of antibiotics" and "fungal prophylaxis during antibiotic therapy may prevent some cases of *Candida* peritonitis in programs that have high rates of fungal peritonitis" ([Piraino 2011](#)). The KHA-CARI guidelines recommend "oral antifungal prophylaxis should be considered when antibiotics are administered to patients undergoing PD to reduce the risk of developing fungal peritonitis" ([Walker 2014](#)). This review indicates that fluconazole reduced the risk of fungal peritonitis following antibiotic treatment and that nystatin reduced the rate of *Candida* peritonitis in PD patients. The authors of the fluconazole study ([Restrepo 2010](#)) noted that a growing number of *Candida* strains were resistant to fluconazole during their study, and this would limit its use.

The ISPD no longer recommends that the exit site be regularly disinfected with antibacterial soap or a medical antiseptic to keep the exit site clean and reduce the numbers of resident bacteria. The current position statement states that "water and antibacterial soap are recommended by many centres. Use of an antiseptic to clean the exit site is preferred in some programs, but the agent must be non-cytotoxic" ([Piraino 2011](#)). The four studies in this review which compared the use of disinfectant against standard care did not show any benefit with the use of disinfectant (povidone-iodine 10% ointment; povidone-iodine 2.5% dry powder spray; povidone-iodine 20g/L solution; sodium hypochlorite 10% solution) compared with standard care (povidone-iodine 10% solution; alcohol chlorhexidine hand wash and use of alcohol wipes; non-disinfectant soap and water; pH neutral soap and water). Three of the studies did not report on adverse effects of the interventions and one study observed that skin rashes/pruritus occurred in 6% of patients following use of the povidone-iodine dry powder spray ([Wilson 1997](#)). The three studies in this review which looked at the use of disinfectant versus antibiotic or other disinfectant also did not show any benefit with the use of disinfectant (sodium hypochlorite 10% solution; sodium

hypochlorite 5% solution; antibacterial honey 10 mg) compared with antibiotic (2% mupirocin ointment) or other disinfectant (povidone iodine 10% solution). Adverse effects were reported in each of these studies. Sodium hypochlorite solution was associated with more irritation around the exit site than povidone iodine solution (Wadhwa 1995; Wadhwa 1997) and 5.9% of patients using antibacterial honey at the exit site in HONEYPOT Study 2009 reported local reaction as the reason for withdrawing from the study whereas no patients in the control group reported this adverse effect.

AUTHORS' CONCLUSIONS

Implications for practice

This update of a systematic review identified low quality evidence for the outcomes under consideration. Our findings are as follows.

- The use of oral or topical antibiotic had uncertain effects on the risk of exit-site/tunnel infection and the risk of peritonitis
- It is uncertain whether the use of nasal antibiotic reduces the risk of exit-site/tunnel infection or the risk of peritonitis
- The use of pre/perioperative intravenous vancomycin may reduce the risk of early peritonitis but has an uncertain effect on the risk of exit-site/tunnel infection
- The use of topical disinfectant has an uncertain effect on the risk of exit-site/tunnel infection and the risk of peritonitis
- Antifungal prophylaxis with oral nystatin/fluconazole may reduce the risk of fungal peritonitis occurring after a PD patient has had an antibiotic course.

Implications for research

Many of the studies included in this review have significant methodological limitations, including lack of statistical power, and potential for bias. Further large randomised studies with sufficiently long follow-up periods are required. These need to assess patient-important outcomes such as adverse effects of the

interventions given as well as quality of life. Studies need to be designed so they yield useful data on the key outcomes of exit-site/tunnel infection, peritonitis, catheter loss/replacement, and technique failure due to infection.

These studies should be large enough to enable subgroup analyses to determine which patients would benefit most from a prophylactic intervention and to clearly identify any harms associated with an intervention. There is a pressing need for more well-designed RCTs in this area, which adequately assess safety, as well as efficacy.

ACKNOWLEDGEMENTS

2004 review

We acknowledge the contribution of Drs Peter Wilson, Ignatius Fong, Gerald Coles and Cliff Holmes of the Mupirocin Study Group, David Churchill and Judy Bernardini, who responded to our queries about their studies. We are indebted to Dr R Russo and Dr R Curciolo of the University of Bari, Italy, who commented on the original project and provided useful background information. Particular thanks to Dr Paolo Strippoli, Head of the Nephrology Unit of Ospedale "A. Perrino", Brindisi, Italy, for his intellectual input in this manuscript with comments on the original project and final manuscript and providing abundant background information and advice. We acknowledge the contribution of Narelle Willis, Coordinator of the Cochrane Renal Group, who coordinated our activities throughout the project and edited the latest draft of this review.

2017 review

We would like to thank Drs Chu, Danguilan, Johnson, Jassal, Ayliffe and Selgas for their responses to our queries about their studies.

We would like to thank Dr E Hodson for her comments and feedback during the preparation of this updated review.

REFERENCES

References to studies included in this review

Axelrod 1973 {published data only}

Axelrod J, Meyers BR, Hirschman SZ, Stein R. Prophylaxis with cephalothin in peritoneal dialysis. *Archives of Internal Medicine* 1973;**132**(3):368-71. [MEDLINE: 4593192]

Bennet-Jones 1988 {published data only}

Bennet-Jones D, Martin J, Barratt AJ, Duffy TJ, Naish PF, Aber GM. Prophylactic gentamicin in the prevention of early exit-site infections and peritonitis in CAPD. *Advances in Peritoneal Dialysis* 1988;**4**:147-50. [CENTRAL: CN-00775909]

Bernardini 1996 {published data only}

Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. *American Journal of Kidney Diseases* 1996;**27**(5):695-700. [MEDLINE: 8629630]

Bernardini 2005 {published data only}

Bernardini J, Bender F, Florio T, Sloand J, Palmmontalbano L, Fried L, et al. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. *Journal of the American Society of Nephrology* 2005;**16**(2):539-45. [MEDLINE: 15625071]

Blowey 1994 {published data only}

Blowey DL, Warady BA, McFarland KS. Treatment of staphylococcus aureus nasal carriage in pediatric peritoneal dialysis patients. *Advances in Peritoneal Dialysis* 1994;**10**:297-9. [MEDLINE: 7999849]

Cheng 1999a {published data only}

Cheng YY, Ho YW, Chiu SW. Exit site care, an open labelled randomized prospective study comparing the use of povidone-iodine and chlorhexidine soap [abstract no: 6]. *Hong Kong Journal of Nephrology* 1999;**1**(1):A3.

Chu 2008 {published data only}

Chu KH, Choy WY, Cheung CC, Fung KS, Tang HL, Lee W, et al. A prospective study of the efficacy of local application of gentamicin versus mupirocin in the prevention of peritoneal dialysis catheter-related infections. *Peritoneal Dialysis International* 2008;**28**(5):505-8. [MEDLINE: 18708544]

Churchill 1988 {published data only}

Churchill DN, Oreopoulos DG, Taylor DW, Vas SI, Manuel MA, Wu G. Peritonitis in CAPD patients - a randomized clinical trial (RCT) of trimethoprim-sulfamethoxazole (TMP/SMX) prophylaxis [abstract]. *Kidney International* 1988;**33**(1):244. [CENTRAL: CN-00636126]

* Churchill DN, Taylor DW, Vas SI, Singer J, Beecroft ML, Wu G, et al. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients: a randomized clinical trial of cotrimoxazole prophylaxis. *Peritoneal Dialysis International* 1988;**8**(2):125-8. [EMBASE: 18252568]

Cocksedge 1993 {published data only}

Cocksedge B, Hunt D, Westerholm W, Heathcote K, Pollock C. Peritoneal dialysis catheter exit site care for the maintenance continuous ambulatory peritoneal dialysis (CAPD) patient: report of a randomised prospective study. *Renal Educator* 1993;**13**(1):4-6. [CENTRAL: CN-00626103]

Danguilan 2003 {published data only}

Danguilan RA, Evangelista LP, Abrenica MS, Rondilla SM. Comparative study of mupirocin and sodium fucidate in the prophylaxis of exit-site infections in CAPD patients. *Peritoneal Dialysis International* 2003;**23**(6):593-5. [MEDLINE: 14703203]

Fuchs 1990 {published data only}

Fuchs J, Gallagher ME, Jackson-Bey D, Krawtz D, Schreiber J. A prospective randomized study of peritoneal catheter exit-site care. *Dialysis & Transplantation* 1990;**19**(2):81-4. [EMBASE: 20066020]

Gadallah 2000c {published data only}

Gadallah MF, Ramdeen G, Mignone J, Patel D, Mitchell L, Tatro S. Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheters. *American Journal of Kidney Diseases* 2000;**36**(5):1014-9. [MEDLINE: 11054359]

* Gadallah MF, Ramdeen G, Torres C, Mignone J, Patel D, Mitchell L, et al. Preoperative vancomycin prophylaxis for newly placed peritoneal dialysis catheters prevents postoperative peritonitis. *Advances in Peritoneal Dialysis* 2000;**16**:199-203. [MEDLINE: 11045293]

HONEYPOT Study 2009 {published data only}

Johnson DW, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, et al. Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial. *Lancet Infectious Diseases* 2014;**14**(1):23-30. [MEDLINE: 24119840]

Johnson DW, Clark C, Isbel NM, Hawley CM, Beller E, Cass A, et al. The HoneyPot study protocol: a randomized controlled trial of exit-site application of medihoney antibacterial wound gel for the prevention of catheter-associated infections in peritoneal dialysis patients. *Peritoneal Dialysis International* 2009;**29**(3):303-9. [MEDLINE: 19458303]

Pascoe EM, Lo S, Scaria A, Badve SV, Beller EM, Cass A, et al. The HONEYPOT randomized controlled trial statistical analysis plan. *Peritoneal Dialysis International* 2013;**33**(4):426-35. [MEDLINE: 23843589]

Zhang L, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, et al. Microbiological results of the HoneyPot study-secondary analysis of a randomised, controlled trial of exit site application of MEDIHONEY for the prevention of catheter-associated infections in PD patients [abstract]. *Nephrology* 2014;**19**(Suppl 4):30. [EMBASE: 71587829]

Zhang L, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, et al. The effect of exit-site antibacterial honey versus nasal mupirocin prophylaxis on the microbiology and outcomes

of peritoneal dialysis-associated peritonitis and exit-site infections: a sub-study of the Honeypot Trial. *Peritoneal Dialysis International* 2015;**35**(7):712-21. [MEDLINE: 26224790]

Lo 1996 {published data only}

Lo WK, Chan CY, Cheng SW, Poon JF, Chan DT, Cheng IK. A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis. *American Journal of Kidney Diseases* 1996;**28**(4):549-52. [MEDLINE: 8840945]

Low 1980 {published data only}

Low DE, Vas S, Oreopoulos DG, Manuel A, Saiphoo C, Finer C, et al. Randomized clinical trial of cephalexin in preventing peritonitis in patients on continuous ambulatory peritoneal dialysis [abstract]. *Kidney International* 1981;**19**(2):392.

Low DE, Vas SI, Oreopoulos DG, Manuel MA, Saiphoo MM, Finer C, et al. Prophylactic cephalexin ineffective in chronic ambulatory peritoneal dialysis. *Lancet* 1980;**2**(8197):753-4. [MEDLINE: 6106868]

Luzar 1990 {published data only}

Luzar MA, Brown CB, Balf D, Hill L, Issad B, Monnier B, et al. Exit-site care and exit-site infection in continuous ambulatory peritoneal dialysis (CAPD): results of a randomized multicenter trial. *Peritoneal Dialysis International* 1990;**10**(1):25-9. [MEDLINE: 2085577]

Lye 1992 {published data only}

Lye WC, Lee EJ, Tan CC. Prophylactic antibiotics in the insertion of Tenckhoff catheters. *Scandinavian Journal of Urology & Nephrology* 1992;**26**(2):177-80. [MEDLINE: 1626207]

* Lye WC, van der Straaten JC, Lee EJ. A prospective study on the use of prophylactic antibiotics for the implantation of tenckhoff catheters in CAPD patients [abstract]. 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel. 1993:343. [CENTRAL: CN-00626018]

Mendoza-Guevara 2007 {published data only}

Mendoza-Guevara L, Castro-Vazquez F, Aguilar-Kitsu A, Morales-Nava A, Rodriguez-Leyva F, Sanchez-Barbosa JL. Amuchina 10% solution, safe antiseptic for preventing infections of exit-site of Tenckhoff catheters, in the pediatric population of a dialysis program. *Contributions to Nephrology* 2007;**154**:139-44. [MEDLINE: 17099309]

Moore 1989 {published data only}

Moore C. A clinical study comparing a polyurethane dressing, blisterfilm, to standard gauze dressing on the tenckhoff catheter [abstract]. *ANNA Journal* 1989;**16**(2):105.

Moore CG. Comparison of Blisterfilm and gauze for peritoneal catheter exit site care. *ANNA Journal* 1989;**16**(7):475-8. [MEDLINE: 2604449]

MP3 Study 2008 {published data only}

Jassal SV, Lok CE, MP3 Study Group. A randomized controlled trial comparing mupirocin versus polysporin triple for the prevention of catheter-related infections in peritoneal dialysis

patients (the MP3 study). *Peritoneal Dialysis International* 2008;**28**(1):67-72. [MEDLINE: 18178950]

McQuillan RF, Chiu E, Nessim S, Lok CE, Roscoe JM, Tam P, et al. A randomized controlled trial comparing mupirocin and polysporin triple ointments in peritoneal dialysis patients: the MP3 Study. *Clinical Journal of the American Society of Nephrology: CJASN* 2012;**7**(2):297-303. [MEDLINE: 22134627]

van Diepen AT, Tomlinson GA, Jassal SV. The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN* 2012;**7**(8):1266-71. [MEDLINE: 22745277]

Mupirocin Study 1996 {published data only}

* Anonymous. Nasal mupirocin prevents staphylococcus aureus exit-site infection during peritoneal dialysis. Mupirocin Study Group. *Journal of the American Society of Nephrology* 1996;**7**(11):2403-8. [MEDLINE: 8959632]

Coles GA, Mupirocin Study Group. The effect of intranasal mupirocin on CAPD exit site infection (ESI) [abstract]. *Journal of the American Society of Nephrology* 1994;**5**(3):439. [CENTRAL: CN-00550592]

Davey P, Craig AM, Hau C, Malek M. Cost-effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomized placebo-controlled trial. *Journal of Antimicrobial Chemotherapy* 1999;**43**(1):105-12. [MEDLINE: 10381107]

Nolph 1985 {published data only}

Nolph KD, Prowant B, Serkes KD, Morgan LM. A randomized multicenter clinical trial to evaluate the effects of an ultraviolet germicidal system on peritonitis rate in continuous ambulatory peritoneal dialysis. *Peritoneal Dialysis Bulletin* 1985;**5**(1):19-24. [EMBASE: 15143789]

Nunez-Moral 2014 {published data only}

Nunez-Moral M, Sanchez-Alvarez E, Gonzalez-Diaz I, Pelaez-Requejo B, Fernandez-Vina A, Quintana-Fernandez A, et al. Exit-site infection of peritoneal catheter is reduced by the use of polyhexanide. results of a prospective randomized trial. *Peritoneal Dialysis International* 2014;**34**(3):271-7. [MEDLINE: 24497599]

Perez-Fontan 1992 {published data only}

Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Moncalian J, Femindez-Rivera C, Cao M, et al. Treatment of staphylococcus aureus nasal carriers in CAPD with mupirocin. *Advances in Peritoneal Dialysis* 1992;**8**:242-5. [MEDLINE: 1361797]

Poole-Warren 1991 {published data only}

Poole-Warren LA, Hallett MD, Hone PW, Burden SH, Farrell PC. Vaccination for prevention of CAPD associated staphylococcal infection: results of a prospective multicentre clinical trial. *Clinical Nephrology* 1991;**35**(5):198-206. [MEDLINE: 1855327]

Restrepo 2010 {published data only}

Restrepo C, Chacon J, Manjarres G. Fungal peritonitis in peritoneal dialysis patients: successful prophylaxis with

fluconazole, as demonstrated by prospective randomized control trial. [Erratum appears in *Perit Dial Int*. 2011 Mar-Apr;31(2):120]. *Peritoneal Dialysis International* 2010;**30**(6):619-25. [MEDLINE: 20634438]

Ryckelynck 1987 {published data only}

Ryckelynck JP, Verger C, Cam G, Faller B, Pierre D. A prospective study to evaluate the role of antiseptics in CAPD Y-line systems [abstract]. 24th Annual Congress. EDTA-ERA; 1987 Oct 25-29; West Berlin, Germany. 1987:161. [CENTRAL: CN-00644147]

Sesso 1994 {published data only}

Sesso R, Parisio K, Dalboni A, Rabelo T, Barbosa D, Cendoroglo M, et al. Effect of sodium fusidate and ofloxacin on staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. *Clinical Nephrology* 1994;**41**(6):370-6. [MEDLINE: 8076441]

Sesso R, Parisio K, Draibe S, Ajzen H. Effect of sodium fusidate and ofloxacin on staphylococcus aureus carriage and infection in patients on peritoneal dialysis (CAPD) [abstract]. *Journal of the American Society of Nephrology* 1993;**4**(Program & Abstracts):417. [CENTRAL: CN-00485819]

Sharma 1971 {published data only}

Sharma BK, Rodriguez H, Ghandi VC, Smith EC, Pillay VK, Dunea G. Trial of oral neomycin during peritoneal dialysis. *American Journal of the Medical Sciences* 1971;**262**(3):175-8. [MEDLINE: 4946828]

SIPROCE Study 1997 {published data only}

Pommer W. The efficiency of a silver ring to prevent exit-site and other catheter-related infections in PD-patients-final results of the SIPROCE study [abstract]. *Journal of the American Society of Nephrology* 1997;**8**:182A. [CENTRAL: CN-00447255]

* Pommer W, Brauner M, Westphale HJ, Brunkhorst R, Kramer R, Bundschu D, et al. Effect of a silver device in preventing catheter-related infections in peritoneal dialysis patients: silver ring prophylaxis at the catheter exit study. *American Journal of Kidney Diseases* 1998;**32**(5):752-60. [MEDLINE: 9820444]

SIPROCE Study. Efficiency of a silver ring in preventing exit-site infections in adult PD patients: results of the SIPROCE Study. Silver ring Prophylaxis of the Catheter Exit Site. *Advances in Peritoneal Dialysis* 1997;**13**:227-32. [MEDLINE: 9360688]

Sit 2007 {published data only}

Sit D, Kadiroglu AK, Kayabasi H, Yilmaz ME. Prophylactic intranasal mupirocin ointment in the treatment of peritonitis in continuous ambulatory peritoneal dialysis patients. *Advances in Therapy* 2007;**24**(2):387-93. [MEDLINE: 17565930]

Swartz 1991 {published data only}

Swartz R, Messana J, Starmann B, Weber M, Reynolds J. Preventing Staphylococcus aureus infection during chronic peritoneal dialysis. *Journal of the American Society of Nephrology* 1991;**2**(6):1085-91. [MEDLINE: 1777589]

Wadhwa 1995 {published data only}

Wadhwa NK, Suh H, Cabralda T, Stratos J, Cascio C, Irwin C, et al. A randomized trial of amuchina 10% versus povidone-iodine 10% solution for exit-site care/infection in peritoneal dialysis patients [abstract]. *Peritoneal Dialysis International* 1995;**15**(Suppl 1):S64.

Wadhwa 1997 {published data only}

Wadhwa NK, Suh H, Cabralda T. Amuchina 5% versus povidone-iodine 10% solution for exit-site care/infection in peritoneal dialysis patients [abstract]. *Peritoneal Dialysis International* 1997;**17**(Suppl 1):S46.

Waite 1997 {published data only}

Waite N, Webster N, Laurel M, Johnson M, Fong IW. The efficacy of exit site povidone-iodine ointment in the prevention of early peritoneal dialysis-related infections. *American Journal of Kidney Diseases* 1997;**29**(5):763-8. [MEDLINE: 9159313]

Wikdahl 1997 {published data only}

Wikdahl AM, Engman U, Stegmayr BJ, Sorenson JG. One-dose cefuroxime i.v. and i.p. reduces microbial growth in PD patients after catheter insertion. *Nephrology Dialysis Transplantation* 1997;**12**(1):157-60. [MEDLINE: 9027792]

Wilson 1997 {published data only}

Wilson AP, Lewis C, O'Sullivan HO, Shetty N, Neild GH, Mansell M. The use of povidone iodine in exit site care for patients undergoing continuous peritoneal dialysis (CAPD). *Journal of Hospital Infection* 1997;**35**(4):287-93. [MEDLINE: 9152821]

Wong 2003 {published data only}

Wong SS, Chu KH, Cheuk A, Tsang WK, Fung SK, Chan HW, et al. Prophylaxis against gram-positive organisms causing exit-site infection and peritonitis in continuous ambulatory peritoneal dialysis patients by applying mupirocin ointment at the catheter exit site. *Peritoneal Dialysis International* 2003;**23** Suppl 2:S153-8. [MEDLINE: 17986538]

Zimmerman 1991 {published data only}

* Zimmerman SW, Ahrens E, Johnson CA, Craig W, Leggett J, O'Brien M, et al. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. *American Journal of Kidney Diseases* 1991;**18**(2):225-31. [MEDLINE: 1867179]

Zimmerman SW, Ahrens E, Johnson CA, Craig W, Leggett J, O'Brien M, et al. Randomized, controlled trial of prophylactic rifampin (RIF) for PD catheter-related infections (CRI) and peritonitis (P) [abstract]. *Kidney International* 1990;**37**(1):335.

References to studies excluded from this review

Cavdar 2004 {published data only}

Cavdar C, Saglam F, Sifil A, Celik A, Atay T, Gungor O, et al. Effect of once-a-week vs thrice-a-week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: three years of experience. *Renal Failure* 2008;**30**(4):417-22. [MEDLINE: 18569916]

Cavdar C, Zeybel M, Atay T, Sifil A, Sanlidag C, Gulay Z, et al. The effects of once- or thrice-weekly mupirocin application on mupirocin resistance in patients on continuous ambulatory peritoneal dialysis--first 6 months' experience. *Advances in Peritoneal Dialysis* 2004;**20**:62-6. [MEDLINE: 15384797]

Churchill 1989 {published data only}

Churchill DN, Canadian CAPD Clinical Trials Group. Randomized clinical trial (RCT) comparing peritonitis rates among new CAPD patients using the Y set disinfectant system (Y) to standard systems (S) [abstract]. *Kidney International* 1989;**35**(1):268. [CENTRAL: CN-00602155]

Churchill DN, Taylor DW, Vas SI, Oreopoulos DG, Bettcher KB, Fenton SA, et al. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multi-centre randomized clinical trial comparing the Y connector disinfectant system to standard systems. *Peritoneal Dialysis International* 1989;**9**(3):159-63. [MEDLINE: 2488361]

Crabtree 2003 {published data only}

Crabtree JH, Burchette RJ, Siddiqi RA, Huen IT, Hadnott LL, Fishman A. The efficacy of silver-ion implanted catheters in reducing peritoneal dialysis-related infections. *Peritoneal Dialysis International* 2003;**23**(4):368-74. [MEDLINE: 12968845]

de Fijter 1992a {published data only}

de Fijter CW, Biemond A, Oe LP, Moesker HL, Verhoef J, Donker AJ, et al. Pharmacokinetics of ciprofloxacin after intraperitoneal administration in uninfected patients undergoing CCPD. *Advances in Peritoneal Dialysis* 1992;**8**:18-21. [MEDLINE: 1361781]

Gadallah 2000 {published data only}

Gadallah MF, Tamayo A, Sandborn M, Ramdeen G, Moles K. Role of intraperitoneal urokinase in acute peritonitis and prevention of catheter loss in peritoneal dialysis patients. *Advances in Peritoneal Dialysis* 2000;**16**:233-6. [MEDLINE: 11045301]

Maiorca 1983 {published data only}

Maiorca R, Cantaluppi A, Cancarini GC, Scalomogna A, Broccoli R, Graziani G, et al. Prospective controlled trial of a Y-connector and disinfectant to prevent peritonitis in continuous ambulatory peritoneal dialysis. *Lancet* 1983;**2**(8351):642-4. [MEDLINE: 6136794]

Maiorca R, Cantaluppi A, Cancarini GC, Scalomogna A, Strada A, Graziani G, et al. 'Y' connector system for prevention of peritonitis in CAPD: a controlled study. *Proceedings of the European Dialysis & Transplant Association* 1983;**20**:223-9. [MEDLINE: 6361737]

Naylor 1997 {published data only}

Naylor M, Roe B. A study of the efficacy of dressings in preventing infections of continuous ambulatory peritoneal dialysis catheter exit sites. *Journal of Clinical Nursing* 1997;**6**(1):17-24. [MEDLINE: 9052106]

Oh 2000 {published data only}

Klaus G, van Baum H, Wuhl E, Schaefer F, European Pediatric Peritoneal Dialysis Study Group (EPPS). Efficacy of Mupirocin prophylaxis in reducing the incidence of peritoneal dialysis

(PD)-related Staphylococcus aureus infections in children on chronic PD: results of a double blind, placebo-controlled trial [abstract]. *Peritoneal Dialysis International* 2002;**22**(1):149. [CENTRAL: CN-00401508]

Oh J, von Baum H, Klaus G, Schaefer F. Nasal carriage of staphylococcus aureus in families of children on peritoneal dialysis. European Pediatric Peritoneal Dialysis Study Group (EPPS). *Advances in Peritoneal Dialysis* 2000;**16**:324-7. [MEDLINE: 11045321]

Plum 1997a {published data only}

Artic S, Busch T, Sahin K, Grabensee B, Plum J. Oral versus intraperitoneal application of clindamycin in tunnel infections: a prospective, randomized study in CAPD patients [abstract]. *Journal of the American Society of Nephrology* 1997;**8**(Program & Abstracts):260A-1A.

* Plum J, Artic S, Busch T, Sahin K, Grabensee B. Oral versus intraperitoneal application of clindamycin in tunnel infections: a prospective, randomized study in CAPD patients. *Peritoneal Dialysis International* 1997;**17**(5):486-92. [MEDLINE: 9358531]

Rodriguez-Perez 1989 {published data only}

Rodriguez-Perez JC, Vega N, Plaza C, Fernandez A, Hortal L, Palop L. Prospective randomized trial with the use of antibiotic bonding to peritoneal catheters. A method to reduce tunnel and exit site infection in CAPD patients [abstract]. *Kidney International* 1989;**36**(1):154.

Thomae 1982 {published data only}

Thomae U, Boos W, Adam D. Transperitoneal resorption of ampicillin, cefuroxim and gentamicin in continuous ambulatory peritoneal dialysis [Transperitoneale resorption von ampicillin, cefuroxim und gentamicin unter kontinuierlicher ambulanter peritonealdialyse]. *Medizinische Welt* 1982;**33**(5):182-4. [MEDLINE: 7070273]

Trooskin 1990 {published data only}

Trooskin SZ, Harvey RA, Lennard TW, Greco RS. Failure of demonstrated clinical efficacy of antibiotic-bonded continuous ambulatory peritoneal dialysis (CAPD) catheters. *Peritoneal Dialysis International* 1990;**10**(1):57-9. [MEDLINE: 2085584]

References to ongoing studies

NCT02547103 {published data only}

Ruengorn C. Efficacy and safety of local application of chlorhexidine gluconate versus mupirocin ointment in the prevention of peritoneal dialysis-related infection: a pilot study, double-blind, stratified randomized controlled trial. www.clinicaltrials.gov/ct2/show/NCT02547103 (accessed 28 December 2016).

Additional references

Annigeri 2001

Annigeri R, Conly J, Vas S, Dedier H, Prakashan K P, Bargman JM, et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin

prophylaxis to prevent exit-site infection. *Peritoneal Dialysis International* 2001;**21**(6):554-9. [MEDLINE: 11783763]

Campbell 2015

Campbell DJ, Johnson DW, Mudge DW, Gallagher MP, Craig JC. Prevention of peritoneal dialysis-related infections. *Nephrology Dialysis Transplantation* 2015;**30**(9):1461-72. [MEDLINE: 25294849]

Canadian CAPD Clinical Trials Group 1989

Anonymous. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multi-centre randomized clinical trial comparing the Y connector disinfectant system to standard systems. Canadian CAPD Clinical Trials Group. *Peritoneal Dialysis International* 1989;**9**(3):159-63. [MEDLINE: 2488361]

Cho 2014

Cho Y, Johnson DW. Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. *American Journal of Kidney Diseases* 2014;**64**(2):278-89. [MEDLINE: 24751170]

Choi 2004

Choi P, Nemati E, Banerjee A, Preston E, Levy J, Brown E. Peritoneal dialysis catheter removal for acute peritonitis: a retrospective analysis of factors associated with catheter removal and prolonged postoperative hospitalization. *American Journal of Kidney Diseases* 2004;**43**(1):103-11. [MEDLINE: 14712433]

Chow 2005

Chow KM, Szeto CC, Leung CB, Kwan BC, Law MC, Li PK. A risk analysis of continuous ambulatory peritoneal dialysis-related peritonitis. *Peritoneal Dialysis International* 2005;**25**(4):374-9. [MEDLINE: 16022095]

Churchill 1997

Churchill DN, Thorpe KE, Vonesh EF, Keshaviah PR. Lower probability of patient survival with continuous peritoneal dialysis in the United States compared with Canada. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. *Journal of the American Society of Nephrology* 1997;**8**(6):965-71. [MEDLINE: 9189865]

Collier 2008

Collier M, Evans D, Farrington M, Gibbs E, Gould K, Jenkinson H, et al. Surgical site infection: prevention and treatment. Clinical guideline [CG74], 2008. www.nice.org.uk/guidance/cg74 (accessed 28 December 2016):1-31.

Daly 2001

Daly CD, Campbell MK, MacLeod AM, Cody DJ, Vale LD, Grant AM, et al. Do the Y-set and double-bag systems reduce the incidence of CAPD peritonitis? A systematic review of randomized controlled trials. *Nephrology Dialysis Transplantation* 2001;**16**(2):341-7. [MEDLINE: 11158410]

Dasgupta 1994

Dasgupta MK. Silver peritoneal catheters reduce bacterial colonization. *Advances in Peritoneal Dialysis* 1994;**10**:195-8. [MEDLINE: 7999826]

Davies 1989

Davies SJ, Ogg CS, Cameron JS, Poston S, Noble WC. Staphylococcus aureus nasal carriage, exit-site infection and catheter loss in patients treated with continuous ambulatory peritoneal dialysis (CAPD). *Peritoneal Dialysis International* 1989;**9**(1):61-4. [MEDLINE: 2488184]

Digenis 1990

Digenis GE, Abraham G, Savin E, Blake P, Dombros N, Sombolos K, et al. Peritonitis-related deaths in continuous ambulatory peritoneal dialysis (CAPD) patients. *Peritoneal Dialysis International* 1990;**10**(1):45-7. [MEDLINE: 2085582]

Farias 1994

Farias MG, Soucie JM, McClellan W, Mitch WE. Race and the risk of peritonitis: an analysis of factors associated with the initial episode. *Kidney International* 1994;**46**(5):1392-6. [MEDLINE: 7853799]

Figueiredo 2010

Figueiredo A, Goh BL, Jenkins S, Johnson DW, Mactier R, Ramalakshmi S, et al. Clinical practice guidelines for peritoneal access. *Peritoneal Dialysis International*. 2010; Vol. 30, issue 4:424-9. [MEDLINE: 20628103]

Fine 1994

Fine A, Cox D, Bouw M. Higher incidence of peritonitis in native Canadians on continuous ambulatory peritoneal dialysis. *Peritoneal Dialysis International* 1994;**14**(3):227-30. [MEDLINE: 7948232]

Fried 1996

Fried LF, Bernardini J, Johnston JR, Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. *Journal of the American Society of Nephrology* 1996;**7**(10):2176-82. [MEDLINE: 8915978]

Fung 1996

Fung LC, Khoury AE, Vas SI, Smith C, Oreopoulos DG, Mittelman MW. Biocompatibility of silver-coated peritoneal dialysis catheter in a porcine model. *Peritoneal Dialysis International* 1996;**16**(4):398-405. [MEDLINE: 8863334]

Ghali 2011

Ghali JR, Bannister KM, Brown FG, Rosman JB, Wiggins KJ, Johnson DW, et al. Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients. *Peritoneal Dialysis International* 2011;**31**(6):651-62. [MEDLINE: 21719685]

Golper 1996

Golper TA, Brier ME, Bunke M, Schreiber MJ, Bartlett DK, Hamilton RW, et al. Risk factors for peritonitis in long-term peritoneal dialysis: the Network 9 peritonitis and catheter survival studies. Academic Subcommittee of the Steering Committee of the Network 9 Peritonitis and Catheter Survival Studies. *American Journal of Kidney Diseases* 1996;**28**(3):428-36. [MEDLINE: 8804243]

Guyatt 2008

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating

quality of evidence and strength of recommendations. *BMJ* 2008;**336**(7650):924-6. [MEDLINE: 18436948]

Heaf 2004

Heaf J. Underutilization of peritoneal dialysis. *JAMA* 2004;**291**(6):740-2. [MEDLINE: 14871920]

HICPAC 1995

Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance.[Erratum appears in *Infect Control Hosp Epidemiol* 1995 Sep;**16**(9):498]. *Infection Control & Hospital Epidemiology* 1995;**16**(2):105-13. [MEDLINE: 7759811]

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**(7414):557-60. [MEDLINE: 12958120]

Higgins 2011

Higgins JP, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Holley 1993

Holley JL, Bernardini J, Piraino B. A comparison of peritoneal dialysis-related infections in black and white patients. *Peritoneal Dialysis International* 1993;**13**(1):45-9. [MEDLINE: 8443276]

Jaar 2009

Jaar BG, Plantinga LC, Crews DC, Fink NE, Hebah N, Coresh J, et al. Timing, causes, predictors and prognosis of switching from peritoneal dialysis to hemodialysis: a prospective study. *BMC Nephrology* 2009;**10**:3. [MEDLINE: 19200383]

Jain 2012

Jain AK, Blake P, Cordy P, Garg AX. Global trends in rates of peritoneal dialysis. *Journal of the American Society of Nephrology* 2012;**23**(3):533-44. [MEDLINE: 22302194]

Johnson 2014

Johnson DW, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, et al. Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial. *Lancet Infectious Diseases* 2014;**14**(1):23-30. [MEDLINE: 24119840]

Keane 2000

Keane WF, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, et al. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update.[Erratum appears in *Perit Dial Int* 2000 Nov-Dec;**20**(6):828-9]. *Peritoneal Dialysis International* 2000;**20**(4):396-411. [MEDLINE: 11007371]

Lim 2005

Lim WH, Johnson DW, McDonald SP. Higher rate and earlier peritonitis in Aboriginal patients compared to non-Aboriginal patients with end-stage renal failure maintained on peritoneal dialysis in Australia: analysis of ANZDATA. *Nephrology* 2005;**10**(2):192-7. [MEDLINE: 15877681]

Lloyd 2013

Lloyd A, Tangri N, Shafer LA, Rigatto C, Perl J, Komenda P, et al. The risk of peritonitis after an exit site infection: a time-matched, case-control study. *Nephrology Dialysis Transplantation* 2013;**28**(7):1915-21. [MEDLINE: 23382265]

McDonald 2004

McDonald SP, Collins JF, Rumpsfeld M, Johnson DW. Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations. *Peritoneal Dialysis International* 2004;**24**(4):340-6. [MEDLINE: 15335147]

Moher 1998

Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. *Lancet* 1998; Vol. 352, issue 9128:609-13. [MEDLINE: 9746022]

Morton 2011

Morton RL, Tong A, Webster AC, Snelling P, Howard K. Characteristics of dialysis important to patients and family caregivers: a mixed methods approach. *Nephrology Dialysis Transplantation* 2011;**26**(12):4038-46. [MEDLINE: 21482637]

Nessim 2009

Nessim SJ, Bargman JM, Austin PC, Nisenbaum R, Jassal SV. Predictors of peritonitis in patients on peritoneal dialysis: results of a large, prospective Canadian database. *Clinical Journal of The American Society of Nephrology: CJASN* 2009;**4**(7):1195-200. [MEDLINE: 19406969]

Nolph 1987

Nolph KD, Cutler SJ, Steinberg SM, Novak JW, Hirschman GH. Factors associated with morbidity and mortality among patients on CAPD. *ASAIO Transactions* 1987;**33**(2):57-65. [MEDLINE: 3606901]

Oxton 1994

Oxton LL, Zimmerman SW, Roecker EB, Wakeen M. Risk factors for peritoneal dialysis-related infections. *Peritoneal Dialysis International* 1994;**14**(2):137-44. [MEDLINE: 8043666]

Perez-Fontan 1993

Perez-Fontan M, Garcia-Falcon T, Rosales M, Rodriguez-Carmona A, Adeva M, Rodriguez-Lozano I, et al. Treatment of *Staphylococcus aureus* nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long-term results. *American Journal of Kidney Diseases* 1993;**22**(5):708-12. [MEDLINE: 8238017]

Piraino 1989

Piraino B, Bernardini J, Sorkin M. Catheter infections as a factor in the transfer of continuous ambulatory peritoneal dialysis patients to hemodialysis. *American Journal of Kidney Diseases* 1989;**13**(5):365-9. [MEDLINE: 2719024]

Piraino 1990

Piraino B. A review of *Staphylococcus aureus* exit-site and tunnel infections in peritoneal dialysis patients. *American Journal of Kidney Diseases* 1990;**16**(2):89-95. [MEDLINE: 2200261]

Piraino 1998

Piraino B. Peritonitis as a complication of peritoneal dialysis. *Journal of the American Society of Nephrology* 1998;**9**(10):1956-64. [MEDLINE: 9773798]

Piraino 2000

Piraino B. Staphylococcus aureus infections in dialysis patients: focus on prevention. *ASAIO Journal* 2000;**46**(6):S13-7. [MEDLINE: 11110288]

Piraino 2002

Piraino B. ADEMEX: how should it change our practice? Adequacy of peritoneal dialysis in Mexico. *Peritoneal Dialysis International* 2002;**22**(5):552-4. [MEDLINE: 12455564]

Piraino 2011

Piraino B, Bernardini J, Brown E, Figueiredo A, Johnson DW, Lye WC, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. *Peritoneal Dialysis International* 2011;**31**(6):614-30. [MEDLINE: 21880990]

Salusky 1997

Salusky IB, Holloway M. Selection of peritoneal dialysis for pediatric patients. *Peritoneal Dialysis International* 1997;**17** Suppl 3:S35-7. [MEDLINE: 9304656]

Schaefer 2003

Schaefer F. Management of peritonitis in children receiving chronic peritoneal dialysis. *Paediatric Drugs* 2003;**5**(5):315-25. [MEDLINE: 12716218]

Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;**273**(5):408-12. [MEDLINE: 7823387]

Schünemann 2011a

Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Schünemann 2011b

Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Sutherland 1985

Sutherland R, Boon RJ, Griffin KE, Masters PJ, Slocombe B, White AR. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. *Antimicrobial Agents & Chemotherapy* 1985;**27**(4):495-8. [MEDLINE: 3923922]

Thodis 2000

Thodis E, Passadakis P, Panagoutsos S, Bacharaki D, Euthimiadou A, Vargemesis V. The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis. *Advances in Peritoneal Dialysis* 2000;**16**:257-61. [MEDLINE: 11045306]

Troidle 1998

Troidle L, Gorban-Brennan N, Kliger A, Finkelstein F. Differing outcomes of gram-positive and gram-negative peritonitis. *American Journal of Kidney Diseases* 1998;**32**(4):623-8. [9774124]

Troidle 2003

Troidle L, Watnick S, Wuerth DB, Gorban-Brennan N, Kliger AS, Finkelstein FO. Depression and its association with peritonitis in long-term peritoneal dialysis patients. *American Journal of Kidney Diseases* 2003;**42**(2):350-4. [MEDLINE: 12900818]

Van Biesen 2014

Van Biesen W, Jorres A. Medihoney: let nature do the work?. *Lancet Infectious Diseases* 2014;**14**(1):2-3. [MEDLINE: 24119839]

van Diepen 2012

van Diepen AT, Tomlinson GA, Jassal SV. The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients. *Clinical Journal of The American Society of Nephrology: CJASN* 2012;**7**(8):1266-71. [MEDLINE: 22745277]

Walker 2014

Walker A, Bannister K, George C, Mudge D, Yehia M, Lonergan M, et al. KHA-CARI Guideline: peritonitis treatment and prophylaxis. *Nephrology* 2014; Vol. 19, issue 2:69-71. [MEDLINE: 23944845]

Ward 1986

Ward RA, Chang BS. Systems and devices used for peritoneal dialysis. *Medical Instrumentation* 1986;**20**(2):85-92. [MEDLINE: 3702785]

Woodrow 1997

Woodrow G, Turney JH, Brownjohn AM. Technique failure in peritoneal dialysis and its impact on patient survival. *Peritoneal Dialysis International* 1997;**17**(4):360-4. [MEDLINE: 9284463]

Woodrow 2010

Woodrow G, Davies S. Peritoneal dialysis in CKD. 2010. www.renal.org/guidelines/modules/peritoneal-dialysis-in-ckd#sthash.gkEx1Y5v.dpbs (accessed 28 December 2016).

References to other published versions of this review

Strippoli 2003

Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC. Anti-infective (antiseptics and antibiotics) agents for preventing peritonitis in peritoneal dialysis patients. *Cochrane Database of Systematic Reviews* 2003, Issue 4. [DOI: [10.1002/14651858.CD004679](https://doi.org/10.1002/14651858.CD004679)]

Strippoli 2004a

Strippoli GF, Tong A, Johnson DW, Schena FP, Craig JC.
Antimicrobial agents for preventing peritonitis in peritoneal
dialysis patients. *Cochrane Database of Systematic Reviews*
2004, Issue 4. [DOI: [10.1002/14651858.CD004679.pub2](https://doi.org/10.1002/14651858.CD004679.pub2)]

Strippoli 2004b

Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC.
Antimicrobial agents to prevent peritonitis in peritoneal
dialysis: A systematic review of randomized controlled trials.
American Journal of Kidney Diseases 2004;**44**(4):591-603.
[MEDLINE: 15384009]

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Axelrod 1973

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: 2 months at Bronx VA Hospital; 12 months at Mt Sinai Hospital Follow-up period: not reported
Participants	<ul style="list-style-type: none"> Setting: 2 tertiary centres Country: USA Health status: PD patients Number: 36 (no numbers given for intervention and control group) Mean age: Bronx VA Hospital (47 years); Mt Sinai Hospital (not reported) Sex (M/F): Bronx VA Hospital (24/0); Mt Sinai Hospital (3/9) Proportion of diabetic patients: Bronx VA Hospital (8.3%); Mt Sinai Hospital (8.3%) Exclusion criteria: not reported
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Cephalothin added to 2 L bottle of dialysate (100 µg/mL) <p>Control group</p> <ul style="list-style-type: none"> Placebo solution added to 2 L bottle of dialysate
Outcomes	<ul style="list-style-type: none"> Peritonitis (number of dialyses)
Notes	<ul style="list-style-type: none"> Funding source: Public Health Service grant and Eli Lilly & Company, Indianapolis Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table "Patients were selected to receive placebo or antibiotic according to a random number list kept by the pharmacy..."
Allocation concealment (selection bias)	Low risk	Central allocation (pharmacy)
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Blinding, and unlikely that the blinding could have been broken

Axelrod 1973 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding, and unlikely that the blinding could have been broken. "We conducted a random double-blind trial of cephalothin sodium as the prophylactic agent."
Incomplete outcome data (attrition bias) All outcomes	High risk	10/105 (9.5%) dialyses excluded from analysis because pre-dialysis serum showed antibiotic activity (9) and antibiotic had not been added to dialysate fluid (1). Data reported as no. episodes peritonitis/no. dialyses not no. episodes peritonitis/total patient-months on PD
Selective reporting (reporting bias)	High risk	Outcomes not reported as expected. Also, only 1 of 3 expected primary outcomes reported (peritonitis)
Other bias	High risk	Partly funded by Eli Lilly & Company, Indianapolis

Bennet-Jones 1988

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: 28 days Follow-up period: 28 days
Participants	<ul style="list-style-type: none"> Setting: single centre Country: UK Health status: all patients who were to undergo the insertion of a Tenckhoff catheter prior to starting CAPD Number: treatment group (13); control group (14) Mean age $\pm$ SD (years): treatment group (52.7 $\pm$ 18.6); control group (53.1 $\pm$ 13.0) Sex (M/F): treatment group (8/5); control group (9/4) Proportion of diabetic patients: 0% in either group Exclusion criteria: receiving any antibiotic in the previous 7 days; receiving vancomycin in the previous 3 weeks; history of gentamicin toxicity; any pre-existing hearing deficit
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Gentamicin (IV) 1.5 mg/kg at time of catheter placement <p>Control group</p> <ul style="list-style-type: none"> No antibiotic treatment
Outcomes	<ul style="list-style-type: none"> Peritonitis (number of patients) Exit-site/tunnel infection (number of patients)
Notes	<ul style="list-style-type: none"> Funding source: not reported Exclusions post-randomisation but pre-intervention: none Stop or end point/s: review after 25 patients had completed 28 day follow-up period

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Consecutively numbered sealed envelopes
Allocation concealment (selection bias)	Low risk	"Patients were randomised by being assigned consecutively numbered sealed envelopes, which contained either a prescription for gentamicin to be admin-

Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients (Review)

Bennet-Jones 1988 (Continued)

		istered with the anaesthetic, or an instruction to the anaesthetist to give no antibiotic."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Neither the surgeon nor physician knew whether or not the patient had received the antibiotic."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"Neither the surgeon nor physician knew whether or not the patient had received the antibiotic." Physician assessing outcomes did not know whether patient had received antibiotic or not.
Incomplete outcome data (attrition bias) All outcomes	Low risk	1/27 (3.7%) patients not included in the analysis
Selective reporting (reporting bias)	High risk	2 of 3 primary outcomes of interest reported (exit-site infection, peritonitis). No report of adverse effects of intervention
Other bias	Unclear risk	No information provided about funding source

Bernardini 1996

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: August 1992 to end September 1994 Follow-up period: 1 year (mean)
Participants	<ul style="list-style-type: none"> Setting: 2 tertiary centres Country: USA Health status: adult CAPD and CCPD patients (prevalent and incident); no catheter infection or peritonitis; no antibiotics for at least 2 weeks prior to the study Number: treatment group 1 (41); treatment group 2 (41) Mean age $\pm$ SD (years): not reported Sex (M/F): treatment group 1 (24/17); treatment group 2 (20/21) Proportion of diabetic patients: treatment group 1 (27%); treatment group 2 (41%) Exclusion criteria: refusal to participate; contraindication to rifampin; patient on daily erythromycin therapy
Interventions	<p>Treatment group 1</p> <ul style="list-style-type: none"> Mupirocin ointment (2%) daily application to exit site <p>Treatment group 2</p> <ul style="list-style-type: none"> Rifampin (oral) 300 mg, twice/day for 5 days, every 3 months
Outcomes	<ul style="list-style-type: none"> Peritonitis (rate) Peritonitis (number of patients) Catheter removal/replacement Adverse effects
Notes	<ul style="list-style-type: none"> Funding source: not reported Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: when patient ceased PD or study ended

Bernardini 1996 (Continued)

- Additional data requested from authors: further information on methods and more detailed results were obtained from the corresponding author

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Study said to be randomised but no further information provided
Allocation concealment (selection bias)	Unclear risk	Study said to be randomised but no further information provided
Blinding of participants and personnel (performance bias) All outcomes	High risk	Blinding not possible - topical antibiotic ointment vs oral antibiotic therapy. The outcome could be influenced by lack of blinding and knowledge of the interventions
Blinding of outcome assessment (detection bias) All outcomes	High risk	"Catheter infections were defined as ... and were diagnosed by the peritoneal dialysis nurse and physician, who were not blinded to the patient's treatment arm."
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients included in analysis including patients who ceased therapy
Selective reporting (reporting bias)	Unclear risk	All pre-specified outcomes for this review were reported, however unable to meta-analyse exit-site infections (reported as infection rate/dialysis-year)
Other bias	Unclear risk	No information on funding provided

Bernardini 2005

Methods	<ul style="list-style-type: none"> • Study design: parallel RCT • Study duration/time frame: July 2001 to August 2003 • Duration of follow-up: to December 2003 (8 months median)
Participants	<ul style="list-style-type: none"> • Setting: 3 tertiary centres • Country: USA • Health status: ≥ 18 years; on PD; able to give informed consent; already enrolled in a registry permitting data collection • Number: treatment group 1 (67); treatment group 2 (66) • Mean age $\pm$ SD (years): treatment group 1 (54 ± 15); treatment group 2 (51 ± 15) • Sex (M/F): treatment group 1 (34/33); treatment group 2 (38/28) • Proportion of diabetic patients: treatment group 1 (40%); treatment group 2 (41%) • Exclusion criteria: allergy to either study cream; those in another interventional study; those with catheter infections or peritonitis in the past 30 days
Interventions	<p>Treatment group 1</p> <ul style="list-style-type: none"> • Daily application of gentamicin cream (gentamicin sulfate 0.1%) <p>Treatment group 2</p> <ul style="list-style-type: none"> • Mupirocin cream (mupirocin 2%) at exit site

Bernardini 2005 (Continued)

Outcomes	<ul style="list-style-type: none"> • <i>P. aeruginosa</i> and <i>S. aureus</i> catheter infection rate • Gram-negative and gram-positive peritonitis • Overall catheter infection rate • Overall peritonitis rate • Causative organisms • catheter removal (due to infection) • Time to first catheter infection
Notes	<ul style="list-style-type: none"> • Funding source: National Kidney Foundation of Western Pennsylvania, National Kidney Foundation of Upstate New York, Paul Teschan Fund of Dialysis Clinic, Inc • Exclusions post-randomisation but pre-intervention: 3 in mupirocin group (did not start PD) • Stop or end point/s: stopped at 118 patient-years when a difference in peritonitis rates between the groups was found

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer generated using a random number generator "Randomization lists were computer generated using a random number generator."
Allocation concealment (selection bias)	Low risk	"The sequence of allocation was known only by the investigators at the coordinating center."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Investigators and patients were blinded to the cream used."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcome assessors were blinded to the cream used
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients who received intervention included in analysis
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes for this review were reported
Other bias	Low risk	Supported by National Kidney Foundations of Western Pennsylvania and Upstate New York and by Paul Teschan Fund of Dialysis Clinic Inc

Blowey 1994

Methods	<ul style="list-style-type: none"> • Study design: parallel RCT • Study duration/time frame: 1991 to 1993 • Duration of follow-up: 1 month
Participants	<ul style="list-style-type: none"> • Setting: single centre • Country: USA • Health status: no evidence of a dialysis-related infection in the preceding month; no antibiotic therapy in the preceding month; duration of dialysis of at least 3 months • Number: treatment group (7); control group (8)

Blowey 1994 (Continued)

- Mean age (range): 11.5 years (8 months to 21 years)
- Sex (M/F): 18/16
- Proportion of diabetic patients: not reported
- Exclusion criteria: not reported

Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> • Rifampin: 20 mg/kg/d in 2 doses for 5 days • Nasal bacitracin (mupirocin): twice/d for 7 days <p>Control group</p> <ul style="list-style-type: none"> • No antibiotic treatment
Outcomes	<ul style="list-style-type: none"> • Peritonitis (number of patients) • exit-site/tunnel infection (number of patients)
Notes	<ul style="list-style-type: none"> • Funding source: not reported • Exclusions post-randomisation but pre-intervention: not reported • Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Patients said to be randomised but no further information provided
Allocation concealment (selection bias)	Unclear risk	Patients said to be randomised but no further information provided
Blinding of participants and personnel (performance bias) All outcomes	High risk	Blinding not done - oral antibiotic + topical antibiotic ointment vs no therapy. The outcome could be influenced by lack of blinding and knowledge of the interventions
Blinding of outcome assessment (detection bias) All outcomes	High risk	Clinical assessment of outcome could be influenced by knowledge of treatment group
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients completed the study
Selective reporting (reporting bias)	Unclear risk	Only 2 of 3 primary outcomes of interest for this review were reported (exit-site/tunnel infection, peritonitis)
Other bias	Unclear risk	No information on funding provided

Cheng 1999a

Methods	<ul style="list-style-type: none"> • Study design: parallel RCT • Study duration/time frame: not reported • Duration of follow-up: treatment group 1 (17.2 ± 5 months); treatment group 2 (16.6 ± 6 months)
---------	--

Cheng 1999a (Continued)

Participants	<ul style="list-style-type: none"> • Setting: Single centre • Country: Hong Kong • Health status: CAPD patients with infection-free exit sites • Number: treatment group 1 (33); treatment group 2 (33) • Mean age: not reported • Sex (M/F): not reported • Proportion of diabetic patients: not reported • Exclusion criteria: not reported
Interventions	<p>Treatment group 1</p> <ul style="list-style-type: none"> • Chlorhexidine soap at exit site: daily <p>Treatment group 2</p> <ul style="list-style-type: none"> • Povidone iodine at exit site: daily
Outcomes	<ul style="list-style-type: none"> • Exit-site infection (rate) • Catheter removal (number)
Notes	<ul style="list-style-type: none"> • Abstract-only publication • Funding source: not reported • Exclusions post-randomisation but pre-intervention: not reported • Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Study said to be randomised but no information on method provided
Allocation concealment (selection bias)	Unclear risk	Study said to be randomised but no information on method provided
Blinding of participants and personnel (performance bias) All outcomes	High risk	Lack of blinding could influence patient management
Blinding of outcome assessment (detection bias) All outcomes	High risk	Knowledge of interventions could influence outcome assessment
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement; abstract only available
Selective reporting (reporting bias)	Unclear risk	Only 2 of 3 expected primary outcomes were reported (exit-site infection, catheter removal)
Other bias	Unclear risk	No information on funding provided

Chu 2008

Methods	<ul style="list-style-type: none"> Study design: quasi RCT Study duration/time frame: June to November 2005 Duration of follow-up: not reported
Participants	<ul style="list-style-type: none"> Setting: Single centre Country: Hong Kong Health status: adult PD patients without any exclusion criteria Number (analysed/randomised): 81/95; treatment group 1 (43); treatment group 2 (38) Mean age: treatment group 1 (57.6 years); treatment group 2 (61.2 years) Sex (M/F): treatment group 1 (27/16); treatment group 2 (31/7) Proportion of diabetic patients: treatment group 1 (41.9%); treatment group 2 (28.9%) Exclusion criteria: active infection; exit-site infection or peritonitis within the previous 4 weeks; allergy to either gentamicin or mupirocin; inability to apply the drug; inability to give consent
Interventions	<p>Treatment group 1</p> <ul style="list-style-type: none"> Gentamicin cream: daily at exit site <p>Treatment group 2</p> <ul style="list-style-type: none"> Mupirocin ointment: daily at exit site
Outcomes	<ul style="list-style-type: none"> Peritonitis (number of patients) Peritonitis rate Exit-site/tunnel infection (number of patients) Exit-site/tunnel infection rate All-cause mortality
Notes	<ul style="list-style-type: none"> Funding source: not reported Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: not reported Additional data requested from authors: further information on methods were obtained from the corresponding author (KH Chu)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Alternate allocation "The patients were assigned to either drug on a one-to-one alternate basis."
Allocation concealment (selection bias)	High risk	Alternate allocation "The patients were assigned to either drug on a one-to-one alternate basis."
Blinding of participants and personnel (performance bias) All outcomes	High risk	"Patients were not informed of which cream/ointment they were using. However the cream/ointment were not covered or blinded." (email from author)
Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding and knowledge of interventions could influence outcome assessment
Incomplete outcome data (attrition bias) All outcomes	High risk	14/95 (15%) withdrew from the study and were excluded from analysis

Chu 2008 (Continued)

Selective reporting (reporting bias)	Unclear risk	Only 2 of 3 expected primary outcomes were reported (peritonitis, exit-site/tunnel infection)
Other bias	Unclear risk	No information on funding provided

Churchill 1988

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: 12 months Duration of follow-up: 12 months
Participants	<ul style="list-style-type: none"> Setting: 4 tertiary centres Country: Canada Health status: CAPD patients aged 18 to 80 years Number: treatment group (56); control group (49) Mean age: not reported Sex (M/F): not reported Proportion of diabetic patients: not reported Exclusion criteria: allergy to either trimethoprim or sulfamethoxazole; elective transplantation; move from study area; unlikely to survive the study period; noncompliance; active tunnel infection; no previous peritonitis in patients who had been on CAPD for 18 months or more
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Trimethoprim 160 mg/sulfamethoxazole 800 mg/day for 12 months <p>Control group</p> <ul style="list-style-type: none"> No antibiotic treatment
Outcomes	<ul style="list-style-type: none"> All-cause mortality Mortality due to peritonitis Peritonitis (number of patients) Transfers to HD or transplantation Withdrawals Adverse reactions Response to peritonitis treatment Peritoneal catheter loss
Notes	<ul style="list-style-type: none"> Funding source: Hoffman La Roche supplied the antibiotic (cotrimoxazole) and placebo tablets Exclusions post-randomisation but pre-intervention: 49 eligible patients refused to participate Stop or end point/s: 12 months from start of treatment Additional data requested from authors: Further information on methods and more detailed results were obtained from the corresponding author

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Stratified or block randomisation

Churchill 1988 (Continued)

Allocation concealment (selection bias)	Low risk	Central allocation by pharmacy
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Blinding, and unlikely that the blinding could have been broken
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding, and unlikely that the blinding could have been broken
Incomplete outcome data (attrition bias) All outcomes	Low risk	Intention to treat analysis for primary outcome; loss to follow-up: 20 in cotrimoxazole group (35.7%); 9 in placebo group (18.4%)
Selective reporting (reporting bias)	High risk	2 of 3 primary outcomes not reported (exit-site/tunnel infection, catheter removal/replacement)
Other bias	High risk	Hoffman La Roche supplied the antibiotic (cotrimoxazole) and placebo tablets

Cocksedge 1993

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: 1 January 1988 to 31 December 1989 Duration of follow-up: not reported
Participants	<ul style="list-style-type: none"> Setting: single tertiary centre Country: Australia Health status: current and new adult CAPD patients Number: treatment group 1 (30); treatment group 2 (30) Mean age: not reported (most patients were > 60 years) Sex (M/F): not reported Proportion of diabetic patients: 11.7% (7/60) Exclusion criteria: not reported
Interventions	<p>Treatment group 1</p> <ul style="list-style-type: none"> Shower and gauze <p>Treatment group 2</p> <ul style="list-style-type: none"> Dressing pack and Fixomull dressing at exit site
Outcomes	<ul style="list-style-type: none"> Exit-site infection (rate) Exit-site infection (number of patients)
Notes	<ul style="list-style-type: none"> Funding source: not reported Excluded from analysis: not reported Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: not reported

Risk of bias

Cocksedge 1993 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Sealed envelopes "New patients to the program were asked to select a sealed envelope from a pack. Each envelope contained a card allocating the patient to either Method One or Method Two."
Allocation concealment (selection bias)	Unclear risk	Do not know if the envelopes were opaque
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding and the outcome is likely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding and knowledge of interventions could influence outcome assessment
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No details given re loss to follow-up or any patient withdrawals
Selective reporting (reporting bias)	High risk	Only 1 of 3 expected primary outcomes are reported (exit-site infection). No report of adverse effects of either intervention
Other bias	Unclear risk	No report of funding source

Danguilan 2003

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: May 1998 to 31 January 2000 Duration of follow-up: 1.5 years
Participants	<ul style="list-style-type: none"> Setting: Single centre Country: Philippines Health status: new exit-site infection-free CAPD patients Number: treatment group 1 (50); treatment group 2 (50) Mean age: not reported Sex (M/F): not reported Proportion of diabetic patients (%): not reported Exclusion criteria: not reported
Interventions	<p>Treatment group 1</p> <ul style="list-style-type: none"> Sodium fusidate ointment at exit site after weekly dressing change <p>Treatment group 2</p> <ul style="list-style-type: none"> Mupirocin ointment at exit site after weekly dressing change (weekly)
Outcomes	<ul style="list-style-type: none"> Exit-site infection (number of patients) Exit-site infection (rate)
Notes	<ul style="list-style-type: none"> Funding source: not reported Exclusions post-randomisation but pre-intervention: not reported

Danguilan 2003 (Continued)

- Stop or end point/s: not reported
- Additional data requested from authors: Further information on methods and results were obtained from the corresponding author (R Danguilan)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation method not stated. "One hundred patients were enrolled in the study... 50 patients were randomly assigned to each treatment group."
Allocation concealment (selection bias)	Unclear risk	No details given re concealment of patient allocation
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions
Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding and knowledge of interventions could influence outcome assessment. "Exit sites were monitored weekly during regular follow up."
Incomplete outcome data (attrition bias) All outcomes	High risk	Total of 22/100 dropouts from the study (22%). Proportion missing enough to have a clinically relevant effect
Selective reporting (reporting bias)	Unclear risk	Only 2 of 3 expected primary outcomes are reported (exit-site infection, peritonitis)
Other bias	Unclear risk	No report of funding source

Fuchs 1990

Methods	<ul style="list-style-type: none"> • Study design: parallel RCT • Study duration/time frame: 1 October 1987 to 31 December 1988 • Duration of follow-up: 15 months
Participants	<ul style="list-style-type: none"> • Setting: single centre • Country: USA • Health status: CAPD and APD patients over 18 years of age with well-healed non-inflamed exit sites; no previous exit-site infection associated with the current catheter • Number: treatment group 1 (18); treatment group 2 (13); treatment group 3 (20) • Mean age (years): treatment group 1 (46); treatment group 2 (47); treatment group 3 (55) • Sex (M/F): treatment group 1 (7/11); treatment group 2 (7/6); treatment group 3 (13/7) • Proportion of diabetic patients: treatment group 1 (55.6%); treatment group 2 (53.8%); treatment group 3 (25%) • Exclusion criteria: not reported
Interventions	<p>Treatment group 1</p> <ul style="list-style-type: none"> • Exit-site cleaning with chlorhexidine gluconate and water <p>Treatment group 2</p> <ul style="list-style-type: none"> • Exit-site cleaning with sodium hypochlorite solution

Fuchs 1990 (Continued)

Treatment group 3

- Exit-site cleaning with povidone-iodine solution

Outcomes	<ul style="list-style-type: none"> Exit-site infection (number of patients)
Notes	<ul style="list-style-type: none"> Funding source: not reported Exclusions post-randomisation but pre-intervention: none Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation method not stated "Fifty-one patients were randomly assigned to one of three catheter exit site care regimens."
Allocation concealment (selection bias)	Unclear risk	No details given re concealment of patient allocation
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions
Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding and knowledge of interventions could influence outcome assessment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Proportion missing not enough to have a clinically relevant effect. 2/13 (15.4%) in sodium hypochlorite group withdrew from the study
Selective reporting (reporting bias)	High risk	Only 1 of 3 expected primary outcomes reported (exit-site infection)
Other bias	Unclear risk	No report of funding source

Gadallah 2000c

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: 8 years Duration of follow-up: 14 days
Participants	<ul style="list-style-type: none"> Setting: single tertiary centre Country: USA Health status: patients undergoing permanent PD catheter placement Number: treatment group 1 (90); treatment group 2 (88); control group (87) Mean age, range (years): treatment group 1 (46, 15 to 72); treatment group 2 (47, 20 to 81); control group (45, 19 to 76) Sex (M/F): treatment group 1 (38/52); treatment group 2 (43/45); control group (38/49) Proportion of diabetic patients: treatment group 1 (35.6%); treatment group 2 (34.1%); control group (32.2%) Exclusion criteria: not reported

Gadallah 2000c (Continued)

Interventions	<p>Treatment group 1</p> <ul style="list-style-type: none"> Vancomycin (IV): 1000 mg 12 h before catheter placement <p>Treatment group 2</p> <ul style="list-style-type: none"> Cefazolin (IV): 1000 mg 3 h before catheter placement <p>Control group</p> <ul style="list-style-type: none"> No antibiotic treatment
Outcomes	<ul style="list-style-type: none"> Peritonitis (number of patients) Exit-site/tunnel infection (number of patients, within 14 days of date of catheter insertion)
Notes	<ul style="list-style-type: none"> Funding source: not reported Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Consecutive allocation of intervention "first patient received vancomycin; second, cefazolin; third, neither; fourth, vancomycin; and so on."
Allocation concealment (selection bias)	High risk	Non-random, predictable sequence
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions
Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding and knowledge of interventions could influence outcome assessment
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing data re peritonitis outcome; data for exit-site/tunnel infection excluded from analysis (vancomycin (3); cefazolin (6); no antibiotic (8))
Selective reporting (reporting bias)	Unclear risk	2 of 3 expected outcomes of interest are reported
Other bias	Unclear risk	No report of funding source

HONEYPOT Study 2009

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: 17 September 2008 to 16 June 2012 Duration of follow-up: minimum of 12 months; maximum of 24 months
Participants	<ul style="list-style-type: none"> Setting: 26 tertiary centres Country: Australia; New Zealand Health status: adults and children of all ages with ESKD who were undergoing PD

HONEYPOT Study 2009 (Continued)

- Number: treatment group 1 (186); treatment group 2 (185)
- Mean age $\pm$ SD (years): treatment group 1 (61.2 ± 14.5); treatment group 2 (62.1 ± 14.6)
- Sex (M/F): treatment group 1 (108/78); treatment group 2 (116/69)
- Proportion of diabetic patients: treatment group 1 (34%); treatment group 2 (28%)
- Exclusion criteria: exit-site infection, tunnel infection or peritonitis in the preceding month; current or recent (within the preceding 4 weeks) treatment with an antibiotic administered by any route; nasal carriage of mupirocin-resistant *S. aureus*; known hypersensitivity to or intolerance of honey or mupirocin; inability to provide informed consent; history of psychological illness or disorder that interfered with the ability to understand or comply with the requirements of the study

Interventions	<p>Treatment group 1</p> <ul style="list-style-type: none"> • Daily topical exit-site application of antibacterial honey (10 mg) plus standard exit-site care <p>Treatment group 2</p> <ul style="list-style-type: none"> • Intranasal application of mupirocin ointment (2% mupirocin) (only in carriers of nasal <i>S. aureus</i>) plus standard exit-site care. Mupirocin to be applied twice daily for 5 days, each month
Outcomes	<ul style="list-style-type: none"> • Time to first episode of exit-site infection, tunnel infection or peritonitis, whichever came first • Time to first exit-site infection • Time to first tunnel infection • Time to first peritonitis • Time to infection-associated catheter removal • Death • Serious adverse events
Notes	<ul style="list-style-type: none"> • Funding source: Baxter Healthcare; Queensland government; Comvita; Gambro • Exclusions post-randomisation but pre-intervention: none • Stop or end point/s: once 185 individuals per group had been followed up for at least 12 months • Additional data requested from authors: Further information about results were obtained from the biostatistician (E Pascoe)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Minimization method "Participants were randomly assigned in a 1:1 ratio by use of an adaptive allocation algorithm designed to minimise imbalance in treatment groups for the three variables."
Allocation concealment (selection bias)	Low risk	Central allocation (web). "To ensure adequate concealment of allocation, the randomisation was done with a password-protected internet-based system."
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions. "Blinding of investigators and patients is not possible because of the completely different characteristics of Medihoney and mupirocin ointment."
Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding and knowledge of the interventions could influence outcome assessment. "The trial was open label, but microbiology staff at the local laboratories were not informed of the treatment allocation."
Incomplete outcome data (attrition bias) All outcomes	High risk	<p>Missing data not balanced between groups. 17/185 (9.2%) withdrew from control group; 54/186 (29%) withdrew from honey group</p> <p>Loss to follow-up: 1 in honey group (0.5%); 3 in mupirocin group (1.6%)</p>

HONEYPOT Study 2009 (Continued)

Selective reporting (reporting bias)	Low risk	3 of 3 expected primary outcomes are reported
Other bias	Unclear risk	The study appears to be free of other sources of risk. Although 3 of 4 funders are pharmaceutical companies, there is an explicit statement about their role on page 26 of the paper

Lo 1996

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: 1 May 1991 to 30 April 1993 Duration of follow-up: treatment group (8.0 ± 7.6 months); control group (16.6 ± 8.5 months)
Participants	<ul style="list-style-type: none"> Setting: 2 tertiary centres Country: Hong Kong Health status: all patients receiving CAPD Number: treatment group (199); control group (198) Mean age $\pm$ SD (years): treatment group (48.4 ± 14.5); control group (48.5 ± 14.2) Sex (M/F): treatment group (86/113); control group (98/100) Proportion of diabetic patients: treatment group (18.6%); control group (15.2%) Exclusion criteria: not reported
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Nystatin: 500,000 units, 4 times/day (whenever antibiotics were prescribed to patient) <p>Control group</p> <ul style="list-style-type: none"> No fungal treatment
Outcomes	<ul style="list-style-type: none"> Peritonitis (number of patients) Peritonitis (rate due to <i>Candida</i> spp.)
Notes	<ul style="list-style-type: none"> Study focusing on prophylaxis to prevent <i>Candida</i> peritonitis in CAPD patients receiving antibiotics for any indication Funding source: not reported Excluded from analysis: not reported Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Patients were randomised according to odd or even identity numbers
Allocation concealment (selection bias)	High risk	A non-random, predictable sequence was used
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions

Lo 1996 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding and knowledge of the interventions could influence outcome assessment
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis for primary outcome
Selective reporting (reporting bias)	High risk	The expected primary outcome is reported (peritonitis), however catheter removal and exit-site infection not reported
Other bias	Unclear risk	No report of funding source

Low 1980

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: April to September 1979 Duration of follow-up: not reported 	
Participants	<ul style="list-style-type: none"> Setting: 2 tertiary centres Country: Canada Health status: patients receiving CAPD Number: treatment group (25); control group (25) Mean age: not reported Sex (M/F): not reported Proportion of diabetic patients: not reported Exclusion criteria: not reported 	
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Cefalexin: 500 mg, twice/d <p>Control group</p> <ul style="list-style-type: none"> Placebo 	
Outcomes	<ul style="list-style-type: none"> Peritonitis (number of patients) Peritonitis (rate) Catheter removal/replacement (number of patients) 	
Notes	<ul style="list-style-type: none"> Funding source: National Institutes of Health Excluded from analysis: not reported Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: not reported 	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Minimisation method used
Allocation concealment (selection bias)	Low risk	Allocation done by a third party

Low 1980 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	Blinding, and unlikely that the blinding could have been broken
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding, and unlikely that the blinding could have been broken
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing data
Selective reporting (reporting bias)	Unclear risk	1 of 3 primary outcomes not reported (exit-site/tunnel infection)
Other bias	Low risk	Study appears to be free of other sources of risk. Funding was from a National Institutes of Health contract

Luzar 1990

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: May 1987 to September 1988 Duration of follow-up: 9.03 months/patient
Participants	<ul style="list-style-type: none"> Setting: 8 tertiary centres Country: UK, France, Belgium Health status: new and current CAPD patients Number: treatment group (74); control group (53) Mean age: not reported Sex (M/F): treatment group (47/27); control group (31/22) Proportion of diabetic patients: treatment group (17%); control group (11%) Exclusion criteria: patients with any current infection
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Povidone iodine (20 g/L) and nonocclusive dressing 2 to 3 times/wk <p>Control group</p> <ul style="list-style-type: none"> Non-disinfectant soap and water
Outcomes	<ul style="list-style-type: none"> All-cause mortality Peritonitis (rate) Exit-site/tunnel infection (rate)
Notes	<ul style="list-style-type: none"> Funding source: not reported but lead author employed by Baxter R & D Europe, Belgium Excluded from analysis: not reported Exclusions post-randomisation but pre-intervention: 9 patients randomised to control group refused to do that type of exit-site care Stop or end point/s: 1 year of follow-up per patient or until a significant difference in rate of exit-site infection Four patients in control group changed to treatment group

Luzar 1990 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table
Allocation concealment (selection bias)	Low risk	Central allocation
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions
Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding and knowledge of interventions could influence outcome assessment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Proportion missing not enough to have a clinically relevant effect; loss to follow-up: 8 of 127 (6.3%)
Selective reporting (reporting bias)	Unclear risk	3 of 3 primary outcomes of interest are reported, however unable to meta-analyse catheter removal
Other bias	High risk	Funding source not specified but seems to be Baxter Healthcare Corporation

Lye 1992

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: 1 May 1989 to 31 May 1990 Duration of follow-up: not reported
Participants	<ul style="list-style-type: none"> Setting: single tertiary centre Country: Singapore Health status: patients having CAPD catheters inserted Number: treatment group (33); control group (33) Mean age $\pm$ SD (years): treatment group (56.2 $\pm$ 12.3); control group (55.6 $\pm$ 13.4) Sex (M/F): treatment group (12/21); control group (18/15) Proportion of diabetic patients: treatment group (68%); control group (52%) Exclusion criteria: recognised infection at the time of surgery; antibiotic therapy in the week prior to surgery; vancomycin therapy in the 2 weeks before surgery; history of allergy to beta-lactam antibiotics and aminoglycosides
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Cefazolin (IV) 500 mg and gentamicin (IV) 80 mg 0.5 to 1.0 hour before catheter placement <p>Control group</p> <ul style="list-style-type: none"> No antibiotic treatment
Outcomes	<ul style="list-style-type: none"> All-cause mortality peritonitis (number of patients)

Lye 1992 (Continued)

- Exit-site/tunnel infection (number of patients within 4 weeks of catheter insertion)

Notes

- Funding source: not reported
- Exclusions post-randomisation but pre-intervention: not reported
- Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Alternate allocation
Allocation concealment (selection bias)	High risk	Non-random, predictable sequence
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions
Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding and knowledge of interventions could influence outcome assessment
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing data balanced across groups, and reasons similar; 4 (16%) excluded from analysis in treatment group due to lack of effect of study antibiotics on MRSA bacteria; 3 (12%) excluded from analysis in control group for the same reason
Selective reporting (reporting bias)	Low risk	3 of 3 primary outcomes of interest are reported
Other bias	Unclear risk	No report of funding source

Mendoza-Guevara 2007

Methods

- Study design: parallel RCT
- Study duration/time frame: 22 January 2004 to 15 March 2005
- Duration of follow-up: not reported

Participants

- Setting: single centre
- Country: Mexico
- Health status: CCPD patients that had been at least 3 months on the PD program and free of peritonitis or exit-site infection for at least 1 month since the last episode
- Number: treatment group (30); control group (30)
- Median age, Q25 to 75 (years): treatment group (12, 10 to 14); control group (12 8.75 to 14.25)
- Sex (M/F): treatment group (19/11); control group (11/19)
- Proportion of diabetic patients: not reported
- Exclusion criteria: patients on steroids; patients with cancer; HIV positive patients

Interventions

- Treatment group
- Amuchina 10% (sodium hypochlorite) solution for cleaning exit site

Mendoza-Guevara 2007 (Continued)

Control group

- pH neutral soap for cleaning exit site

Outcomes	<ul style="list-style-type: none"> • Exit-site infection (number of patients)
Notes	<ul style="list-style-type: none"> • Funding source: not reported • Excluded from analysis: not reported • Exclusions post-randomisation but pre-intervention: not reported • Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number tables "Patients were assigned 1:1 in two groups, with only one treatment; the Rand Corporation tables were used for randomization."
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Patient cleans own exit site - impossible to conceal intervention allocation. "The study was blind for the investigators and laboratory personnel."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding, and unlikely that the blinding could have been broken. "The study was blind for the investigators and laboratory personnel."
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	High risk	Only 1 of 3 expected primary outcomes reported (exit-site infection)
Other bias	Unclear risk	No report of funding source

Moore 1989

Methods	<ul style="list-style-type: none"> • Study design: parallel quasi RCT • Study duration/time frame: 1 October 1987 to 1 February 1988 • Duration of follow-up: 4 months
Participants	<ul style="list-style-type: none"> • Setting: Single centre • Country: USA • Health status: current CAPD patients (adult) • Number: treatment group (15); control group (14) • Mean age, range (years): treatment group (54, 30 to 75); control group (59, 28 to 72) • Sex (M/F): not reported • Proportion of diabetic patients (%): not reported • Exclusion criteria: history of exit-site infection 2 months prior to possible study admission
Interventions	Treatment group

Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients (Review)

Moore 1989 (Continued)

- Blisterfilm adhesive dressing at exit site

Control group

- Gauze dressing at exit site

Outcomes	<ul style="list-style-type: none"> • Exit-site infection (number of patients)
Notes	<ul style="list-style-type: none"> • Funding source: not reported • Excluded from analysis: not reported • Exclusions post-randomisation but pre-intervention: not reported • Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Alternate allocation "The numbering was consecutive so all participants were given an equal chance of being admitted to either group." "Odd numbers were admitted to the Blisterfilm group and even numbers admitted to the gauze group."
Allocation concealment (selection bias)	High risk	Non-random, predictable sequence. However, allocation concealment not possible - the two dressings are of different sizes and types
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of interventions
Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding and knowledge of the interventions could influence outcome assessment
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	The published report states percentage of patients in each group that experienced exit-site infection but does not state actual patient numbers. No report of loss to follow-up or withdrawals
Selective reporting (reporting bias)	High risk	Only 1 of 3 expected primary outcomes of interest reported (exit-site infection)
Other bias	Unclear risk	No report of funding source

MP3 Study 2008

Methods	<ul style="list-style-type: none"> • Study design: parallel RCT • Study duration/time frame: not reported • Duration of follow-up (median, range): 18, 0.1 to 18 months
Participants	<ul style="list-style-type: none"> • Setting: 3 tertiary centres • Country: Canada • Health status: current or new PD patients; ≥ 18 years; have a PD catheter in situ; medically stable • Number: treatment group 1 (103); treatment group 2 (101) • Mean age $\pm$ SD (years): treatment group 1 (59.36 $\pm$ 15.04); treatment group 2 (61.02 $\pm$ 13.66) • Sex (M/F): treatment group 1 (63/37); treatment group 2 (66/34)

MP3 Study 2008 (Continued)

- Proportion of diabetic patients: treatment group 1 (45.5%); treatment group 2 (42%)
- Exclusion criteria: AKI; catheter-related infection at the time of recruitment or within the previous 3 months; use of an oral, IV or IP antibiotic at the time of randomisation or within the previous 1 week; a known allergy to any component of P3 or mupirocin; or a scheduled date for living donor transplant surgery within 6 months of the study completion date

Interventions	<p>Treatment group 1</p> <ul style="list-style-type: none"> • Polysporin triple (P3) antibiotic ointment (bacitracin 500 U/g, gramicidin 0.25 mg/g, polymyxin B 10 000 U/g) at exit site when dressing was changed <p>Treatment group 2</p> <ul style="list-style-type: none"> • Mupirocin ointment at exit site when dressing was changed
Outcomes	<ul style="list-style-type: none"> • Time to first catheter-related infection (exit-site infection, tunnel infection, PD peritonitis) • Catheter removal (catheter-related infection) • Hospitalisation (catheter-related infection) • Death due to catheter-related infection • All-cause mortality • Technique failure (i.e. transfer to HD)
Notes	<ul style="list-style-type: none"> • Funding source: Kidney Foundation of Canada • Exclusions post-randomisation but pre-intervention: none • Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer random number generator "All randomization is determined by a computer-generated random number list..." "...201 patients from two centers were randomly assigned to either mupirocin or P3 using stratified block randomization as per protocol."
Allocation concealment (selection bias)	Low risk	Central allocation (pharmacy) "Randomization occurs centrally in coordination with the central clinical trials pharmacy... The ointments are placed in containers that are labeled only with the site investigator, study number, and expiry date."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Blinding, and unlikely that the blinding could have been broken "The treatments resemble each other in odor, color, and consistency to allow for a double blinded controlled trial." "Neither the healthcare workers nor the participants know which intervention the participant will receive."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding, and unlikely that the blinding could have been broken
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing data balanced across groups, and reasons similar (2 from each group lost to follow-up); data for 3 patients from 1 site were excluded
Selective reporting (reporting bias)	Low risk	Protocol is available and all pre-specified outcomes of interest to the review are reported in the pre-specified way
Other bias	Low risk	Funded by the Kidney Foundation of Canada. Study appears to be free of other sources of risk

Mupirocin Study 1996

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: up to 18 months Duration of follow-up: up to 18 months
Participants	<ul style="list-style-type: none"> Setting: 9 centres Country: Europe Health status: patients undergoing CAPD who were identified as <i>S. aureus</i> nasal carriers Number: treatment group (134); control group (133) Mean age (years): treatment group (60.3); control group (60.3) Sex (M/F): treatment group (81/53); control group (80/53) Proportion of diabetic patients: treatment group (17.2%); control group (22.6%) Exclusion criteria: patient negative for <i>S. aureus</i> nasal carriage; patient who had received antibiotics for a PD-related infection within the preceding month; patient with active exit-site infection
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Mupirocin (2%) nasal ointment twice/day for 5 days, every 1 month <p>Control group</p> <ul style="list-style-type: none"> Placebo nasal ointment twice/day for 5 days, every 1 month
Outcomes	<ul style="list-style-type: none"> All-cause mortality Peritonitis (rate) Exit-site/tunnel infection (number of patients) Exit-site/tunnel infection (rate) Catheter removal or replacement
Notes	<ul style="list-style-type: none"> Funding source: SmithKline Beecham, UK; Baxter Healthcare, USA Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: 1413 patient-months in each group Additional data requested from authors: further information on obtained from study authors

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Blinding, and unlikely patients were aware of treatment group. Unclear if personnel were aware of patient treatment groups
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details given re who did the outcome assessment and if they were blind to patient treatment group
Incomplete outcome data (attrition bias)	Low risk	Missing data balanced across groups, and reasons similar; ITT analysis used

Mupirocin Study 1996 (Continued)

All outcomes

Selective reporting (reporting bias)	Low risk	3 of 3 expected primary outcomes of interest are reported
Other bias	High risk	Funding source: SmithKline Beecham, UK, and Baxter Healthcare, USA

Nolph 1985

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: 9 months Duration of follow-up: 9 months
Participants	<ul style="list-style-type: none"> Setting: 10 tertiary centres Country: USA Health status: patients with ESKD treated with CAPD Number: treatment group (74); control group (93) Mean age $\pm$ SD (years): treatment group (49 ± 14); control group (49 ± 14) Sex (M/F): treatment group (50/24); control group (49/44) Proportion of diabetic patients: treatment group (16.2%); control group (23.7%) Exclusion criteria: not reported
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Ultraviolet germicidal chamber for spike and bag outlet port <p>Control group</p> <ul style="list-style-type: none"> No treatment
Outcomes	<ul style="list-style-type: none"> All-cause mortality Peritonitis (number of patients) Peritonitis (rate)
Notes	<ul style="list-style-type: none"> Funding source: Travenol Laboratories Inc., USA Excluded from analysis: not reported Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table
Allocation concealment (selection bias)	Low risk	Central allocation (Travenol Laboratories)
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions

Nolph 1985 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding and knowledge of the interventions could influence outcome assessment
Incomplete outcome data (attrition bias) All outcomes	High risk	12.9% withdrew from control group; 24.3% withdrew from intervention group. Proportion missing enough to have a clinically relevant effect
Selective reporting (reporting bias)	High risk	Only 1 of 3 primary expected outcomes of interest is reported (peritonitis)
Other bias	High risk	Funding source: Travenol Laboratories Inc., USA

Nunez-Moral 2014

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: March 2009 to June 2010 Duration of follow-up: 12 months
Participants	<ul style="list-style-type: none"> Setting: Single tertiary centre Country: Spain Health status: patients > 18 years in PD program in which a peritoneal catheter had been implanted at least 6 weeks before; absence of infectious complications which had required either hospital admission or antibiotic treatment at least three months before entering the study; absence of known reaction or contingent polyhexanide intolerance; the patient or representatives had signed the informed consent form Number: treatment group (30); control group (30) Mean age $\pm$ SD (years): treatment group (61 ± 15); control group (60 ± 19) Sex (M/F): treatment group (17/13); control group (16/14) Proportion of diabetic patients: treatment group (41%); control group (40%) Exclusion criteria: presence of exit-site infection at randomisation time; history of bad adherence to treatment and/or medical advice; withdrawal of the informed consent
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Polyhexanide solution at exit site <p>Control group</p> <ul style="list-style-type: none"> Standard care: 0.9% saline solution and povidone iodine solution
Outcomes	<ul style="list-style-type: none"> All-cause mortality Exit-site/tunnel infection (number of patients) Exit-site/tunnel infection (rate) Catheter removal or replacement (due to infection)
Notes	<ul style="list-style-type: none"> Funding source: Nephrological Nursing Investigation Baxter award 2010 Excluded from analysis: none Exclusions post-randomisation but pre-intervention: none Stop or end point/s: not reported Additional data requested from authors: further information on peritonitis data were requested from the corresponding author

Risk of bias

Nunez-Moral 2014 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table "Randomization was performed by means of a randomization code via random number table..."
Allocation concealment (selection bias)	Unclear risk	Randomisation stated but no information on method used is available
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing outcome data
Selective reporting (reporting bias)	Unclear risk	Only 2 of 3 expected primary outcomes of interest reported fully
Other bias	Unclear risk	Disclosure states that "Part of these data belong to Baxter S. L. funds as we received the Nephrological Nursing Investigation Baxter award 2010"

Perez-Fontan 1992

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: July to October 1990 Duration of follow-up: 9.5 ± 3.3 months
Participants	<ul style="list-style-type: none"> Setting: single centre Country: Spain Health status: patients undergoing CAPD and their assisting partners Number (patients/partners): treatment group 1 (11/1); treatment group 2 (8/2) Mean age ± SD (years): treatment group 1 (51 ± 15); treatment group 2 (48 ± 21) Sex (M/F): treatment group 1 (5/7); treatment group (5/5) Proportion of diabetic patients: treatment group 1 (25%); treatment group (20%) Exclusion criteria: not reported
Interventions	<p>Treatment group 1</p> <ul style="list-style-type: none"> Mupirocin (2%) nasal ointment 3 times/d for 7 days <p>Treatment group 2</p> <ul style="list-style-type: none"> Neomycin sulphate (0.1%) nasal ointment 3 times/d for 7 days
Outcomes	<ul style="list-style-type: none"> Peritonitis (number of patients) Peritonitis (rate) Exit-site/tunnel infection (number of patients) Exit-site/tunnel infection (rate)

Perez-Fontan 1992 (Continued)

Notes	• Funding source: not reported • Excluded from analysis: not reported • Exclusions post-randomisation but pre-intervention: not reported • Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Stratified randomisation method used "Staph. aureus nasal carriers were assigned to one of two groups, randomized for age, time on CAPD and prevalence of diabetes."
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	Reasons for missing data not related to outcome "Patients of Group 2 in whom eradication was not obtained after two neomycin cycles were treated with mupirocin."
Selective reporting (reporting bias)	Unclear risk	2 of 3 expected primary outcomes of interest are reported
Other bias	Unclear risk	No report of funding source

Poole-Warren 1991

Methods	<ul style="list-style-type: none"> • Study design: parallel RCT • Study duration/time frame: 12 months • Duration of follow-up: 12 months
Participants	<ul style="list-style-type: none"> • Setting: 8 tertiary centres • Country: Australia and New Zealand • Health status: current CAPD patients stabilised on the therapy • Number: treatment group (65); control group (59) • Mean age $\pm$ SD (years): treatment group (54 ± 11); control group (52 ± 14) • Sex (M/F): treatment group (39/26); control group (24/35) • Proportion of diabetic patients: treatment group (18.5%); control group (15.3%) • Exclusion criteria: current peritoneal infection; receipt of an antibiotic course within the 2 week period prior to study enrolment; use of assist devices; use of disconnect systems
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> • Staphypan Berna vaccine

Poole-Warren 1991 (Continued)

Control group

- Saline placebo

Outcomes	<ul style="list-style-type: none"> • Peritonitis (number of patients) • Peritonitis (rate) • Exit-site/tunnel infection (number of patients) • Exit-site/tunnel infection (rate)
Notes	<ul style="list-style-type: none"> • Funding source: Baxter Healthcare Corporation, USA • Excluded from analysis: not reported • Exclusions post-randomisation but pre-intervention: not reported • Stop or end point/s: 43 patient years/treatment group

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation method not stated "Patients were randomly assigned by an independent third party to either the vaccinated group or the saline solution (SS) placebo administered group."
Allocation concealment (selection bias)	Low risk	Central allocation (independent third party) "The assigned injection group was not known to either patient or staff immediately connected with the patient's care at any time during the study."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Blinding, and unlikely that the blinding could have been broken
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding, and unlikely that the blinding could have been broken
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing data balanced across groups, and reasons similar
Selective reporting (reporting bias)	Low risk	3 of 3 expected primary outcomes of interest are reported
Other bias	High risk	Funding source: Baxter Healthcare Corporation, USA

Restrepo 2010

Methods	<ul style="list-style-type: none"> • Study design: parallel RCT • Study duration/time frame: 1 June 2004 to 30 October 2007 • Duration of follow-up: 30 to 150 days after the end of treatment
Participants	<ul style="list-style-type: none"> • Setting: single centre • Country: Colombia • Health status: CKD patients stage 5 on PD (CAPD or APD) were included if they experienced peritonitis, exit-site infection or tunnel infection • Number: treatment group (210); control group (210)

Restrepo 2010 (Continued)

- Mean age: 50.9 years (men); 47.9 years (women)
- Sex (M/F): treatment group (93/117); control group (116/94)
- Proportion of diabetic patients: treatment group (33.3%); control group (37.1%)
- Exclusion criteria: allergy to fluconazole, imidazoles, or triazoles; hepatic disease; pregnancy; < 18 years; > 70 years; patients that did not wish to participate

Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> • Oral fluconazole (200 mg every 48 hours) <p>Control group</p> <ul style="list-style-type: none"> • No oral fluconazole with an antibiotic course for a PD-related infection
Outcomes	<ul style="list-style-type: none"> • Fungal peritonitis in the time period 30 to 150 days following the end of antibacterial treatment
Notes	<ul style="list-style-type: none"> • Funding source: not reported • Excluded from analysis: not reported • Exclusions post-randomisation but pre-intervention: not reported • Stop or end point/s: when 434 episodes of peritonitis had occurred

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Drawing of lots "The randomization procedure was performed by drawing from a bag cards indicating whether the patient would or would not receive this treatment."
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No details of missing data given
Selective reporting (reporting bias)	Unclear risk	The expected primary outcome is reported. However, adverse effects of anti-fungal use are not reported
Other bias	Unclear risk	No report of funding source

Ryckelynck 1987

Methods	<ul style="list-style-type: none"> • Study design: parallel quasi RCT • Study duration/time frame: not reported • Duration of follow-up: not reported
---------	--

Ryckelynck 1987 (Continued)

Participants	<ul style="list-style-type: none"> Setting: 5 tertiary centres Country: France Health status: current CAPD patients using Y-line systems Number: treatment group (24); control group (26) Mean age: not reported Sex (M/F): not reported Proportion of diabetic patients not reported Exclusion criteria: not reported
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Connector soaked in antiseptic prior to bag exchange <p>Control group</p> <ul style="list-style-type: none"> No use of antiseptic
Outcomes	<ul style="list-style-type: none"> Peritonitis (rate)
Notes	<ul style="list-style-type: none"> Abstract-only publication Funding source: not reported Excluded from analysis: not reported Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation method not stated "24 patients using a single use Y-set and 26 using a reusable Y-set (O-set) were separately randomized into two groups."
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No details of missing data given
Selective reporting (reporting bias)	High risk	Only 1 of 3 expected primary outcomes is reported
Other bias	Unclear risk	No report of funding source; abstract-only publication

Sesso 1994

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: January 1991 through June 1992 Duration of follow-up: 7.8 months (mean)
Participants	<ul style="list-style-type: none"> Setting: single centre Country: Brazil Health status: continuing and new patients undergoing CAPD identified as <i>S. aureus</i> carriers Number: treatment group 1 (9); treatment group 2 (9); control group (13) Mean age $\pm$ SE (years): treatment group 1 (36.6 ± 4.6); treatment group 2 (46.1 ± 3.8); control group (42.1 ± 4.6) Sex (M/F): treatment group 1 (6/3); treatment group 2 (6/3); control group (9/4) Proportion of diabetic patients: treatment group (33.3%); treatment group (11.1%); control group (7.7%) Exclusion criteria: patients who had peritonitis or exit-site infection within 1 month of the beginning of the study were excluded until being asymptomatic for at least 1 month; patients who had received antimicrobial therapy within 78 hours before the start of the study; < 15 years
Interventions	<p>Treatment group 1</p> <ul style="list-style-type: none"> Ofloxacin 200 mg every 2 days over 5 days, repeated monthly <p>Treatment group 2</p> <ul style="list-style-type: none"> Sodium fusidate (2%) ointment applied twice daily (nasal and exit-site) for 5 days, repeated monthly <p>Control group</p> <ul style="list-style-type: none"> Placebo tablets, repeated monthly
Outcomes	<ul style="list-style-type: none"> All-cause mortality Peritonitis (number of patients) Peritonitis (rate) Exit-site/tunnel infection (number of patients) Exit-site/tunnel infection (rate) Catheter removal or replacement Nasal irritation
Notes	<ul style="list-style-type: none"> Funding source: Instituto Paulista de Estudos e Pesquisas em Nefrologia e Hipertensao Excluded from analysis: not reported Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: June 1992 or date patient ceased CAPD, if earlier

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation method not stated "Each carrier was then randomly assigned to one of the three groups".
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement

Sesso 1994 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	High risk	44.4% withdrew from sodium fusidate group; 77.7% withdrew from ofloxacin group; 53.8% withdrew from control group. Proportion missing enough to have a clinically relevant effect
Selective reporting (reporting bias)	Low risk	3 of 3 expected primary outcomes of interest are reported
Other bias	Low risk	Supported by a grant from Instituto Paulista de Estudos e Pesquisas em Nefrologia e Hipertensao. Study appears to be free of other sources of risk

Sharma 1971

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: not reported Duration of follow-up: not reported
Participants	<ul style="list-style-type: none"> Setting: single tertiary centre Country: USA Health status: PD patients with AKI or CKD Number: 41 patients Age range: 11 to 75 years Sex (M/F): 22/19 Proportion of diabetic patients: not reported Exclusion criteria: not reported
Interventions	Treatment group <ul style="list-style-type: none"> Oral neomycin 0.5 g in suspension every 12 hours Control group <ul style="list-style-type: none"> Placebo
Outcomes	<ul style="list-style-type: none"> Peritonitis (number of dialyses)
Notes	<ul style="list-style-type: none"> Funding source: not reported Excluded from analysis: 6 dialyses excluded (6.3%) Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Low risk	Central allocation (pharmacy)

Sharma 1971 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	Blinding, and unlikely that the blinding could have been broken
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding, and unlikely that the blinding could have been broken
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No details of missing data given on a patient basis; 6 dialyses excluded from analysis
Selective reporting (reporting bias)	High risk	Outcomes not reported as expected - number of episodes peritonitis/number of dialyses not number of episodes peritonitis/total patient-months on dialysis. Also, only 1 of 3 expected primary outcomes reported (peritonitis)
Other bias	Unclear risk	No report of funding source

SIPROCE Study 1997

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: 1 October 1994 to 1 April 1996 Duration of follow-up: treatment group (857 months); control group (937 months)
Participants	<ul style="list-style-type: none"> Setting: 10 dialysis centres (7 adult; 3 paediatric) Country: Germany Health status: all current patients on PD; new patients until December 1995 Number: treatment group (97); control group (98) Mean age $\pm$ SD (years): treatment group (44.74 $\pm$ 17.6); control group (47.01 $\pm$ 18.5) Sex (M/F): treatment group (63/34); control group (52/46) Proportion of diabetic patients: treatment group (19.6%); control group (21.4%) Exclusion criteria: patients with acute or chronic exit-site infections, sinus tract/tunnel infections, or peritonitis during the ascertainment period
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Silver ring mounted on PD catheter <p>Control group</p> <ul style="list-style-type: none"> No silver ring
Outcomes	<ul style="list-style-type: none"> First occurrence of exit-site infection Exit-site infection (number of patients) Tunnel infection (number of patients) Peritonitis (number of patients) Catheter loss All-cause mortality
Notes	<ul style="list-style-type: none"> Funding source: supported in part by Baxter Deutschland GmbH, Ettlingen, Germany Excluded from analysis: not reported Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: not reported

SIPROCE Study 1997 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Stratified randomisation "After informed consent had been obtained, the patients were stratified by diabetes mellitus status (types I and II) and randomly assigned by the coordinating study center (Berlin) to either the silver ring or the control group."
Allocation concealment (selection bias)	Low risk	Central allocation (coordinating study centre)
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding and the outcome is likely to be influenced by lack of blinding and knowledge of the interventions
Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding and knowledge of the interventions could influence outcome assessment
Incomplete outcome data (attrition bias) All outcomes	High risk	Proportion missing enough to have a clinically relevant effect. Dropouts: 29/97 (29.9%) in silver ring group; 30/98 (30.6%) in control group. Withdrawals: 6/97 (6.2%) in silver ring group; 0/98 (0%) in control group
Selective reporting (reporting bias)	Low risk	3 of 3 expected primary outcomes are reported
Other bias	Unclear risk	"Supported in part by Baxter Deutschland GmbH, Ettlingen, Germany."

Sit 2007

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: not reported Duration of follow-up: 12 months
Participants	<ul style="list-style-type: none"> Setting: single tertiary centre Country: Turkey Health status: current CAPD patients (for at least 6 months) Number: treatment group (25); control group (24) Mean age $\pm$ SD (years): treatment group (42.0 $\pm$ 12.1); control group (37.5 $\pm$ 12.9) Sex (M/F): treatment group (10/13); control group (11/13) Proportion of diabetic patients: not reported Exclusion criteria: treated with intranasal mupirocin before randomisation; known allergy to intranasal mupirocin; infection related to CAPD who were transferred to HD or transplantation
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Intranasal mupirocin ointment applied to nares twice/day for 5 days every 4 weeks <p>Control group</p> <ul style="list-style-type: none"> No ointment
Outcomes	<ul style="list-style-type: none"> Peritonitis (number of patients)

Sit 2007 (Continued)

Notes	Funding source: not reported Excluded from analysis: 2 (8%) excluded from analysis in mupirocin group due to kidney transplantation (1) and death (1) Exclusions post-randomisation but pre-intervention: none Stop or end point/s: When patient had been followed for 12 months

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Coin toss "Randomization was guided by the flip of a coin..."
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	Proportion missing not enough to have a clinically relevant effect; 2 (8%) excluded from analysis in mupirocin group due to kidney transplantation (1) and death (1)
Selective reporting (reporting bias)	Unclear risk	2 of 3 expected primary outcomes are reported (exit-site/tunnel infection, peritonitis)
Other bias	Unclear risk	No report of funding source

Swartz 1991

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: early 1987 to 1991 Duration of follow-up: (mean $\pm$ SE): treatment group (11.4 $\pm$ 1.3 months); control group (12.3 $\pm$ 1.4 months)
Participants	<ul style="list-style-type: none"> Setting: single tertiary centre Country: USA Health status: patients beginning chronic PD with a new catheter Number: treatment group (29); control group (30) Mean age $\pm$ SE (years): treatment group (49 $\pm$ 3.4); control group (51 $\pm$ 3.1) Sex (M/F): treatment group (16/13); control group (16/14) Proportion of diabetic patients: treatment group (34.5%); control group (33.3%) Exclusion criteria: beginning chronic PD with a new catheter children; extensive prior surgery; given general anaesthesia; catheter placement incidental to another surgical procedure
Interventions	Treatment group

Swartz 1991 (Continued)

- Trimethoprim/sulfamethoxazole (low dose) or cephalexin (250 mg) or clindamycin (300 mg) 3 days/week

Control group

- No prophylaxis

Outcomes	<ul style="list-style-type: none"> All-cause mortality Peritonitis (rate) Exit-site/tunnel infection (rate)
Notes	<ul style="list-style-type: none"> Funding source: not reported Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing data balanced across groups, and reasons similar; loss to follow-up: 2 of 29 in antibiotic prophylaxis group (6.9%)
Selective reporting (reporting bias)	High risk	3 of 3 expected primary outcomes of interest are reported, however peritonitis, exit-site infection and catheter removal could not be meta-analysed
Other bias	Unclear risk	No report of funding source

Wadhwa 1995

Methods	<ul style="list-style-type: none"> Study design: parallel quasi-RCT Study duration/time frame: not reported Duration of follow-up: not reported
Participants	<ul style="list-style-type: none"> Setting: single centre Country: USA Health status: PD patients (presume they were current) Number: treatment group 1 (25); treatment group 2 (25) Mean age (years): treatment group 1 (59); treatment group 2 (53) Sex (M/F): not reported

Wadhwa 1995 (Continued)

- Proportion of diabetic patients: treatment group 1 (48%); treatment group 2 (32%)
- Exclusion criteria: not reported

Interventions	<p>Treatment group 1</p> <ul style="list-style-type: none"> • Amuchina 10% (sodium hypochlorite) at exit site <p>Treatment group 2</p> <ul style="list-style-type: none"> • Povidone iodine 10% solution at exit site
Outcomes	<ul style="list-style-type: none"> • Exit-site infection (number of patients) • Peritonitis (number of patients) • Catheter removal (number of patients)
Notes	<ul style="list-style-type: none"> • Abstract-only publication • Funding source: not reported • Excluded from analysis: not reported • Exclusions post-randomisation but pre-intervention: not reported • Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation method not stated "Fifty PD patients were prospectively randomized to perform daily exit-site care with soap and water followed by Amuchina 10% or Povidone Iodine 10% solution."
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement; no details re missing data provided
Selective reporting (reporting bias)	Low risk	3 of 3 expected primary outcomes are reported (exit-site infection, peritonitis, catheter loss)
Other bias	Unclear risk	No report of funding source

Wadhwa 1997

Methods	<ul style="list-style-type: none"> • Study design: parallel quasi-RCT • Study duration/time frame: not reported • Duration of follow-up: not reported
---------	--

Wadhwa 1997 (Continued)

Participants	<ul style="list-style-type: none"> Setting: single centre Country: USA Health status: PD patients (presume they were current) Number: treatment group 1 (18); treatment group 2 (21) Mean age (years): treatment group 1 (55); treatment group 2 (60) Sex (M/F): not reported Proportion of diabetic patients: treatment group 1 (27.8%); treatment group 2 (28.6%) Exclusion criteria: not reported
Interventions	<p>Treatment group 1</p> <ul style="list-style-type: none"> Amuchina 5% (sodium hypochlorite) at exit site <p>Treatment group 2</p> <ul style="list-style-type: none"> Povidone iodine 10% solution at exit site
Outcomes	<ul style="list-style-type: none"> Exit-site infection (number of patients) Peritonitis (number of patients) Catheter removal (number of patients)
Notes	<ul style="list-style-type: none"> Abstract-only publication Funding source: not reported Excluded from analysis: not reported Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation method not stated "Thirty nine PD patients were prospectively randomized to perform daily exit-site care with soap and water followed by Amuchina 5% or povidone iodine 10% solution."
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement. No details re missing data provided
Selective reporting (reporting bias)	Low risk	3 of 3 expected primary outcomes are reported (exit-site infection, peritonitis, catheter loss)
Other bias	Unclear risk	No report of funding source

Waite 1997

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: not reported Duration of follow-up: 6 months
Participants	<ul style="list-style-type: none"> Setting: single tertiary centre Country: Canada Health status: patients with ESKD requiring PD catheter insertion Number: treatment group (61); control group (56) Mean age $\pm$ SD (years): treatment group (54.4 $\pm$ 15.1); control group (53.2 $\pm$ 14.5) Sex (M/F): treatment group (33/28); control group (30/26) Proportion of diabetic patients: treatment group (31.2%); control group (35.7%) Exclusion criteria: not reported
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Povidone iodine (10%) ointment 3.5 g at every dressing change <p>Control group</p> <ul style="list-style-type: none"> Standard care
Outcomes	<ul style="list-style-type: none"> All-cause mortality Peritonitis (number of patients) Exit-site/tunnel infection (number of patients) Catheter removal or replacement
Notes	<ul style="list-style-type: none"> Funding source: Purdue-Frederick, Toronto, Canada Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: 6 months after catheter insertion Additional data requested from authors: further information on methods and more detailed results were obtained from the corresponding author

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"Investigators assessing response (presence or absence of infection) were blinded to the treatment received by the individual patients"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Proportion missing not enough to have a clinically relevant effect; 3 (2.5%) excluded from analysis due to withdrawal (2) and failure to have PD catheter inserted (1) - group allocation not reported

Waite 1997 (Continued)

Selective reporting (reporting bias)	Unclear risk	2 of 3 expected primary outcomes of interest are reported
Other bias	High risk	Funding source: Purdue-Frederick

Wikdahl 1997

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: 27 months Duration of follow-up: 10 days post surgery
Participants	<ul style="list-style-type: none"> Setting: single tertiary centre Country: Sweden Health status: new PD patients Number: treatment group (18); control group (20) Mean age, range (years): treatment group (56, 33 to 84); control group (61, 34 to 84) Sex (M/F): treatment group (12/6); control group (15/5) Proportion of diabetic patients: treatment group (33.3%); control group (35%) Exclusion criteria: not reported
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Cefuroxime: (IV) 1.5 g 0.5 to 2.0 h before surgery + 250 mg (IP) in first dialysis bag <p>Control group</p> <ul style="list-style-type: none"> No antibiotic
Outcomes	<ul style="list-style-type: none"> Peritonitis (number of patients) Exit-site/tunnel infection (number of patients) within 10 days of catheter insertion
Notes	<ul style="list-style-type: none"> Funding source: not reported Excluded from analysis: not reported Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	High risk	Sealed envelopes without all safeguards
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement

Wikdahl 1997 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing data
Selective reporting (reporting bias)	Unclear risk	3 of 3 expected primary outcomes of interest are reported, however unable to meta-analyse catheter removal
Other bias	Unclear risk	No report of funding source

Wilson 1997

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: not reported Duration of follow-up: 12 months
Participants	<ul style="list-style-type: none"> Setting: Single tertiary centre Country: UK Health status: all patients in the PD program Number: treatment group (77); control group (72) Mean age, range (years): treatment group (53, 18 to 82); control group (51, 21 to 76) Sex (M/F): treatment group (55/22); control group (43/29) Proportion of diabetic patients: not reported Exclusion criteria: not reported
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Povidone iodine (2.5%) dry powder spray at exit-site at every dressing change <p>Control group</p> <ul style="list-style-type: none"> No treatment
Outcomes	<ul style="list-style-type: none"> All-cause mortality Peritonitis (number of patients) Exit-site/tunnel infection (number of patients) Catheter removal or replacement Technique failure due to infection Local pruritus/rash
Notes	<ul style="list-style-type: none"> Funding source: not reported Follow-up period: 12 months Exclusions post-randomisation but pre-intervention: not reported Stop or end point/s: 12 months or until a significant difference was found between groups Additional data requested from authors: further information on methods and more detailed results were obtained from the corresponding author

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table

Wilson 1997 (Continued)

Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	Proportion missing not enough to have a clinically relevant effect; loss to follow-up: 1 in spray group (1.3%), 3 in control group (4.2%) Withdrawals: 5 in spray group (6.5%) (adverse events) 1 (1.3%) excluded from analysis in povidone iodine spray group due to missing results
Selective reporting (reporting bias)	Low risk	3 of 3 expected primary outcomes of interest are reported
Other bias	Unclear risk	No report of funding source

Wong 2003

Methods	<ul style="list-style-type: none"> Study design: parallel RCT Study duration/time frame: 5 months Duration of follow-up: varied according to the patients clinical condition
Participants	<ul style="list-style-type: none"> Setting: single tertiary centre Country: Hong Kong Health status: current CAPD patients Number: treatment group (73); control group (81) Mean age $\pm$ SD (years): treatment group (60 ± 12); control group (59 ± 13) Sex (M/F): treatment group (32/41); control group (47/34) Proportion of diabetic patients: treatment group (26%); control group (33.3%) Exclusion criteria: presence of significant mental disorder; presence of a significant skin problem; antibiotic treatment within 1 month of the start of the study; regular daily mupirocin ointment prophylaxis at the catheter exit-site already prescribed before the start of the study; active exit-site infection or peritonitis; ill health; use of any exit-site dressing method other than 10% povidone iodine
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> Application of mupirocin ointment to exit site once/day after routine exit-site dressing <p>Control group</p> <ul style="list-style-type: none"> Usual daily exit-site care
Outcomes	<ul style="list-style-type: none"> Exit-site infection (number of patients) Exit-site infection (rate) Peritonitis (number of patients) Peritonitis (rate)
Notes	<ul style="list-style-type: none"> Funding source: not reported

Wong 2003 (Continued)

- Exclusions post-randomisation but pre-intervention: not reported
- Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation method not stated "Patients not excluded were randomized into two groups." No description of sequence generation
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing data balanced across groups, and reasons similar. Outcome data for tunnel infection not reported - this is ok as this infection is the least frequent one in PD patients; 1 withdrawal (not stated which intervention group) Excluded from analysis: 5 (6.4%) from mupirocin group; 7 (8.0%) from control group
Selective reporting (reporting bias)	Low risk	3 of 3 expected primary outcomes are reported (exit-site infection, peritonitis, catheter loss)
Other bias	Unclear risk	No report of funding source

Zimmerman 1991

Methods	<ul style="list-style-type: none"> • Study design: parallel RCT • Study duration/time frame: 1 September 1987 to 31 May 1989 • Duration of follow-up (mean $\pm$ SEM): treatment group (10.2 $\pm$ 1.2 months); control group (12.0 $\pm$ 1.3 months)
Participants	<ul style="list-style-type: none"> • Setting: single tertiary centre • Country: USA • Health status: adults who had completed at least 6 months of PD • Number: treatment group (32); control group (32) • Mean age $\pm$ SEM (years): treatment group (53 $\pm$ 3); control group (55 $\pm$ 4) • Sex (M/F): treatment group (17/15); control group (24/8) • Proportion of diabetic patients: treatment group (43.8%); control group (37.5%) • Exclusion criteria: not reported
Interventions	<p>Treatment group</p> <ul style="list-style-type: none"> • Rifampin 300 mg, twice/day for 5 days, every 3 months <p>Control group</p>

Zimmerman 1991 (Continued)

- No treatment

Outcomes	<ul style="list-style-type: none"> • Peritonitis (number of patients) • Peritonitis (rate) • Catheter removal or replacement • Toxicity
Notes	<ul style="list-style-type: none"> • Funding source: Baxter Healthcare • Excluded from analysis: not reported • Exclusions post-randomisation but pre-intervention: not reported • Stop or end point/s: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding and the outcomes are likely to be influenced by lack of blinding and knowledge of the interventions
Blinding of outcome assessment (detection bias) All outcomes	High risk	No blinding and knowledge of the interventions could influence outcome assessment
Incomplete outcome data (attrition bias) All outcomes	High risk	12.5% in rifampin group withdrew; 0% in control group withdrew. Proportion missing enough to have a clinically relevant effect
Selective reporting (reporting bias)	Unclear risk	Protocol not available but all expected outcomes of interest are reported, however unable to meta-analyse exit-site infection
Other bias	High risk	Funding source: Baxter Healthcare

AKI - acute kidney injury; APD - automated peritoneal dialysis; CAPD - continuous ambulatory peritoneal dialysis; CCPD - continuous cycling peritoneal dialysis; CKD - chronic kidney disease; ESKD - end-stage kidney disease; HD - haemodialysis; HIV - human immunodeficiency virus; IP - intraperitoneal; ITT - intention-to-treat; IV - intravenous; M/F - male/female; PD - peritoneal dialysis; RCT - randomised controlled trial; SD - standard deviation; SE - standard error; SEM - standard error of the mean

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Cavdar 2004	Not an intervention of interest
Churchill 1989	Not an intervention of interest
Crabtree 2003	Not an intervention of interest

Study	Reason for exclusion
de Fijter 1992a	Pharmacokinetics study not prevention
Gadallah 2000	Urokinase is not an antimicrobial agent; treatment study not prevention
Maiorca 1983	Not an intervention of interest
Naylor 1997	Small pilot study
Oh 2000	It is an RCT but peritonitis data is not readily available; no reply from authors to query email
Plum 1997a	Treatment study not prevention
Rodriguez-Perez 1989	Not an intervention of interest
Thomae 1982	Study only went for 84 hours; of the 7 patients, 3 had previously had peritonitis
Trooskin 1990	Not an intervention of interest

RCT - randomised controlled trial

Characteristics of ongoing studies *[ordered by study ID]*

[NCT02547103](#)

Trial name or title	Efficacy and safety of local application of chlorhexidine gluconate versus mupirocin ointment in the prevention of peritoneal dialysis-related infection: a pilot study, double- blind, stratified randomized controlled trial
Methods	Allocation: randomised, parallel RCT Double blind (subject, caregiver, investigator, outcomes assessor)
Participants	Inclusion criteria <ul style="list-style-type: none"> Patients with ESKD who were undergoing PD; either CAPD or APD Exclusion criteria <ul style="list-style-type: none"> History of psychological illness or condition that interferes with ability to understand or comply with the requirements of the study Recent (within 1 month) exit-site or tunnel infection, or peritonitis Known hypersensitivity to, or intolerance of, chlorhexidine gluconate, or mupirocin Current or recent (within 1 month) treatment with an antibiotic administered by any route Nasal carriage of mupirocin-resistant <i>Staphylococcus aureus</i> or chlorhexidine-resistant <i>S. aureus</i>
Interventions	<ul style="list-style-type: none"> 2% chlorhexidine gluconate-soaked cloths: clean topical area around catheter exit site with soaked cloths Normal saline: clean topical area around catheter exit site Mupirocin ointment 2%: clean topical area around catheter exit site with Mupirocin ointment
Outcomes	<ul style="list-style-type: none"> PD-related infection Adverse events related to treatments Hospitalisation due to PD-related infection Technical failure (change of modal of dialysis) Death due to PD-related infection

NCT02547103 (Continued)

- Costs
- Utility using Euro 5D-5L
- Adherence

Starting date	May 2016
Contact information	Surapon Nochaiwong Chidchanok Ruengorn Maharaj Nakorn Chiang Mai Hospital Chiang Mai, Thailand, 50200
Notes	Sponsors and Collaborators Chiang Mai University, Health Systems Research Institute, Thailand

APD - automated peritoneal dialysis; CAPD - continuous ambulatory peritoneal dialysis; ESKD - end-stage kidney disease; PD - peritoneal dialysis

DATA AND ANALYSES

Comparison 1. Oral or topical antibiotics versus placebo/no treatment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Peritonitis (number of patients with one or more episodes)	5	395	Risk Ratio (M-H, Random, 95% CI)	0.82 [0.57, 1.19]
1.1 Oral antibiotic versus placebo	4	241	Risk Ratio (M-H, Random, 95% CI)	0.87 [0.58, 1.32]
1.2 Mupirocin ointment versus standard care	1	154	Risk Ratio (M-H, Random, 95% CI)	0.55 [0.22, 1.40]
2 Peritonitis rate (episodes/total patient-months on PD)	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Any systemic antibiotic versus placebo/no treatment (excluding nystatin)	3	1440	Risk Ratio (M-H, Random, 95% CI)	0.68 [0.40, 1.14]
3 Exit-site/tunnel infection (number of patients with one or more episodes)	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
3.1 Any systemic antibiotic versus placebo/no treatment	3	191	Risk Ratio (M-H, Random, 95% CI)	0.45 [0.19, 1.04]
4 Exit-site/tunnel infection rate (episodes/total patient-months on PD)	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
4.1 Any systemic antibiotic versus placebo/no treatment	2	939	Risk Ratio (M-H, Random, 95% CI)	0.42 [0.17, 1.05]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5 Catheter removal or replacement (number of patients)	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
5.1 Any systemic antibiotic versus placebo/no treatment	5	395	Risk Ratio (M-H, Random, 95% CI)	0.82 [0.46, 1.46]
6 Mortality (all-cause)	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
6.1 Any systemic antibiotic versus placebo/no treatment	4	201	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.41, 1.89]
7 Mortality due to peritonitis	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
7.1 Oral antibiotic versus placebo	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
8 Adverse effects	2		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
8.1 Diarrhoea	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
8.2 Nausea	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
8.3 Pruritus (generalised)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
8.4 Nasal irritation	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
8.5 Allergy	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]

Analysis 1.1. Comparison 1 Oral or topical antibiotics versus placebo/no treatment, Outcome 1 Peritonitis (number of patients with one or more episodes).

Analysis 1.2. Comparison 1 Oral or topical antibiotics versus placebo/no treatment, Outcome 2 Peritonitis rate (episodes/total patient-months on PD).

Analysis 1.3. Comparison 1 Oral or topical antibiotics versus placebo/no treatment, Outcome 3 Exit-site/tunnel infection (number of patients with one or more episodes).

Analysis 1.4. Comparison 1 Oral or topical antibiotics versus placebo/no treatment, Outcome 4 Exit-site/tunnel infection rate (episodes/total patient-months on PD).

Analysis 1.5. Comparison 1 Oral or topical antibiotics versus placebo/no treatment, Outcome 5 Catheter removal or replacement (number of patients).

Analysis 1.6. Comparison 1 Oral or topical antibiotics versus placebo/no treatment, Outcome 6 Mortality (all-cause).

Analysis 1.7. Comparison 1 Oral or topical antibiotics versus placebo/no treatment, Outcome 7 Mortality due to peritonitis.

Analysis 1.8. Comparison 1 Oral or topical antibiotics versus placebo/no treatment, Outcome 8 Adverse effects.

Comparison 2. Oral or topical antibiotics versus other antibiotic

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Peritonitis (number of patients with one or more episodes)	4	314	Risk Ratio (M-H, Random, 95% CI)	1.28 [0.89, 1.84]
1.1 Sodium fusidate ointment versus ofloxacin (oral)	1	18	Risk Ratio (M-H, Random, 95% CI)	0.25 [0.03, 1.82]
1.2 Mupirocin ointment versus rifampin (oral)	1	82	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.67, 2.33]
1.3 Mupirocin ointment/cream versus gentamicin cream (topical)	2	214	Risk Ratio (M-H, Random, 95% CI)	1.39 [0.93, 2.07]
2 Peritonitis rate (episodes/total patient-months on PD)	5		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
2.1 Mupirocin ointment versus polysporin triple ointment (exit site)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.2 Sodium fusidate ointment versus ofloxacin (oral)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2.3 Mupirocin ointment versus neomycin sulphate ointment (nasal)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2.4 Mupirocin ointment versus rifampin (oral)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2.5 Mupirocin ointment versus gentamicin cream (exit site)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
3 Exit-site/tunnel infection (number of patients with one or more episodes)	4	336	Risk Ratio (M-H, Random, 95% CI)	1.28 [0.71, 2.31]
3.1 Mupirocin ointment versus sodium fusidate ointment (topical)	1	100	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.42, 1.95]
3.2 Sodium fusidate ointment versus ofloxacin (oral)	1	22	Risk Ratio (M-H, Random, 95% CI)	2.41 [0.76, 7.62]
3.3 Mupirocin ointment/cream versus gentamicin cream (topical)	2	214	Risk Ratio (M-H, Random, 95% CI)	1.19 [0.41, 3.46]
4 Exit-site/tunnel infection rate (episodes/total patient-months on PD)	3		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
4.1 Mupirocin ointment versus polysporin triple ointment (exit site)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
4.2 Mupirocin ointment versus gentamicin cream (exit site)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
4.3 Sodium fusidate ointment versus ofloxacin (oral)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
5 Catheter removal or replacement (number of patients)	4		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
5.1 Mupirocin ointment versus polysporin triple ointment (exit site)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
5.2 Sodium fusidate ointment versus ofloxacin (oral)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
5.3 Mupirocin ointment (exit site) versus rifampin (oral)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
5.4 Mupirocin cream versus gentamicin cream (exit site)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6 Mortality (all-cause)	4		Risk Ratio (M-H, Random, 95% CI)	Totals not selected

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6.1 Mupirocin ointment versus polysporin triple ointment (exit site)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6.2 Sodium fusidate ointment versus ofloxacin (oral)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6.3 Mupirocin ointment versus rifampin (oral)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
6.4 Mupirocin ointment versus gentamicin cream (exit site)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
7 Technique failure	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
7.1 Mupirocin ointment versus polysporin triple ointment (exit site)	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
8 Adverse effects	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
8.1 Nausea	1	82	Risk Ratio (M-H, Random, 95% CI)	0.09 [0.01, 1.59]
8.2 Pruritus (local)	2	337	Risk Ratio (M-H, Random, 95% CI)	0.65 [0.29, 1.49]

Analysis 2.1. Comparison 2 Oral or topical antibiotics versus other antibiotic, Outcome 1 Peritonitis (number of patients with one or more episodes).

Analysis 2.2. Comparison 2 Oral or topical antibiotics versus other antibiotic, Outcome 2 Peritonitis rate (episodes/total patient-months on PD).

Analysis 2.3. Comparison 2 Oral or topical antibiotics versus other antibiotic, Outcome 3 Exit-site/tunnel infection (number of patients with one or more episodes).

Analysis 2.4. Comparison 2 Oral or topical antibiotics versus other antibiotic, Outcome 4 Exit-site/tunnel infection rate (episodes/total patient-months on PD).

Analysis 2.5. Comparison 2 Oral or topical antibiotics versus other antibiotic, Outcome 5 Catheter removal or replacement (number of patients).

Analysis 2.6. Comparison 2 Oral or topical antibiotics versus other antibiotic, Outcome 6 Mortality (all-cause).

Analysis 2.7. Comparison 2 Oral or topical antibiotics versus other antibiotic, Outcome 7 Technique failure.

Analysis 2.8. Comparison 2 Oral or topical antibiotics versus other antibiotic, Outcome 8 Adverse effects.

Comparison 3. Nasal antibiotics versus placebo/no treatment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Peritonitis (number of patients with one or more episodes)	3	338	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.67, 1.31]
2 Peritonitis rate (episodes/total patient-months on PD)	2	2797	Risk Ratio (M-H, Random, 95% CI)	0.67 [0.16, 2.77]
3 Exit site and tunnel infection (number of patients with one or more episodes)	3	338	Risk Ratio (M-H, Random, 95% CI)	1.34 [0.62, 2.87]
4 Exit site and tunnel infection rate (episodes/total patient-months on PD)	2	2796	Risk Ratio (M-H, Random, 95% CI)	0.91 [0.29, 2.92]
5 Catheter removal or replacement (number of patients)	2	289	Risk Ratio (M-H, Random, 95% CI)	0.92 [0.48, 1.78]
6 Mortality (all-cause)	3	338	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.53, 1.47]
7 Adverse effects	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
7.1 Headache	1	267	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.14, 6.94]
7.2 Diarrhoea	1	267	Risk Ratio (M-H, Random, 95% CI)	1.65 [0.40, 6.78]
7.3 Nausea	1	267	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.14, 6.94]
7.4 Vomiting	1	267	Risk Ratio (M-H, Random, 95% CI)	2.98 [0.61, 14.49]
7.5 Pruritus	1	267	Risk Ratio (M-H, Random, 95% CI)	1.49 [0.25, 8.77]
7.6 Nasal irritation/rhinitis	2	289	Risk Ratio (M-H, Random, 95% CI)	0.93 [0.30, 2.94]

Analysis 3.1. Comparison 3 Nasal antibiotics versus placebo/no treatment, Outcome 1 Peritonitis (number of patients with one or more episodes).

Analysis 3.2. Comparison 3 Nasal antibiotics versus placebo/no treatment, Outcome 2 Peritonitis rate (episodes/total patient-months on PD).

Analysis 3.3. Comparison 3 Nasal antibiotics versus placebo/no treatment, Outcome 3 Exit site and tunnel infection (number of patients with one or more episodes).

Analysis 3.4. Comparison 3 Nasal antibiotics versus placebo/no treatment, Outcome 4 Exit site and tunnel infection rate (episodes/total patient-months on PD).

Analysis 3.5. Comparison 3 Nasal antibiotics versus placebo/no treatment, Outcome 5 Catheter removal or replacement (number of patients).

Analysis 3.6. Comparison 3 Nasal antibiotics versus placebo/no treatment, Outcome 6 Mortality (all-cause).

Analysis 3.7. Comparison 3 Nasal antibiotics versus placebo/no treatment, Outcome 7 Adverse effects.

Comparison 4. Pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Peritonitis (number of patients with one or more episodes)	4		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
1.1 Vancomycin versus placebo	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
1.2 Cefazolin versus placebo	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
1.3 IV gentamicin versus no antibiotics	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
1.4 IV cefazolin + gentamicin versus no antibiotics	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
1.5 IV cefuroxime + cefuroxime (in-traperitoneal) versus no antibiotics	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
1.6 Vancomycin versus cefazolin	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2 Exit site/tunnel infection (number of patients with one or more episodes)	4		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
2.1 Vancomycin versus placebo	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2.2 Cefazolin versus placebo	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2.3 IV gentamicin versus no antibiotics	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2.4 IV cefazolin + gentamicin versus no antibiotics	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2.5 IV cefuroxime + cefuroxime (in-traperitoneal) versus no antibiotics	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2.6 Vancomycin versus cefazolin	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
3 Catheter removal or replacement (number of patients)	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
4 Mortality (all-cause)	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected

Analysis 4.1. Comparison 4 Pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic, Outcome 1 Peritonitis (number of patients with one or more episodes).

Analysis 4.2. Comparison 4 Pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic, Outcome 2 Exit site/tunnel infection (number of patients with one or more episodes).

Analysis 4.3. Comparison 4 Pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic, Outcome 3 Catheter removal or replacement (number of patients).

Study or subgroup	Prophylaxis n/N	Control n/N	Risk Ratio M-H, Random, 95% CI	Risk Ratio M-H, Random, 95% CI
Bennet-Jones 1988	0/13	1/14		0.36[0.02,8.06]
Favours prophylaxis 0.01 0.1 1 10 100 Favours control				

Analysis 4.4. Comparison 4 Pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic, Outcome 4 Mortality (all-cause).

Study or subgroup	Prophylaxis n/N	Control n/N	Risk Ratio M-H, Random, 95% CI	Risk Ratio M-H, Random, 95% CI
Lye 1992	1/25	1/25		1[0.07,15.12]
Favours prophylaxis 0.01 0.1 1 10 100 Favours control				

Comparison 5. Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Peritonitis (number of patients with one or more episodes)	6	853	Risk Ratio (M-H, Random, 95% CI)	0.83 [0.65, 1.06]
1.1 Disinfectant versus standard care	3	393	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.52, 1.26]
1.2 Disinfectant versus other active treatment (antibiotics, other disinfectant)	3	460	Risk Ratio (M-H, Random, 95% CI)	0.84 [0.62, 1.13]
2 Exit site/tunnel infection (number of patients with one or more episodes)	8	973	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.75, 1.33]
2.1 Disinfectant versus standard care	4	453	Risk Ratio (M-H, Random, 95% CI)	0.74 [0.45, 1.20]
2.2 Disinfectant versus other active treatment (antibiotics, other disinfectant)	4	520	Risk Ratio (M-H, Random, 95% CI)	1.19 [0.89, 1.60]
3 Exit site/tunnel infection rate (episodes/total patient-months on PD)	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
3.1 Disinfectant versus other active treatment (antibiotics, other disinfectant)	2	1752	Risk Ratio (M-H, Random, 95% CI)	1.25 [0.31, 4.93]
4 Catheter removal or replacement (number of patients)	7	852	Risk Ratio (M-H, Random, 95% CI)	0.89 [0.57, 1.38]
4.1 Disinfectant versus standard care	2	266	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.34, 1.55]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.2 Disinfectant versus other active treatment (antibiotics, other disinfectant)	5	586	Risk Ratio (M-H, Random, 95% CI)	0.98 [0.57, 1.69]
5 Mortality (all-cause)	4	697	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.53, 1.44]
5.1 Disinfectant versus standard care	2	266	Risk Ratio (M-H, Random, 95% CI)	1.24 [0.54, 2.84]
5.2 Disinfectant versus other active treatment (antibiotics, other disinfectant)	2	431	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.39, 1.35]
6 Technique failure	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
7 Pruritus (local)	4	609	Risk Ratio (M-H, Random, 95% CI)	2.80 [1.21, 6.48]

Analysis 5.1. Comparison 5 Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant), Outcome 1 Peritonitis (number of patients with one or more episodes).

Analysis 5.2. Comparison 5 Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant), Outcome 2 Exit site/tunnel infection (number of patients with one or more episodes).

Analysis 5.3. Comparison 5 Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant), Outcome 3 Exit site/tunnel infection rate (episodes/total patient-months on PD).

Analysis 5.4. Comparison 5 Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant), Outcome 4 Catheter removal or replacement (number of patients).

Analysis 5.5. Comparison 5 Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant), Outcome 5 Mortality (all-cause).

Analysis 5.6. Comparison 5 Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant), Outcome 6 Technique failure.

Analysis 5.7. Comparison 5 Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant), Outcome 7 Pruritus (local).

Comparison 6. Germicidal chamber versus none

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Peritonitis rate (episodes/total patient-months on PD)	2	1855	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.74, 1.51]
2 Mortality (all-cause)	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected

Analysis 6.1. Comparison 6 Germicidal chamber versus none, Outcome 1 Peritonitis rate (episodes/total patient-months on PD).

Analysis 6.2. Comparison 6 Germicidal chamber versus none, Outcome 2 Mortality (all-cause).

Comparison 7. Dressing systems; (any)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Exit site/tunnel infection (number of patients with one or more episodes)	3		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
1.1 Chlorhexidine gluconate + water versus povidone-iodine solution	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
1.2 Sodium hypochlorite solution versus povidone-iodine solution	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
1.3 Shower + gauze versus dressing pack + fixomull	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
1.4 Blisterfilm versus gauze	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
2 Exit site/tunnel infection rate (episodes/total patient-months on PD)	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
2.1 Shower + gauze versus dressing pack + fixomull	1		Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]

Analysis 7.1. Comparison 7 Dressing systems (any), Outcome 1 Exit site/tunnel infection (number of patients with one or more episodes).

Analysis 7.2. Comparison 7 Dressing systems (any), Outcome 2 Exit site/tunnel infection rate (episodes/total patient-months on PD).

Comparison 8. Silver ring system on catheter versus none

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Peritonitis (number of patients with one or more episodes)	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
2 Exit site/tunnel infection (number of patients with one or more episodes)	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
3 Catheter removal or replacement (number of patients)	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
4 Mortality (all-cause)	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected

Analysis 8.1. Comparison 8 Silver ring system on catheter versus none, Outcome 1 Peritonitis (number of patients with one or more episodes).

Study or subgroup	Silver ring n/N	Control n/N	Risk Ratio M-H, Random, 95% CI	Risk Ratio M-H, Random, 95% CI
SIPROCE Study 1997	16/97	18/98		0.9[0.49,1.66]
Favours silver ring 0.2 0.5 1 2 5 Favours control				

Analysis 8.2. Comparison 8 Silver ring system on catheter versus none, Outcome 2 Exit site/tunnel infection (number of patients with one or more episodes).

Study or subgroup	Silver ring n/N	Control n/N	Risk Ratio M-H, Random, 95% CI	Risk Ratio M-H, Random, 95% CI
SIPROCE Study 1997	35/97	28/98		1.26[0.84,1.9]
Favours silver ring 0.5 0.7 1 1.5 2 Favours control				

Analysis 8.3. Comparison 8 Silver ring system on catheter versus none, Outcome 3 Catheter removal or replacement (number of patients).

Study or subgroup	Silver ring n/N	Control n/N	Risk Ratio M-H, Random, 95% CI	Risk Ratio M-H, Random, 95% CI
SIPROCE Study 1997	5/97	4/98		1.26[0.35,4.56]
Favours silver ring 0.2 0.5 1 2 5 Favours control				

Analysis 8.4. Comparison 8 Silver ring system on catheter versus none, Outcome 4 Mortality (all-cause).

Study or subgroup	Silver ring n/N	Control n/N	Risk Ratio M-H, Random, 95% CI	Risk Ratio M-H, Random, 95% CI
SIPROCE Study 1997	5/97	8/98		0.63[0.21,1.86]
Favours silver ring 0.2 0.5 1 2 5 Favours control				

Comparison 9. Antistaphylococcal vaccine (Staphypan) versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Peritonitis rate (episodes/total patient-months on PD)	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected
2 Exit site/tunnel infection rate (episodes/total patient-months on PD)	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected

Analysis 9.1. Comparison 9 Antistaphylococcal vaccine (Staphypan) versus placebo, Outcome 1 Peritonitis rate (episodes/total patient-months on PD).

Study or subgroup	Vaccine n/N	Control n/N	Risk Ratio M-H, Random, 95% CI	Risk Ratio M-H, Random, 95% CI
Poole-Warren 1991	57/552	51/547		1.11[0.77,1.59]
Favours vaccine 0.5 0.7 1 1.5 2 Favours control				

Analysis 9.2. Comparison 9 Antistaphylococcal vaccine (Staphypan) versus placebo, Outcome 2 Exit site/tunnel infection rate (episodes/total patient-months on PD).

Study or subgroup	Vaccine n/N	Control n/N	Risk Ratio M-H, Random, 95% CI	Risk Ratio M-H, Random, 95% CI
Poole-Warren 1991	43/565	42/542		0.98[0.65,1.48]
Favours vaccine 0.5 0.7 1 1.5 2 Favours control				

Comparison 10. Antifungal versus placebo/no treatment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Fungal peritonitis (number of patients with one or more episodes)	2	817	Risk Ratio (M-H, Random, 95% CI)	0.28 [0.12, 0.63]
2 Fungal peritonitis rate (episodes/total patient-months on PD)	1		Risk Ratio (M-H, Random, 95% CI)	Totals not selected

Analysis 10.1. Comparison 10 Antifungal versus placebo/no treatment, Outcome 1 Fungal peritonitis (number of patients with one or more episodes).

Study or subgroup	Antifungal n/N	Control n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
Restrepo 2010	3/210	15/210		45.87%	0.2[0.06,0.68]
Lo 1996	4/199	11/198		54.13%	0.36[0.12,1.12]
Total (95% CI)	409	408		100%	0.28[0.12,0.63]
Total events: 7 (Antifungal), 26 (Control)					
Heterogeneity: Tau ² =0; Chi ² =0.49, df=1(P=0.48); I ² =0%					
Test for overall effect: Z=3.04(P=0)					
Favours antifungal 0.05 0.2 1 5 20 Favours control					

Analysis 10.2. Comparison 10 Antifungal versus placebo/no treatment, Outcome 2 Fungal peritonitis rate (episodes/total patient-months on PD).

ADDITIONAL TABLES

Table 1. Guidelines on antimicrobial interventions to prevent peritonitis in PD

Guideline	Country	Year	Recommendation
Kidney-Disease Outcomes Quality Initiative	United States of America	NA	No guideline
The Renal Association	United Kingdom	April 2008	Guideline 3.1 - PD Access: Implantation Protocol
		July 2010	<ul style="list-style-type: none"> Recommended that renal units have clear protocols for peri-operative catheter care including the use of antibiotic prophylaxis (1A)
			Guideline 5.1.4 - PD Infectious Complications: Prevention Strategies
			<ul style="list-style-type: none"> Recommended that initial catheter insertion be accompanied by antibiotic prophylaxis (1B)
Canadian Society of Nephrology	Canada	NA	Guideline 5.1.5 - PD Infectious Complications: Prevention Strategies
			<ul style="list-style-type: none"> Recommended that invasive procedures be accompanied by antibiotic prophylaxis and emptying the abdomen of dialysis fluid for a period commensurate with the procedure (1C)
			Guideline 5.1.6 - PD Infectious Complications: Prevention Strategies
			<ul style="list-style-type: none"> Recommended that topical antibiotic administration be used to reduce the frequency of <i>S. aureus</i> and Gram-negative exit-site infection and peritonitis (1A)
European Renal Best Practice	Europe	NA	No guideline
International Society for Peritoneal Dialysis	NA	July 2010	Guideline 3.1: Implantation Protocol (1A)
		November 2011	<ul style="list-style-type: none"> Recommended that renal units have clear protocols for peri-operative catheter care, including the use of antibiotic prophylaxis Recommended that perioperative catheter care protocol include screening for MRSA and nasal carriage of <i>S. aureus</i>

Table 1. Guidelines on antimicrobial interventions to prevent peritonitis in PD *(Continued)*

- Recommended that prophylactic antibiotics be administered to reduce the risk of catheter-site infection, peritonitis and wound sepsis and there is RCT evidence for the use of vancomycin

Position Statement: Catheter Placement to Prevent Catheter Infections and the Related Peritonitis Episodes

- Prophylactic antibiotics administered at the time of insertion decrease the infection risk. A first-generation cephalosporin or vancomycin can be used, but suggested each program should weigh the potential benefit against the risk of vancomycin use (development of resistant organisms)
- There is no data on the effectiveness of obtaining nose cultures before catheter insertion, and treating patients positive for *S. aureus* nasal carriage

Position Statement: Exit-Site Care to Prevent Peritonitis

- Antibiotic protocols against *S. aureus* are effective in reducing the risk of *S. aureus* catheter infections
- All PD patients should use topical antibiotic either at the catheter exit-site or intranasally or both
- Topical antibiotic ointments (as opposed to antibiotic creams) should not be used at the exit site of polyurethane catheters

Position Statement: Prevention of Fungal Peritonitis

- Most episodes of fungal peritonitis are preceded by courses of antibiotics
- Fungal prophylaxis during antibiotic therapy may prevent some cases of *Candida* peritonitis in programs that have high rates of fungal peritonitis

Kidney Health Australia-Caring for Australasians with Renal Impairment

Australia/ New Zealand

February 2014

Guideline 6. Prophylactic Antibiotics for Insertion of PD Catheters

- Recommended that intravenous antibiotic prophylaxis be used prior to peritoneal dialysis catheter insertion to reduce the risk of early peritonitis
- Vancomycin, cephalosporins and gentamicin have demonstrated effectiveness in reducing the risk of peritonitis

Guideline 8. Treatment of Peritoneal Dialysis-Associated Fungal Peritonitis

- Oral antifungal prophylaxis should be considered when antibiotics are administered to patients undergoing peritoneal dialysis to reduce the risk of developing fungal peritonitis
- Prophylactic antifungals should be administered before gynaecological procedures

Guideline 10. Prophylaxis for Exit-site/Tunnel Infections Using Mupirocin

- Recommended that prophylactic therapy using mupirocin ointment be used, especially for *S. aureus* carriage (intranasally or at the exit site) to decrease the risk of *S. aureus* catheter exit-site/tunnel infections and peritonitis

Table 1. Guidelines on antimicrobial interventions to prevent peritonitis in PD (Continued)

- Suggested that clean the PD catheter exit site daily and apply a topical antimicrobial agent (either mupirocin or gentamicin)

MRSA - methicillin-resistant *S. aureus*; NA - not applicable; PD - peritoneal dialysis

Table 2. Comparisons in original review and updated review

Comparisons in 2004 review	Comparisons in 2017 review
Oral antibiotics versus none	Oral or topical antibiotics versus placebo/no treatment
Nasal antibiotics versus none	Oral or topical antibiotics versus other antibiotic
Peri-operative IV prophylaxis versus none	Nasal antibiotics versus no treatment
Peri-operative IV prophylaxis head-to-head	Pre/peri-operative IV prophylaxis versus none or head-to-head
Topical disinfectants versus none	Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant)
Germicidal chamber versus none	Germicidal chamber versus none
Antistaphylococcal vaccine (Staphypan) versus placebo	Dressing systems (any)
Antibiotic prophylaxis head-to-head agents	Silver ring system on catheter versus none
--	Antistaphylococcal vaccine (Staphypan) versus placebo
--	Antifungal versus placebo/no treatment

Table 3. Other outcomes analysed

Outcome analysed	Number of studies	Number of patients	RR (95% CI)
Oral antibiotic prophylaxis			
Pruritus	1	64	3.00 (0.13 to 71.00)
Diarrhoea	1	64	0.09 (0.01 to 1.58)
Nausea	1	64	9.00 (0.50 to 160.59)
Allergy	1	64	5.00 (0.25 to 100.20)
Nasal antibiotic prophylaxis			
Nasal irritation	1	15	2.10 (0.10 to 44.40)
Rhinitis	1	267	0.74 (0.27 to 2.09)

Table 3. Other outcomes analysed *(Continued)*

Headache	1	267	0.99 (0.14 to 6.94)
Diarrhoea	1	267	1.65 (0.40 to 6.78)
Nausea	1	267	0.99 (0.14 to 6.94)
Vomiting	1	267	2.98 (0.61 to 14.94)
Pruritus	1	267	1.49 (0.25 to 8.77)
Topical disinfectants			
Technique failure	1	149	0.19 (0.01 to 3.83)
Pruritus	1	149	10.29 (0.58 to 182.92)

APPENDICES

Appendix 1. Electronic search strategies

Database searched	Search terms
CENTRAL	<ol style="list-style-type: none"> 1. (peritoneal dialysis):ti,ab,kw 2. (CAPD or CCPD or APD):ti,ab,kw 3. {or #1-#2} 4. peritonitis:ti,ab,kw 5. {and #3-#4}
MEDLINE	<ol style="list-style-type: none"> 1. exp Peritoneal Dialysis/ 2. peritoneal dialysis.tw. 3. (PD or CAPD or CCPD or APD).tw. 4. or/1-3 5. Peritonitis/ 6. peritonitis.tw. 7. Catheter-Related Infections/ 8. infection*.tw. 9. or/5-8
EMBASE	<ol style="list-style-type: none"> 1. peritoneal dialysis/ 2. continuous ambulatory peritoneal dialysis/ 3. (PD or CAPD or CCPD).tw. 4. peritoneal dialysis.tw. 5. or/1-4 6. exp Peritonitis/ 7. Catheter Infection/ 8. peritonitis.tw. 9. infect\$.tw. 10.or/6-9

(Continued)

11.and/5,10

Appendix 2. Risk of bias assessment tool

Potential source of bias	Assessment criteria
Random sequence generation Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence	<p><i>Low risk of bias:</i> Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimisation (minimisation may be implemented without a random element, and this is considered to be equivalent to being random).</p> <p><i>High risk of bias:</i> Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.</p> <p><i>Unclear:</i> Insufficient information about the sequence generation process to permit judgement.</p>
Allocation concealment Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment	<p><i>Low risk of bias:</i> Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).</p> <p><i>High risk of bias:</i> Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</p> <p><i>Unclear:</i> Randomisation stated but no information on method used is available.</p>
Blinding of participants and personnel Performance bias due to knowledge of the allocated interventions by participants and personnel during the study	<p><i>Low risk of bias:</i> No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</p> <p><i>High risk of bias:</i> No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</p> <p><i>Unclear:</i> Insufficient information to permit judgement</p>
Blinding of outcome assessment Detection bias due to knowledge of the allocated interventions by outcome assessors.	<p><i>Low risk of bias:</i> No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</p> <p><i>High risk of bias:</i> No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</p> <p><i>Unclear:</i> Insufficient information to permit judgement</p>
Incomplete outcome data Attrition bias due to amount, nature or handling of incomplete outcome data.	<p><i>Low risk of bias:</i> No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect esti-</p>

(Continued)

mate; for continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.

High risk of bias: Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; 'as-treated' analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.

Unclear: Insufficient information to permit judgement

Selective reporting

Reporting bias due to selective outcome reporting

Low risk of bias: The study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).

High risk of bias: Not all of the study's pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. sub-scales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Unclear: Insufficient information to permit judgement

Other bias

Bias due to problems not covered elsewhere in the table

Low risk of bias: The study appears to be free of other sources of bias.

High risk of bias: Had a potential source of bias related to the specific study design used; stopped early due to some data-dependent process (including a formal-stopping rule); had extreme baseline imbalance; has been claimed to have been fraudulent; had some other problem.

Unclear: Insufficient information to assess whether an important risk of bias exists; insufficient rationale or evidence that an identified problem will introduce bias.

WHAT'S NEW

Date	Event	Description
6 June 2017	Amended	Corrections made to numbering in MEDLINE & CENTRAL search strategies

HISTORY

Protocol first published: Issue 1, 2004

Review first published: Issue 4, 2004

Date	Event	Description
12 January 2017	New citation required and conclusions have changed	New studies and comparisons added
12 January 2017	New search has been performed	20 new studies added
30 April 2014	Amended	Minor copy-edit made
18 March 2010	Amended	Contact details updated.
13 May 2009	Amended	Contact details updated.
16 September 2008	Amended	Converted to new review format.
18 December 2007	Amended	New trials sought but none found

CONTRIBUTIONS OF AUTHORS

- Designing the review: GS, DJ, JC
- Coordinating the update of the review: DC, GS, JC
- Data collection for the update of the review: DC and GS, independently
- Developing search strategy: DC and GS, independently
- Undertaking searches: DC and GS, independently
- Screening search results: DC and GS, independently
- Organising retrieval of papers: DC and GS, independently
- Screening retrieved papers against inclusion criteria: DC and GS, independently
- Appraising quality of papers: DC and GS, independently
- Abstracting data from papers (modified Cochrane Kidney and Transplant's data extraction form): DC and GS, independently
- Searching for additional data in unpublished studies: DC and GS, independently
- Entering data into RevMan: DC
- Analysis of data: DC, GS, JC
- Interpretation of data: DC, GS, JC
- Providing a methodological perspective: GS, JC
- Providing a clinical perspective: GS, DJ, JC
- Providing a policy perspective: GS, DJ, JC
- Providing a consumer perspective: GS, DJ, JC
- Writing the review: DC, GS, DJ, JC
- Providing general advice on the review: JC, GS

DECLARATIONS OF INTEREST

- Denise Campbell: none
- David W Mudge has received consultancy fees, speakers' honoraria and travel assistance from Baxter Healthcare for activities unrelated to this review
- Jonathan C Craig: none
- David W Johnson has received consultancy fees, speakers' honoraria, travel sponsorships and research funding from Fresenius Medical Care and Baxter Healthcare for activities unrelated to this review
- Allison Tong: none
- Giovanni FM Strippoli: none

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

- The risk of bias assessment tool has replaced the quality assessment checklist used in the original review

- Summary of findings tables have been incorporated into this update

INDEX TERMS

Medical Subject Headings (MeSH)

*Antibiotic Prophylaxis; Administration, Intranasal; Administration, Topical; Anti-Bacterial Agents [administration & dosage] [*therapeutic use]; Anti-Infective Agents, Local [administration & dosage] [therapeutic use]; Antifungal Agents [administration & dosage] [therapeutic use]; Catheter-Related Infections [epidemiology] [*prevention & control]; Device Removal [adverse effects]; Injections, Intravenous; Mupirocin [administration & dosage] [therapeutic use]; Mycoses [prevention & control]; Peritoneal Dialysis [*adverse effects]; Peritonitis [epidemiology] [*prevention & control]; Randomized Controlled Trials as Topic; Vancomycin [administration & dosage] [therapeutic use]

MeSH check words

Humans